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ABSTRACT OF DISSERTATION

TARGET-DIRECTED BIOSYNTHETIC EVOLUTION:
REDIRECTING PLANT EVOLUTION TO GENOMICALLY
OPTIMIZE A PLANT’S PHARMACOLOGICAL PROFILE

The dissertation describes a novel method for plant drug discovery based
on mutation and selection of plant cells. Despite the industry focus on chemical
synthesis, plants remain a source of potent and complex bioactive metabolites.
Many of these have evolved as defensive compounds targeted on key proteins in
the CNS of herbivorous insects, for example the insect dopamine transporter
(DAT). Because of homology with the human DAT protein some of these
metabolites have high abuse potential, but others may be valuable in treating
drug dependence. This dissertation redirects the evolution of a native Lobelia
species toward metabolites with greater activity at this therapeutic target, i.e. the
human DAT. This was achieved by expressing the human DAT protein in
transgenic plant cells and selecting gain-of-function mutants for survival on
medium containing a neurotoxin that is accumulated by the human DAT. This
created a sub-population of mutants with increased DAT inhibitory activity. Some
of the active metabolites in these mutants are novel (i.e. not detectable in wildtype cells). Others are cytoprotective, and also protect DAergic neurons against
the neurotoxin. This provides proof-of-concept for a novel plant drug discovery
platform, which is applicable to many different therapeutic target proteins and
plant species.	
  
KEYWORDS: Plant secondary metabolites, Lobelia cardinalis, human dopamine
transporter, target-directed biosynthetic evolution, drug dependence
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Chapter 1

Introduction

1.1. Plants as a source of drugs and drug leads
Plant-derived medicines have been used to treat human disease for
millennia. Their utilization likely predates even the earliest records signifying the
therapeutic utilization of plants, such as Sumerian artifacts dating back to 5000
B.C. indicating the clinical use of opium [1]. Plant-derived small molecule natural
products (SMNPs) continue to be used in modern medicine in fields ranging from
neurology (e.g. galantamine) to oncology (e.g. vincristine) [2]. Furthermore,
pharmacotherapies and drug leads continue to be discovered from plant sources
[3]. Undoubtedly, plants are an excellent source of novel drug leads. However,
there are a number of challenges and limitations associated with plant-based
drug discovery including low yields of bioactive metabolites, identifying which of
the thousands of plant species in existence contain metabolites with a desired
bioactivity, the isolation of a single bioactive metabolite of interest from potentially
thousands in a single extract, and threats of extinction to plant species, to name
a few [4, 5].
In the last quarter of the 20th century, many drug discovery programs
largely discontinued screening of plant SMNPs in favor of synthetics as a source
of structurally diverse drug leads [2, 4, 6]. This was largely due to the advent of
combinatorial chemistry (CC) and high-throughput pharmacological screening
(HTPS), as well as the perceived difficulties associated with plant-based drug
discovery [2, 4]. The transition seemed logical. The development of CC gave
medicinal chemists the capacity to generate thousands of novel molecules in a
relatively short period of time, which could be rapidly screened for a given
biological activity using HTPS [2, 7]. Thus, the coupling of CC to HTPS (CC-
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HTPS) enabled drug discovery programs to rapidly sort through thousands of
synthetics to identify novel drug leads. However, CC-HTPS fell short of
expectations, yielding a single small molecule of complete synthetic origin
approved by the FDA for use in humans over the 30 year span between 1981
and 2010 [6]. During that same span of time, 64% of small molecules approved
by the FDA for use in humans were natural products, or natural product derived,
despite reductions in revenue, facilities, and manpower contributed to this effort
[4, 6]. The disparity between the success rates of synthetics and SMNPs, or
derivatives thereof, compelled researchers to investigate the physiochemical
properties of each as compared to those of FDA-approved small molecule
therapeutics. This led to the consensus that SMNPs, including those from plant
sources, share a greater degree of physiochemical similarity to FDA approved
small molecule therapeutics leading to greater “druggability” of bioactive SMNPs
[8, 9]. Furthermore, plant SMNPs must have a certain degree of biocompatibility
to exist in living cells, bioavailability in order to reach and interact with their
target/s in other organisms, and bioactivity to elicit a response upon reaching
their target/s, all of which contribute to the inherent “druggability” of bioactive
plant secondary metabolites [9, 10].
Numerous investigators have made efforts to overcome obstacles
encountered in plant-based drug discovery [5, 11]. Recent advances in analytical
chemistry will undoubtedly facilitate the isolation and structural elucidation of
bioactive plant SMNPs [4, 7]. Progress in the fields of plant molecular biology
and plant sciences are also addressing challenges associated with plant-based
drug discovery [5, 7, 11]. For example, the expression of genes encoding
biosynthetic enzymes to generate transgenic rice containing Vitamin A was one
of the greatest, and most successful efforts to reduce blindness caused by
malnutrition in countries where rice is the major grain consumed by humans [12].
An example of the use of plant cell cultures for the purpose of drug discovery is
the growth of hairy roots to obtain precursors for the semi-synthesis of the
chemotherapeutic Taxol [13]. Another breakthrough in plant molecular biology
enabling the generation of stable, “gain-of-function” mutants, known as activation
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tagging mutagenesis (ATM), has been used to generate mutants with increased
yields of therapeutically valuable plant secondary metabolites [14, 15]. Herein,
“gain-of-function” mutation refers to mutations that cause enhanced gene
transcription. “Gain-of-function” mutations are induced by transforming plant cells
with agrobacterial strains harboring binary vectors carrying a tetramer of the
enhancer element from the Cauliflower Mosaic Virus (CaMV) 35S promoter gene
[14, 16-19]. Successful transformation and integration of the enhancer tetramer
into the plant genome “activates” flanking genes 10-kb upstream and
downstream of the integration site [14, 18]. Using ATM, Littleton (2007)
generated activation tagged Nicotiana tabacum mutants with increased yields of
nicotine, as well as putatively “novel” nicotinic acetylcholine receptor ligands that
were undetectable in the wild-type plant [14, 15]. Utilization of Agrobacterium
tumifaciens in the former study was less than ideal, since the resulting neoplastic
callus cultures are undifferentiated leading to a reduction in their biosynthetic
capacity [19]. However, transformation of plant cells with A. rhizogenes carrying
ATM vectors induces the formation of stable, gain-of-function hairy roots, which
develop from a single transformed cell, are clonal in nature, and are differentiated
retaining much of the biosynthetic capacity of an intact plant [19]. Hairy roots are
easy to culture, do not require hormones to sustain growth, and methods are
available to scale-up the growth of hairy root cultures [19]. However, the use of
ATM alone requires the generation and maintenance of thousands of mutants to
saturate a plant’s genome, as well as the preparation and screening of extracts
from each mutant [14, 15]. The use of ATM alone for the purpose of drug
discovery is inefficient (“positive hit” rate, ~1/1000), timely, and laborious,
limitations we seek to overcome by combining ATM with artificial selection
favoring the survival of mutants with a genotype of interest [14, 15].
The majority of medicinal compounds derived from plants are secondary
metabolites, molecules of astonishing complexity and diversity which evolved to
enable plants to react and respond to stimuli arising from abiotic and biotic
sources in their local environment [13, 20]. Over plants’ ~3 billion year existence,
natural selection has optimized the interactions between plant secondary
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metabolites and macromolecules present in co-existing prokaryotic and
eukaryotic organisms to elicit a required biological response [3, 10, 13, 14].
Plants containing SMNPs with optimal function had a survival advantage, thus
natural selection favored the retention of such molecules and their respective
biosynthetic pathways [3, 4, 13]. The evolutionary process is essentially
analogous to optimization and screening of compound libraries during drug
discovery and development [4]. Variation in plants’ metabolomes and
biosynthetic pathways, arising from sexual reproduction, mutations, and
horizontal gene transfer, leads to the genesis of new metabolites and/or
numerous congeners of a single molecule (optimization), which are retained or
lost through the process of natural selection (screening) depending on the
survival advantage a metabolite/s affords a plant [3, 4, 13]. The evolutionary
plasticity of plants, their remarkable biosynthetic capacity, and “experience”
arising from their ~3 billion year existence gives plants a tremendous advantage
over medicinal chemists [2, 7, 10, 14].
Given biosynthesis plant secondary metabolites, including those of
medicinal value, evolved via natural selection, it should be possible to devise
artificial selection conditions favoring the survival of plants with pharmacologically
optimized genotypes, and resultant phenotypes. Here, we present a novel
approach aimed to overcome the challenges and limitations associated with drug
discovery from plant sources, outlined above, by applying the principles of
natural selection and evolution to harness the biosynthetic capacity of plants to
generate SMNPs with desirable drug-like properties that are active at molecular
targets of interest. Essentially, the evolution of a plant species is redirected to
encourage synthesis of metabolites designed to interact with a specific human
target protein, coined target-directed biosynthesis. This is accomplished by
generating a heterogeneous population of gain-of-function mutant plant cells
expressing a human protein that is a therapeutic molecular target. The
aforementioned population of mutant plant cells is subject to selection conditions
such that survival is contingent upon beneficial mutations that increase yields
and/or cause biosynthesis of novel metabolites with a desired/required
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therapeutic activity. Therefore, we are able to select individual cultures with
optimized pharmacological genotypes/phenotypes, and thereby massively
accelerate the evolution of plant secondary metabolism. This innovative
approach redirects plant biosynthetic evolution to produce molecules with a
specific human target and related potential therapeutic activity. In the example
described below, we have generated mutant cultures of Lobelia cardinalis which
are overproducing inhibitors of the human dopamine transporter, a molecular
target for therapeutics in drug dependence.
1.2. Plants as a source of novel drug leads for the treatment of drug abuse
The vast majority of pharmacotherapies implemented for the treatment of
drug abuse, including those used for the treatment of nicotine use disorders and
opioid dependence, are natural products, natural product-derived, and/or were
inspired by the structure of natural products. Plant-derived SMNPs, such as
nicotine and cytisine, are approved in the United States and many countries in
Eastern Europe, respectively, as smoking cessation agents [20, 21]. Varenicline,
another FDA-approved smoking cessation agent, was inspired by the structure of
cytisine [20-22]. Varenicline and cytisine function as α4β2-nicAchR partial
agonists, whereas nicotine is a full agonist at α4β2-nicAchRs [22]. The
aforementioned nicAchR ligands are utilized as substitution therapies for nicotine
use disorders [20-22]. However, cytisine and varenicline are unique from nicotine
in that they have the capacity to blunt the rewarding effects associated with
smoking by functionally antagonizing the effect of nicotine [21]. Bupropion is a
DAT inhibitor based on the structure of cathinone, an alkaloid present in khat,
which is also approved by the FDA as a smoking cessation agent [23-26].
Buprenorphine is a structural analogue of thebaine, a naturally occurring alkaloid
present in Papaver somniferum [27]. Buprenorphine is a µ-opioid receptor partial
agonist FDA-approved for the treatment of opioid addiction [27]. The structure of
methadone, which is also utilized as a substitution therapy for opioid
dependence, is derived from the structural backbone of atropine, a naturally
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occurring alkaloid present in Atropa belladonna [20]. Furthermore, the structure
of the µ-opioid receptor antagonists, naltrexone and naloxone, were inspired by
that of the alkaloid oripavine (also present in P. somniferum), and are approved
by the FDA for the management of opioid dependence and overdose,
respectively [27]. A summary of select pharmacotherapeutics used for the
treatment of drug abuse, as well as SMNPs on which their structure is based,
and the SMNPs’ plant origin, is presented in Table 1.1. Indeed, plant metabolites’
structural scaffolds may possess the “blueprints” necessary to develop promising
drug leads for the treatment of drug abuse, including psychostimulant addiction.
Plants are an invaluable source of medicines and novel drug leads, and
plant’s repository of SMNPs arguably represents one of the most structurally
complex and diverse small molecule libraries in existence [14, 20, 28]. However
a question remains: why are plant SMNPs biologically active in humans? It would
be egocentric, and quite naïve to think that plants evolved molecules with
therapeutic effects for the sole purpose of curing human disease. A recent review
by Kennedy and Wightman (2012) addressing this topic provides compelling
evidence that natural selection arising from plant’s interaction with co-existing
organisms led to the evolution of SMNPs that are bioactive in humans [13, 14].
Given humans only came into existence relatively recently in evolutionary time,
their impact on the evolution of plant biosynthesis is relatively negligible [13, 14].
The major culprits accredited underlie the evolution of plant SMNPs having
bioactivity in the human CNS are herbivorous insects [13, 14]. Plants and
herbivorous insects have co-existed for 400 million years [13]. Furthermore,
plant-insect interactions occur at a greater frequency owing to the tremendous
number insect species [13]. To date, insect species represent greater than half of
the multicellular species identified on earth, and nearly half of existing insect
species are herbivorous [13]. Additionally, the collective biomass of insects
outweighs that of vertebrates by a factor of 10 to 1 [13]. The co-existence of
plants and insects necessitated the evolution of defense strategies ensuring the
continuing existence of plants, despite threats imposed by herbivorous insects
[13, 14]. Since plants are sessile, their primary means of deterring herbivorous
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insects is the synthesis of chemical defenses in the form of secondary
metabolites [13, 14]. Plant secondary metabolites are not required for plants’
primary metabolism, and thus evolved enabling plants to respond and react to
changes in their local environment [13, 14]. Well-known examples of defensive
metabolites synthesized by plants include nicotine and cocaine [13, 14, 29, 30].
Waxy substances exuded by plant cells immobilize and/or suffocate herbivorous
insects, whereas chemical attractants are released from plants attracting
predators of insects that pose as threats [13]. In order to address the genesis of
plant SMNPs bioactive in the human CNS, a closer examination of insect
neurotransmission and similarity shared between key proteins present in the
human and insect CNS is required.
The major excitatory neurotransmitter in the insect CNS is acetylcholine,
which activates nicotinic acetylcholine receptors (nicAchR) [14]. Given the
importance of cholinergic neurotransmission in insects, the disruption of signaling
at insect nicAchRs presents an excellent target for plant chemical defenses [13,
14]. A variety of nicAchR ligands have been identified in plants, which are
primarily believed to function as natural insecticides, including nicotine and
cytisine [13, 14, 29]. For example, ingestion of nicotine by insects produces
aversive stimuli, paralysis, and/or death, via activation of insect nicAchRs [14,
29]. Acetylcholine is also a prominent excitatory neurotransmitter in the human
CNS, which influences the activity of numerous neurotransmitter systems via the
modulation of nicAchRs [31, 32]. NicAchRs present in the human and insect CNS
share structural homology due to their common evolutionary ancestry [13, 14].
Courtesy of their shared homology, nicAchR ligands synthesized by plants
display bioactivity across Phyla, modulating the activity of nicAchRs present in
the insect CNS, and their human counterparts [13, 14]. This holds true for a
variety

of

proteins

essential

for

regulation

of

human

and

insect

neurotransmission, including the DAT [33, 34].
In contrast to humans, insect DAergic neurotransmission is strongly
implicated with aversive learning [13, 35]. Increased DAergic neurotransmission
in insects has also been reported to signal satiety, attenuate negative geotaxis,
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and even induce convulsions and death in insects [36, 37]. Any of the
aforementioned affects, which can be elicited by cocaine, would deter insects
from

feeding

on

plants

containing

metabolites

that

augment

DAergic

neurotransmission. Thus, inhibition of the DAT represents a viable mechanism to
increase DAergic tone in the insect CNS, thereby preventing insect herbivory [30,
35-37]. As such, natural selection would be predicted to favor the biosynthesis of
metabolites that function as DAT inhibitors, given plants possessing such
compounds would have a survival advantage increasing their evolutionary fitness
[3, 4, 13]. Genes encoding the biosynthetic machinery responsible for the
synthesis of DAT inhibitors would thereby be retained by the forces of natural
selection, and further optimized over time by the forces of evolution [3, 4, 13].
Cocaine, a well-known example of a DAT inhibitor synthesized by the plant
Erythroxylum coca, functions as a natural insecticide [30].
1.3. Psychostimulant drug abuse
Psychostimulant drug abuse is a major public health concern in the United
States and around the world. The abuse of psychostimulants, such as cocaine
and methamphetamine, is associated with a significant socioeconomic burden
arising from healthcare costs, crime, and lost productivity [38, 39]. Detrimental
health effects caused by short-term psychostimulant abuse include hypertension,
tachycardia, cardiac arrhythmia, heart attack, stroke, convulsions, paranoia,
and/or psychosis [38, 39]. Their long-term use can potentially lead to psychosis,
mood disturbances, and/or infection potentially causing death due to bowel
ischemia, amongst other adverse health effects [38, 39]. In 2012, 1.2 million
individuals reported the use of methamphetamine alone in the past year
(National Survey on Drug Use and Health), with an estimated $23.4 billion cost
associated with its abuse in 2005 (RAND report, 2009) [38, 39]. Despite years of
research and substantial effort on the behalf of scientific investigators, at present
there is no pharmacotherapy approved by the United States Food and Drug
Administration (FDA) for the treatment of psychostimulant addiction, a significant
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unmet medical need [23-25, 40-42]. Multiple lines of evidence indicate the
reinforcing effects of cocaine and methamphetamine result from augmentation of
dopaminergic (DAergic) neurotransmission in the mesocorticolimbic DAergic
pathway [43-45]. Increased DAergic tone in the nucleus accumbens, in particular,
is

highly

implicated

in

mediating

the

positive

rewarding

effects

of

psychostimulants and other drugs of abuse [43-45].
The dopamine transporter (DAT) is the primary regulator of DAergic tone
in the striatum and nucleus accumbens, and is recognized as a key molecular
target of cocaine and methamphetamine [33, 43, 46-55]. Cocaine is an inhibitor
of the DAT, and enhances vesicular DA release [23, 45]. Methamphetamine is a
substrate of the DAT, which competitively inhibits DA reuptake, and also
redistributes vesicular DA leading to an increase in cytosolic DA [23, 25, 45].
Subsequently, cytosolic DA is released via methamphetamine-induced reversal
of DAT function [23, 25, 45]. As such, the use of both psychostimulants has a
common outcome: increased DAergic tone in brain regions densely innervated
by DAergic neurons, including the nucleus accumbens [23, 25, 43-45, 56].
Multiple lines of evidence indicate that modulation of DAT function
underlies the locomotor and hedonic effects of cocaine and methamphetamine
[43-45, 57, 58]. In homozygous DAT knockout mice, cocaine and amphetamine
fail to increase locomotor activity above baseline, and do not produce stereotypy
[43]. In homozygous mutant knock-in mice expressing a cocaine-insensitive DAT
(CI-DAT), cocaine failed to produce locomotor stimulation, conditioned place
preference, or an increase in DA levels in the NAcc, yet these effects of
amphetamine are preserved supporting the notion that the interaction of the two
psychostimulants with the DAT are distinct [57]. Of note, cocaine actually
produced conditioned place aversion and suppressed locomotor activity in CIDAT mice [57, 58]. Expression of the wild-type DAT (wtDAT) in adult CI-DAT
mice using adeno-associated viral expression vectors restored cocaine’s ability
to produce psychomotor stimulation and reward [58]. Furthermore, in animal
models of cocaine abuse, “atypical” DAT inhibitors (e.g. JHW-007) reduce
psychostimulant self-administration and display low abuse liability (see section
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1.4 for further details on “atypical” DAT inhibitors) [59, 60]. These observations
led to a renewed interest in the development of DAT ligands capable of inducing
a conformational change in the DAT that attenuates the reinforcing effects of
cocaine [59-62]. DAT inhibitors with the aforementioned profile represent
potentially novel pharmacotherapies for the treatment of cocaine addiction [59].
“Atypical” DAT inhibitors (e.g. JHW-007) also reduce self-administration of
methamphetamine in animal models [59]. Therefore, DAT ligands capable of
antagonizing the hedonic effects of psychostimulants, which possess minimal
abuse potential and acceptable side effect profiles, represent potential novel
pharmacotherapies for the treatment of psychostimulant abuse [63]. Clinical
utilization of pharmacotherapeutic agents with the latter profile would be
analogous to the treatment of opioid dependence with methadone, thus a
delayed rate of onset and a prolonged duration of action would be desirable [42,
59-61, 64, 65]. DAT ligands with the aforementioned profile would not necessarily
have to be devoid of reinforcing effects, as this would likely increase compliance
and reduce attrition rates [41, 65, 66].
The efficacy of a variety of treatment modalities has been evaluated in an
effort to develop effective approaches to combat psychostimulant addiction.
These include cognitive behavioral therapy, pharmacotherapeutic intervention,
and combinations thereof, none of which has been demonstrated as an
efficacious approach to increase abstinence in individuals addicted to cocaine or
methamphetamine [23]. However, of the various pharmacotherapeutic agents
examined in human trials, DAT inhibitors have arguably demonstrated the most
success.
Modafinil, an “atypical” DAT inhibitor that also enhances glutamatergic
neurotransmission, reduced the subjective hedonic effects of cocaine in naïve
human subjects [23, 24, 64, 67]. In cocaine-dependent individuals, modafinil
decreased cocaine intake, and improved the efficacy of cognitive behavioral
therapy [23-25]. Bupropion is a DA reuptake inhibitor that was reported to
decrease the subjective effects of methamphetamine and reduced drug craving
in a Phase I clinical trial [23-25, 41, 67]. In a Phase II clinical study, bupropion
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effectively increased abstinence rates in low-to-moderate methamphetamine
abusers, but was not efficacious in heavy users [23-25, 41, 67]. Methylphenidate
is a selective DAT inhibitor commonly used to treat attention-deficit/hyperactivity
disorder, which has been reported as an effective treatment for cocaine and
amphetamine addiction [23, 25, 40, 68]. Despite these observations, none of the
aforementioned medications has displayed the level of efficacy necessary to
merit approval by the FDA for the indication of treating psychostimulant addiction
[23-25, 40-42].
Numerous structural analogues of cocaine and benztropine have been
synthesized and investigated for their ability to decrease cocaine and/or
methamphetamine self-administration [59, 61, 69]. The “atypical” DAT inhibitor
JHW-007 is a structural congener of benztropine that reduces cocaine and
methamphetamine self-administration in animal models of psychostimulant
abuse [59, 67]. The cocaine analogue RTI-336 antagonized cocaine intake, as
well, although the dose of RTI-336 required to reduce cocaine self-administration
reduced water and food intake [63]. In contrast, JHW-007’s ability to decrease
psychostimulant self-administration occurred at doses that did not significantly
reduce the seeking of natural rewards (e.g. food intake) [59, 70]. A variety of
phenylpiperazine derivatives were also synthesized in an attempt to develop DAT
ligands capable of antagonizing the hedonic effects of cocaine and/or
amphetamine [61, 69]. GBR12909 was perhaps one of the most promising, and
thoroughly investigated phenylpiperazines [56, 59, 61, 63]. In animal models of
psychostimulant abuse, GBR12909 reduced self-administration of cocaine and
methamphetamine at doses that had little effect on the seeking of natural
rewards [42, 56, 59, 61, 63, 66]. Although each of the these DAT inhibitors
demonstrated promise in preclinical models of psychostimulant abuse, their
development was halted due to the realization of undesirable effects unveiled in
latter studies, as described below.
One of the most commonly encountered problems limiting the
development of DAT inhibitors for the treatment of psychostimulant abuse was
their potential abuse liability. GBR12909 and RTI-336 readily are self-
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administered by non-human primates, and produce discriminative stimulus
effects similar to those observed for cocaine [59, 65, 66]. Furthermore,
GBR12909 prolonged the QT interval, which increases the risk of potentially fatal
ventricular arrhythmia [59, 63]. In a Phase I clinical study GBR12909 produced
QT interval prolongation in 5 out of 5 human subjects, leading to the termination
of the clinical trial [63]. This effect of GBR12909 arose due to the inhibition of the
hERG channel [59]. Given ventricular arrhythmia is associated with hERG
inhibition, binding and inhibitory activity at this channel has received increased
attention by drug discovery programs [71]. Given both 4-chlorobenztropine and
4,4-dichlorobenztropine bind the hERG channel, molecules structurally related to
these compounds (e.g. JHW-007) are also likely to interact with the ion channel
[72]. As such, a deviation from the structural scaffolds commonly utilized to
synthesize DAT inhibitors may be necessary to identify and develop DAT
inhibitors for the treatment of psychostimulant abuse, which are both effective
and lack potentially fatal adverse effects.
1.4. The dopamine transporter
The DAT is the primary regulator of extracellular DAergic tone, and is a
member of the neurotransmitter sodium symporter (NSS) superfamily [33, 43, 4655]. NSSs couple the energetically unfavorable “uphill” (up concentration
gradient) movement of their respective substrate/s to the “downhill” (down
concentration gradient) movement of Na+ to drive substrate translocation [33, 47,
48, 50-52, 54, 55, 73]. As such, NSS transporters are electrochemically-coupled
secondary active transporters [33, 47, 54, 55]. Members of the NSS superfamily
(the SLC6 gene family) include transporters for dopamine, norepinephrine (NET),
serotonin (SERT), glycine (GlyT1 and GlyT2), and gamma-aminobutyric acid
(GAT1-4) [33, 48, 49, 51, 52, 54, 73].
Jardetzky proposed one of the first mechanistic models for secondary
active transporters [54]. This model hypothesized that secondary active
transporters must meet three general criteria to have the capacity to translocate
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substrate: 1) the transporter much have a central binding cavity at it’s core of
sufficient and appropriate structure to enable binding interaction between the
transporter and it’s substrate/s, 2) the transporter must be capable of adopting at
least

two

conformational

states,

an

extracellular-facing

(outward-facing)

conformation and an intracellular facing (inward-facing) conformation, and 3) the
extracellular and intracellular facing conformations of the transporter must have
differing affinities for substrate/s, the extracellular facing conformation having
higher binding affinity than the intracellular facing conformation [54]. Based on
this model, the outward-facing conformation of the transporter initially binds
extracellular substrate at it’s core, a conformational change occurs upon binding
substrate

shifting

the

transporter

to

a

substrate-bound

inward-facing

conformation, then substrate dissociates from transporter to the intracellular
environment due to decreased binding affinity for substrate associated with the
transition to the inward-facing conformation [54]. The release of substrate to the
intracellular environment then triggers a shift back to the outward-facing
conformation [54]. Indeed, this proposed mechanism was quite close to the
current theoretical conformational states that the DAT adopts throughout its
translocation cycle. At present, there are five proposed conformational states of
the transporter which occur in the following stepwise fashion: 1) Na+ and Cl- bind
to the transporter stabilizing the outward-facing conformation priming the
transporter for DA binding, 2) DA binds to the outward facing conformation
promoting a transition to, 3) the occluded conformation in which the transporter is
closed to both the extracellular and intracellular milieu with substrate and
accompanying ions sheltered in its central core, 4) a transition to the inwardfacing conformation and subsequent dissociation of substrate and bound ions
occurs, and then 5) the transporter adopts an inward-facing ligand-free
conformation [54]. The low intracellular concentrations of Na+ and Cl- favors their
dissociation, and that of an accompanying DA molecule, after which the outward
facing conformation is promoting due to high extracellular Na+ and Clconcentrations, which stabilize the outward-facing conformation of the DAT [54].
Thus, the transporter adopts the outward-facing conformation, after which Na+
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and Cl- associate with their respective binding sites priming the DAT to accept
another DA molecule [54].
Translocation of DA is accompanied by the import of two Na+ ions and one
Cl- ion [33, 47, 52, 54, 55, 74]. As such, translocation of DA by DAT is associated
with the net import of two positive charges [33, 47, 52, 54, 55]. The electrogenic
nature of the DAT led to the future realization that DAT influences membrane
potential and neuronal excitability [47, 55, 74]. In addition to inward currents
associated with the translocation of DA, DAT also functions in a channel-like
mode [33, 47, 74]. A non-selective ion current is potentiated by arachidonic acid
(AA), which is inhibited by pretreatment with cocaine [33, 74]. AA also decreases
the rate of DA uptake, as has been observed for other polyunsaturated fatty
acids (PUFAs), including docosahexaenoic acid, linoleic acid, and oleic acid [74,
75]. A higher the degree of unsaturation leads to an increased DAT inhibitory
potency in such PUFAs [75].
As mentioned above, the DAT is the primary regulator of extracellular
DAergic tone [33, 43, 46-54]. A number of studies have been performed, all of
which support the DAT as the key mechanism governing extracellular DA
concentration. In striatal slices from DAT knockout mice, DA’s extracellular
lifetime, monitored using fast-scanning cyclic voltammetry, increased ~100-fold,
in which case diffusion would account for the “disappearance” of DA [43].
Furthermore, in in vivo studies measuring extracellular DA clearance in the rat
striatum or nucleus accumbens using Nafion coated carbon-fiber microelectrodes
coupled to high-speed chronoamperometry, selective DAT inhibitors, but not
select selective serotonin or norepinephrine transporter (SERT and NET,
respectively) inhibitors, significantly prolonged the extracellular lifetime of DA
[46]. Additionally, after producing lesions with the selective DAergic neurotoxin 6OHDA, thereby destroying DAergic terminals expressing the DAT, DA clearance
was again due to diffusion alone [46]. These studies strongly support the role of
the DAT as the primary regulator of extracellular DAergic tone, particularly in
regions receiving dense DAergic innervation, such as the dorsal striatum and
nucleus accumbens [33, 43, 46-55].
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The DAT is a glycoprotein comprised of 12 transmembrane-spanning
domains, with both its amino- and carboxyl- termini located on the intracellular
face of the membrane, modification of which influences DAT function [48, 51, 52,
55]. The importance of DAT is further illustrated by the complexity of its
regulatory mechanisms. DAT substrates and inhibitors are capable of regulating
DAT function [33, 47, 48, 51, 55]. Brief exposure (~30 seconds) to DAT
substrates, such as DA or amphetamine, causes a transient increase in
transporter expression, followed by a downregulation of DAT function after
prolonged exposure intervals (~1 hour) [48]. DAT inhibitors, such as cocaine,
cause an increase in DAT expression [33, 47, 48, 51, 55]. The effects of
substrates are accompanied by a decrease in Vmax, whereas the KD is
unaffected, indicating trafficking of the transporter away from the plasma
membrane is responsible for substrate-induced downregulation of the DAT [47,
48]. These effects are believed to occur, in part, via enzymatic post-translational
modifications to the transporter (e.g. phosphorylation by kinases) [47, 48, 55].
Activation of protein kinase C (PKC) by phorbol esters causes a downregulation
of DAT expression, which is associated with endocytic trafficking of the
transporter via a clathrin-dependent mechanism [47, 48, 55]. Amphetamineinduced internalization of the DAT is prevented by PKC inhibition, supporting the
notion that substrates decrease DAT activity via internalizing the transporter [47,
48, 55].
The tertiary structure of the DAT is also an important determinant of DAT
protein expression [33, 48, 49, 51, 55, 73, 76]. Mutations to residues that prevent
the oligomerization of NSSs prevent trafficking of the transporter to the plasma
membrane [33, 48, 49, 51, 55, 73]. Amphetamine also causes a shift, disrupting
the association of DAT oligomers with a subsequent increase in monomeric DAT,
which is believed to contribute to amphetamine-induced internalization [48, 49,
76].
Numerous proteins influence DAT function. As outlined above, PKC
activation leads to increased phosphorylation of DAT and an accompanying
decrease in DAT surface expression [33, 47, 48, 51-53, 55, 77]. A number of
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other kinases influence DAT activity, including phosphatidylinositol-3-kinase
(PI3K), protein tyrosine kinase (PTK), and mitogen-activated kinase (MAPK)
families [33, 48, 51, 52, 55]. Activation of PI3K and MAPK respective signaling
pathways leads to an increase in DAT activity [33, 48, 51, 52, 55]. Activation of
TrkB, a PTK, by BDNF leads to increased DAT activity, as well [48, 51].
Increased activity of the DAT by PI3K, MAPK, and TrkB is mediated by an
increase in DAT surface expression [33, 48, 51, 52, 55]. Furthermore, activation
of the presynaptic DA D2 receptor, a G protein coupled receptor, increases DAT
activity [33, 47, 48, 51, 52, 78]. The intricacy of the regulatory mechanisms that
influence DAT function highlight’s the importance of the transporter in controlling
DAergic neurotransmission.
“Atypical” DAT inhibitors are another class of DAT ligands that alter the
activity of the transporter, and are of particular interest in the development of
treatments for psychostimulant abuse [60, 67]. In contrast to traditional DAT
inhibitors, such as cocaine and methylphenidate, “atypical” DAT inhibitors are not
associated with significant abuse potential despite inhibiting DA reuptake [79].
“Atypical” DAT inhibitors preferentially bind to the inward-facing conformation of
the DAT transporter, whereas traditional DAT inhibitors prefer the outward-facing
DAT [79]. Examples of “atypical” DAT inhibitors include GBR-12909, JHW-007,
and modafinil, all of which decrease cocaine self-administration in animal models
at doses that minimally influence seeking of natural rewards (e.g. food intake)
[23, 60]. Binding studies with traditional and “atypical” DAT inhibitors were
performed with mutant variants of the human DAT (hDAT) whose conformational
equilibrium was shifted favoring either the inward- or outward-facing conformer
[79]. In these studies, as indicated above, traditional DAT inhibitors interacted
more favorably with outward-facing mutant variants, while “atypical” DAT
inhibitors

preferentially

bound

the

inward-facing

DAT

[79].

As

such,

“atypical” DAT ligands that bind DAT stabilizing a conformation that minimizes
cocaine’s ability to influence the transporter, while minimally affecting normal
transport function, could serve as novel leads to develop treatments for
psychostimulant abuse [61, 62]. Considering “atypical” DAT inhibitors have been
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demonstrated to decrease self-administration of both psychostimulants in animal
models, this holds true for both cocaine and methamphetamine abuse [59, 60].
1.5. Target-directed biosynthetic evolution
Plant-derived medicines have been used to treat human disease for
millennia. Given plant secondary metabolites evolved via natural selection, it
should be possible to design artificial selection pressures to redirect the evolution
of a plant biosynthesis [13, 14]. For drug discovery, selection pressures should
favor the survival of genetically optimized medicinal plants with increased yields
therapeutically valuable SMNPs and/or novel metabolites with a desired/required
bioactivity.

Note

that

plant

secondary

metabolites

evolved

to

target

macromolecules present in organisms other than humans, given species of the
Genus Homo have only come into existence relatively recently in evolutionary
time [13, 14]. Therefore, human’s impact on the evolution of plant secondary
metabolism is negligible (a limited number of exceptions exist, such as increased
yields of nicotine in tobacco as the result of human cultivation) [10, 13].
Bioactivity of plant metabolites in humans arises due to homology that exists
between human macromolecules and those present in other organisms with
which plant secondary metabolites were intended to target and elicit a biological
response [13]. Thus, leads from natural sources often require structural
optimization by medicinal chemists to fine-tune their pharmacologic profile
making them suitable for use in humans [10]. Our approach is designed to
redirect the evolution of plants with medicinal value favoring the biosynthesis of
metabolites meant to interact with human macromolecules. This could potentially
reduce and/or eliminate the need for further optimization of novel chemical
entities to tailor their activity to human systems.
To provide proof-of-concept for this innovative approach to plant-based
drug discovery, coined target-directed biosynthesis, the human dopamine
transporter (hDAT) was functionally expressed in Lobelia cardinalis. L. cardinalis
contains the complex binitrogenous alkaloid lobinaline, which is a relatively low
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potency DAT inhibitor and cannot be synthesized in the laboratory. Although
tracer studies have shed light on the precursors for lobinaline biosynthesis in
planta, methods for the total synthesis of the alkaloid remain elusive [80].
Additionally, the yield of lobinaline from L. cardinalis plant material is low and
purification via recrystallization is particularly challenging [81]. Thus, L. cardinalis
was an ideal candidate species for proof-of-concept studies utilizing targetdirected biosynthesis. Transgenic L. cardinalis primary hairy roots expressing the
hDAT (hDAT-1°HRs) display increased susceptibility to dopaminergic (DAergic)
neurotoxins

that

are

DAT

substrates,

including

1-methyl-1,2,3,6-

tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) [82, 83]. The
selective DAT inhibitor GBR12909 attenuates MPTP-induced cytotoxicity in
hDAT-1°HRs [84-88]. L. cardinalis transgenic plant cells expressing the hDAT
were activation tagged, generating transgenic gain-of-function plant cells
expressing the hDAT. These cells were generated on selection medium
containing 1-methly-4-phenylpyridinium (MPP+), a cytotoxic DAT substrate, such
that selection should favor the survival of cells with beneficial gain-of-function
mutations enabling MPP+-resistance [89, 90]. MPP+ is a selective DAergic
neurotoxin used to model Parkinson’s disease (PD), which is accumulated in
DAergic neurons by the DAT, causing subsequent impairment of mitochondrial
function and ultimately neuronal death [89-92].
To date, 120 gain-of-function mutants functionally expressing the hDAT
that are resistant to MPP+ have been generated. Theoretically, these mutants
may be resistant to MPP+ due to gain-of function mutations causing: 1) increased
synthesis of lobinaline and/or other more potent DAT inhibitors preventing MPP+
accumulation and subsequent toxicity, 2) synthesis of cytoprotective metabolites,
and/or 3) activation of cytoprotective genes that prevent MPP+ toxicity (see
Figure 1.1). Analysis of DAT inhibitory activity of extracts from MPP+-resistant
gain-of-function mutants expressing the hDAT revealed that the population was
greatly enriched with individuals whose extracts inhibit DAT much more potently
than extracts from the wild-type plant, or controls. Chemical analysis by gas
chromatography-mass spectrometry (GC-MS) led to the identification of mutants
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that synthesize increased yields and/or novel metabolites undetectable in the
wild-type plant or controls. Furthermore, individuals were identified which had
increased yields of squalene and/or linoleic acid, a natural products that
attenuate MPP+-induced neurodegeneration in models of PD [93, 94]. DAT
inhibitors generated in the current study may hold therapeutic value in the
treatment of DAergic neurodegeneration, psychostimulant abuse, nicotine use
disorders, ADHD/ADD, depression, and/or other neuropsychiatric disorders [54,
95-104]. Mitochondrial protectants and/or other molecules that prevent
intracellular mechanisms of MPP+ toxicity are of potential therapeutic value in the
treatment of neurodegenerative disorders in which mitochondrial dysfunction is
implicated in the pathogenesis of disease, including PD [92, 105-126]. This novel
approach to re-direct evolution of plant biosynthetic machinery has the potential
to revitalize plant-based drug discovery, and feed the pipelines of many drug
discovery programs.

Copyright © Dustin Paul Brown 2015
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Table 1.1.
FDA-approved pharmacotherapeutics inspired by plant SMNPs used for the
treatment of drug abuse
Medication

Clinical Application

Plant
SMNP

Plant Source#
(common name)

Nicotine*

Smoking cessation1, 2

--------

Nicotiana tabacum
(Tobacco)

Cytisine*

Smoking cessation1, 2

--------

Cytisus laborinum
(Golden Rain acacia)

Varenicline

Smoking cessation1, 2, 3

Cytisine

Cytisus laborinum
(Golden Rain acacia)

Bupropion

Smoking cessation4, 5, 6, 7

Cathinone

Catha edulis
(Khat)

Buprenorphine

Opioid dependence8

Thebaine

Papaver somniferum
(Poppy)

Methadone

Opioid dependence1

Naltrexone

Opioid dependence8
Alcohol use disorder8

Oripavine

Papaver somniferum
(Poppy)

Naloxone

Opioid overdose8

Oripavine

Papaver somniferum
(Poppy)

*Molecule is a naturally occurring plant SMNP
#
Plant SMNP occurs naturally in other plant species
1
Salim et al. (2008) [20]
2
Leaviss et al. (2014) [21]
3
Daly (2005) [22]
4
Vocci et al. (2007) [23]
5
Montoya et al. (2008) [24]
6
Karila et al. (2010) [25]
7
Appendino et al. (2014) [26]
8
Hostzafi (2014) [27]
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Figure 1.1. Schematic of selection process. A) MPP+ is translocated to the
interior of DAergic neurons via DAT-mediated uptake. Inside the DAergic
terminal, MPP+ inhibits complex-I of the electron transport chain causing
excessive production of reactive oxygen species (ROS), which causes
cytotoxicity and ultimately cell death. B) The plant cell’s phenotype is made to
resemble that of DAergic neurons on a fundamental level: the hDAT is
expressed in transgenic plant cells rendering them vulnerable to MPP+. MPP+induced cytotoxicity theoretically ensues by the same/similar mechanism/s as
described in DAergic neurons. C) Activation tagging mutagenesis (ATM)
creates stable gain-of-function mutations randomly throughout plant genome
that should confer resistance to MPP+ via: 1) inducing increased biosynthesis of
DAT inhibitors (lobinaline and/or “novel” DAT inhibitors of greater potency)
preventing intracellular accumulation of MPP+ and ensuing cytotoxicity and/or
2) biosynthesis of metabolites that interfere with MPP+ toxicity intracellularly.
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Chapter 2

General methodology

2.1. Chemicals and Supplies
Methanol, hexane, chloroform, ethyl acetate, butanol, acetonitrile, (-)nicotine (NIC), methyllycaconitine (MLA) citrate salt hydrate, mecamylamine
(MEC) hydrochloride, nomifensine, (-)-lobeline hydrochloride, and 2,2-diphenyl-1picrylhydrazyl (DPPH) were purchased from Sigma Aldrich (St. Louis, MO, USA).
Streptomycin (10,000 µg/ml), penicillin (10,000 units/ml), fetal bovine serum
(FBS), and Dulbecco’s Modified Eagle Medium (DMEM) were purchased from
Life Technologies Corporation (Grand Island, NY, USA). Quercetin was
purchased from Chromadex (Irvine, CA, USA). [3H]-epibatidine (S.A. = 30
Ci/mmol), [3H]-cytisine (S.A. = 16 Ci/mmol), [3H]-MLA (S.A. = 60 Ci/mmol), [3H]GBR12935 (S.A. = 40 Ci/mmol),

45

CaCl2 (S.A. = 12.05 mCi/mg), and [3H]-DA

(S.A. = 60 Ci/mmol) were purchased from American Radiolabeled Chemicals,
Inc. (St. Louis, MO, USA). All other chemicals and materials were purchased
from Fisher Scientific (Pittsburgh, PA, USA), unless otherwise stated.
2.2. Animals
Adult, male Sprague-Dawley rats (200 – 250 g) purchased from Harlan
Laboratories (Indianapolis, IN, USA) were housed in cages in groups of 3 – 4 at
the Division of Laboratory Animal Resources at the University of Kentucky.
Animals had access to food and water ad libitum. All protocols for the handling,
care, and use of animals were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Kentucky and were performed in
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accordance with the National Institute of Health’s Guide for Care and Use of
Laboratory Animals.
2.3. Collection of Plant Material
Plant samples were collected as previously described by Littleton et al.
(2005) [15]. Briefly, plant samples were collected from field sites by a highly
qualified botanist. GPS coordinates were recorded for each accession. Samples
were snap-frozen with liquid nitrogen immediately after field collection, and
stored at -80°C prior to solvent extraction. Reference samples of each species
were deposited at the University of Kentucky Herbarium. Lobelia cardinalis was
grown at the University of Kentucky Spindletop Farm to obtain plant material in
bulk.
2.4. Aqueous plant extract library
A library of aqueous plant extracts was prepared as previously described
[15]. Briefly, snap-frozen plant samples collected from the field were removed
from storage at -80°C, immediately freeze-dried using a lyophilizer, and finely
powdered. Powdered plant material was extracted (100 mg/ml) by suspending
samples in aqueous solution (100% Milli-Q H2O) and placing them on a shaker
overnight. The following day, aqueous extracts were collected via vacuum
filtration, and freeze-dried using a lyophilizer. The resulting residue was resuspended in an appropriate volume of assay buffer to achieve a final
concentration of 100 mg/ml. When necessary, dimethylsulfoxide (DMSO) was
added (<0.05%) to promote solubility of samples in aqueous solution. The
resulting aqueous extracts were stored at -80°C prior to pharmacological
screening.
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2.5. HTPS: Differential smart screen
HTPS was conducted on a library of aqueous plant extracts prepared from
~1,000 species native to the Southeastern United States, completing the
screening of the library previously described by Littleton et al. (2005) [15]. HTPS
was performed using a Packard Multiprobe liquid handling system in a 96-well
plate format (350 µl well volume) as previously described, with minor
modifications [15, 127-129]. An innovative assay design, coined “differential
smart screening” (DSS), was employed to identify extracts that contained
nicAchR ligands with a pharmacological profile unlike that of nicotine [15]. Briefly,
pure compounds or plant extracts were prepared, and dissolved in a volume of
Krebs-Ringers buffer (120 mM NaCl, 3.9 mM KCl, 650 µM MgSO4, 510 µM
CaCl2, 190 µM NaHPO4, 100 µM pargyline, 2 mg/ml glucose, 0.2 mg/ml ascorbic
acid, 20 mM HEPES, pH 7.4, saturated with 95% O2/5% CO2) necessary to
prepare a 100 mg/ml stock solution (see section 2.4). Dilutions of the stock
solution were prepared for screening (1:10, 1:20, 1:50, 1:100, 1:200, 1:500,
1:1,000, 1:2,000). Samples were evaluated over this concentration range to
determine the dilution that effectively displaced 50% of [3H]-epibatidine (168 pM,
3 hour incubation period) from rat cortical membranes (ID50). [3H]-epibatidine is a
potent, high affinity nicAchR ligand with similar binding affinity at most nicAchRs
present in the mammalian CNS [130, 131]. Determination of a plant species’ ID50
enabled the identification of extracts containing nicAchR ligands, and provided a
“reference point” for subsequent binding studies [15]. Plant extracts that inhibited
[3H]-epibatidine binding were tested for their ability to displace [3H]-cytisine (1
nM, 1 hour incubation) and [3H]-MLA (2 nM, 2 hour incubation) at a concentration
equal to their ID50 for [3H]-epibatidine displacement. [3H]-cytisine and [3H]-MLA
displacement studies were performed in rat cortical and hippocampal
membranes, respectively. [3H]-cytisine is a β2-subtype selective ligand, and thus
will reflect mainly α4β2-nicAchR binding in the mammalian CNS, whereas [3H]MLA is α7-nicAchR selective ligand [22, 128, 132, 133]. The final protein
concentration of membrane preparations in HTPS assays was 150 µg/ml. After
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reaching equilibrium, membranes were harvested onto 96-well GF/B filtration
plates (PerkinElmer Inc., Waltham, MA, USA) and rapidly washed three times
with ice-cold 50 mM Tris-HCl buffer (pH 7.4). Filtration plates were allowed to dry
overnight before adding 35 µl of scintillation fluid (Microscint 20, Packard Inc.).
Plates were then kept in the dark for 2 hours, after which radioactivity was
measured using a Packard TopCount® NXT™ microplate scintillation counter.
Non-specific binding was measured in the presence of excess NIC (300 µM) and
total binding was measured in the presence of radioligand alone. Total specific
binding and specific binding in the presence of competitors was calculated by
subtracting non-specific binding. Specific binding in the presence of a competitor
was expressed as a percentage to total specific binding. Dividing the percentage
displacement of [3H]-cytisine by that of [3H]-MLA at a concentration equal to the
ID50 for [3H]-epibatidine displacement yields a “differential displacement ratio”
(DDR) indicative of nicAchR subtype selectivity. DDR values > 5 indicate the
plant extract contains metabolites selective for α4β2-nicAchRs, while DDR values
< 1 indicate the presence of metabolites selective for α7-nicAchR, as previously
described [14, 15]. Likewise, the DDR can also be used to identify plant extracts
containing metabolites with equipotent binding activity at α4β2- and α7-nicAchRs.
In theory, a DDR value of ~3 should indicate the presence of nicAchR ligands
with equipotent binding affinity at α4β2- and α7-nicAchRs. In support of this
hypothesis, anabasine, a nicAchR ligand with relatively equipotent binding affinity
at α4β2- and α7-nicAchRs (Ki = 65 and 58 nM, respectively), was previously
reported to have a DDR value of 4.16 [15, 22]. Similarly, aqueous extracts from
Nicotiana species with greater amounts of nicotine than anabasine produce DDR
values of > 5, whereas those having greater quantities of anabasine produce a
DDR value of ~3 (see Table 2.1 for comparison) [15, 134]. Therefore, plant
extracts that produced DDR values of ~3 were predicted to contain metabolites
with equipotent binding affinity at α4β2- and α7-nicAchRs, thus warranting further
investigation in the present study. Aqueous extracts from species of interest were
evaluated in vitro for their ability to activate nicAchRs and inhibit the DAT (see
sections 2.12 and 2.13). Plant species whose extracts displayed a combination of
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the aforementioned pharmacological activities (presence of a ligand with similar
binding affinity at α4β2- and α7-nicAchRs, ability to activate nicAchRs, and
inhibition of the DAT) were prioritized for further evaluation.
2.6. Fractionation of the L. cardinalis crude methanolic extract
Air-dried aerial portions of L. cardinalis were ground to a coarse powder,
and extracted with 9 volumes of methanol (3 volumes per extraction, 24 hours
per extraction). The methanolic extract obtained was dried under vacuum using a
rotary evaporator, resuspended in water, and partitioned with organic solvents of
increasing polarity in the order that follows: hexane, chloroform (CHCl3), ethyl
acetate, and butanol. Sodium sulfate was added to the organic fractions obtained
to remove any residual water, removed by vacuum filtration, and each organic
fraction was dried under vacuum. The remaining aqueous phase was freezedried using a lyophilizer. Fractions were resuspended in modified Krebs-Ringers
buffer (final concentration, 100 mg/ml) and assessed in the DSS (see section
2.5).

Additionally,

fractions

were

re-suspended

in

uptake

buffer

(final

concentration, 100 mg/ml) and assessed for their ability to inhibit DAT-mediated
[3H]-DA uptake in rat striatal synaptosomes (see section 2.13).
2.7. pHPLC sub-fractionation of the L. cardinalis CHCl3 fraction.
The CHCl3 fraction obtained from the L. cardinalis crude methanolic
extract was sub-fractionated via pHPLC using a Waters XBridge Prep C18 (5 µm
OBD, 19 x 150 mm) column attached to a Waters 600E Multisolvent Delivery
System coupled to a Waters 2998 Photodiode Array Detector and Waters 2767
Sample Manager, Injector, and Collector. The pHPLC instrument was operated
using Waters MassLynx Software (Version 4.1) and FractionLnyx Collection
Control Software (Version 4.1). The mobile phase consisted of a mixture of
Solvent A (100% Milli-Q water, pH 7.0) and Solvent B (100% acetonitrile, HPLC
grade). Separation was performed with the following gradient at a flow rate of 7
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ml/minute: initial conditions, 1% B in A; 0 – 6 minutes, linear gradient, 1 – 20% B
in A; 6 – 12 minutes, linear gradient, 20 – 40% B in A; 12 – 18 minutes, linear
gradient, 40 – 50% B in A; 18 – 24 minutes, linear gradient, 50 – 75% B in A; 24
– 30 minutes, linear gradient, 75 – 95% B in A; 30 – 35 minutes, linear gradient,
95 – 100% B in A; 35 – 43 minutes, isocratic gradient, 100% B. Sub-fractions
were dried, and then re-suspended in modified Krebs-Ringer’s buffer or uptake
buffer (333 µg/ml) for nicAchR binding studies and [3H]-DA uptake studies,
respectively (see section 2.13).
2.8. Isolation of lobinaline
The CHCl3 fraction was obtained from L. cardinalis, as described above.
Acid-base extraction was performed on the CHCl3 fraction to obtain lobinaline.
Briefly, 100 mg of the dried CHCl3 fraction was dissolved in 50 ml of CHCl3. The
solution was acidified with 1 M HCl (final pH, 2 – 3), shaken gently, and the
organic phase was discarded. The remaining aqueous phase was washed 2 – 3
times with CHCl3. The aqueous phase was subsequently basified with
ammonium hydroxide (final pH, 10 – 12), partitioned between CHCl3 and water,
and the resulting organic phase was collected. The basified aqueous layer was
extracted two additional times with CHCl3, and each of the organic phases
obtained from the basified aqueous phase were combined. Sodium sulfate was
added to the combined organic phases to remove any residual water, removed
by vacuum filtration, and the organic phase was dried under vacuum using a
rotary evaporator. Lobinaline obtained using this method was analyzed using gas
chromatographic-mass spectrometric (GC-MS) methods (see section 2.9).
2.9. GC-MS analysis
GC-MS analyses were performed using a Hewlett Packard 6890 Gas
Chromatogram interfaced to a Hewlett Packard 5973 Series Mass Selective
Detector, an Agilent Technologies 7683 Series Injector, and a Hewlett Packard
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7683 Series Autosampler. ChemStation Software (Version 1.02.06) and the
Wiley Spectral Database (Version 4.0) were used for instrument control, data
analysis, and structural elucidation. Separation was performed on a HP-5MS
column ((5%-phenyl)-methylpolysiloxane; 30.0 m x 320 µm x 0.25 µm). Ultra-high
purity helium (flow rate of 1.2 ml/minute) served as the carrier gas. Sample
volumes of 1 µl were injected in split mode (split ratio, 10.0:1; split flow 12.3
ml/minute) at an inlet pressure of 1.60 psi. The inlet temperature was held at
250°C. The oven was operated using the following parameters: initial
temperature, 80°C; 80°C, 2 minute hold; 10°C/minute to 160°C, 1 minute hold;
60°C/minute to 275°C, 12 minute hold; 60°C/min to 60°C, 0 minute hold; total
runtime, 28.50 minutes. The transfer line temperature was held at 280°C. The L.
cardinalis CHCl3 pHPLC sub-fraction of interest (based on its DDR value and
DAT inhibitory activity) was analyzed via GC-MS to identify the most abundant
constituent/s present. Lobinaline isolated from crude plant material was injected
at 2 mg/ml, two runs per sample. Purity of the alkaloid was determined by
integrating the area under the curve (AUC) of lobinaline’s chromatographic peak
(GC-MS run in TIC mode). The identity of the alkaloid was confirmed based on
previously reported MS fragmentation data for lobinaline [135].
2.10. [3H]-Epibatidine, [3H]-cytisine, and [3H]-MLA binding
Radioligand displacement studies with pure compounds were performed
using methods previously described [136]. Briefly, adult male Sprague-Dawley
(200 – 250 g) rats were anesthetized with CO2 and decapitated. Hippocampal
and cortical tissues were rapidly dissected, placed in 10 volumes of ice-cold
sucrose buffer (0.32 M sucrose, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl
fluoride, 0.01% w/v sodium azide, pH 7.4), and homogenized in a glass
homogenization tube with a Teflon pestle. The homogenate was centrifuged at
1,000 x g for 10 minutes at 4°C, and the supernatant was placed on ice. The
pellet was re-suspended in sucrose buffer, and centrifuged again at 1,000 x g for
10 minutes at 4°C. The two supernatants were combined and the pellet was
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discarded. The combined supernatants were centrifuged at 50,000 x g for 10
minutes at 4°C. The resulting supernatant was discarded, and the pellet was
washed twice with assay buffer (50 mM Tris-HCl, 144 mM NaCl, 1.5 mM KCl, 2
mM CaCl2, 1 mM MgSO4, 20 mM HEPES, pH 7.4). The total protein content was
measured using the bicinchoninic acid kit (Sigma Aldrich). The final protein
concentration was adjusted to 3 mg/ml with assay buffer, and membranes were
stored at -80°C prior to further experimentation.
One the day on which competition binding studies were performed,
membrane preparations were removed from storage at -80°C and thawed on ice.
Lobinaline (final concentration, 3.4 mM – 3.4 nM) was dissolved in assay buffer.
DMSO (< 0.1%) was added to promote solubility. Solutions containing lobinaline
were mixed with membrane (final protein concentration, 1 mg/ml) and radioligand
(168 pM [3H]-epibatidine, 3 hour incubation; 2 nM [3H]-cytisine, 2 hour incubation;
2 nM [3H]-MLA, 2 hour incubation) in individual wells in a 96-well plate format.
Experiments were performed at room temperature. After reaching equilibrium (2
– 3 hours), membranes were harvested onto 96-well GF/B filter plates
(PerkinElmer Inc., Waltham, MA, USA) by vacuum filtration, and rapidly washed
three times with ice-cold 50 mM Tris-HCl buffer (pH 7.4). Filter plates were
allowed to dry overnight. The following day, 35 µl of scintillation fluid was added
to each well (Mircoscint 20, Packard Inc.) and plates were placed in the dark for
two hours. Afterward, radioactivity was measured by scintillation counting (2
minutes per well) using a Packard TopCount® NXT™ microplate scintillation
counter. In each plate, non-specific binding was measured in the presence of
excess NIC (final concentration, 300 µM) and total binding was measured with
radioligand alone. Total specific binding and specific binding in the presence of
lobinaline was calculated by subtracting non-specific binding. Specific binding in
the presence of lobinaline was expressed as a percentage of total specific
binding. Binding studies with pHPLC sub-fractions were conducted with
essentially the same methods with the exception that only [3H]-MLA binding was
performed, whereas the displacement of all three nicAchR ligands was
characterized for lobinaline. The CHCl3 sub-fraction that was the most effective at
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displacing [3H]-MLA was analyzed via GC-MS (see section 2.9) to determine the
major constituent/s present.
2.11. [3H]-GBR12935 binding
Competition binding studies were conducted using previously described
methods with minor modifications [84, 86, 137]. Membranes were prepared as
described (see section 2.10) with the exception that striatal tissue was collected,
homogenized in ice-cold homogenization buffer (120 mM NaCl, 50 mM Tris-HCl,
pH = 7.4), centrifuged at 25,000 x g for 20 minutes at 4°C, then washed thrice
with assay buffer (120 mM NaCl, 50 mM Tris-HCl, 0.01% FBS, pH 7.4). Each
wash was performed by re-suspending the pellet 10 volumes of assay buffer
followed by centrifugation at 25,000 x g for 20 minutes at 4°C. Total protein
content was measured using the bicinchoninic acid kit (Sigma Aldrich). The final
protein concentration was adjusted to 3 mg/ml with assay buffer. Striatal
membranes were stored at -80°C prior to further experimentation.
One the day binding experiments were performed, membranes were
removed from storage at -80°C and thawed on ice. Lobinaline (final
concentration, 0.1 nM – 1.0 mM) was dissolved in assay buffer. DMSO (< 0.1%)
was added to promote solubility. Solutions containing lobinaline were mixed with
membrane (final protein concentration, 1 mg/ml) and incubated for 15 minutes
prior to the addition of radioligand (1 nM [3H]-GBR12935, 1 hour incubation) in a
96-well plate format. Experiments were performed at room temperature. After
reaching equilibrium, membranes were harvested onto 96-well GF/B filter plates
(PerkinElmer Inc., Waltham, MA, USA) by vacuum filtration, and rapidly washed
three times with ice-cold 50 mM Tris-HCl buffer (pH 7.4). Filter plates were
pretreated with a solution of 0.1% polyethyleneimine 1 hour prior to harvesting
membranes to reduce non-specific binding. Filter plates were allowed to dry
overnight. The following day, 35 µl of scintillation fluid (Microscint 20, Packard
Inc.) was added to each well and plates were placed in the dark for two hours.
Afterward, radioactivity was measured by scintillation counting (2 minutes per
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well) using a Packard TopCount® NXT™ microplate scintillation counter. In each
plate, non-specific binding was measured in the presence of excess GBR12909
(final concentration, 10 µM) and total binding was measured with radioligand
alone. Total specific binding and specific binding in the presence of lobinaline
was calculated by subtracting non-specific binding. Specific binding in the
presence of lobinaline was expressed as a percentage of total specific binding.
2.12. 45Ca2+ entry in SH-SY5Y cells
Cell-based assays evaluating functional activity of pure compounds or
extracts at nicAchRs were conducted using previously described methods with
modifications [138-140]. SH-SY5Y human neuroblastoma cells were sub-cultured
in

polylysine

coated

petri

dishes

containing

culture

medium

(DMEM

supplemented with 10% FBS, 1 mM glutamine, 50 units/ml penicillin, and 50
µg/ml streptomycin) and maintained in an incubator at 37°C in a humidified
atmosphere (95% O2/5% CO2). The day prior to performing

45

Ca2+ entry studies,

SH-SY5Y cells were plated onto 24-well polylysine coated plates containing 300
µl of culture medium at a seeding density of 20,000 cells/well and placed back in
the incubator. After allowing 24 hours for cells to adhere, culture medium was
aspirated and replaced with 300 µl of assay buffer (130 mM NaCl, 5 mM KCl, 6
mM glucose, 20 mM HEPES, and 1 mM CaCl2, pH 7.4). Pure compounds or
extracts were dissolved in assay buffer to allow direct addition to wells. DMSO
(final concentration, < 0.1%) was added to promote solubility of extracts or
compounds. Control and treatment groups were performed in quadruplicate on
each plate. SH-SY5Y cells were pretreated with vehicle, pure compounds, and/or
extracts for 1 minute prior to the addition of

45

Ca2+ (~5 µCi).

45

Ca2+ entry was

terminated by aspirating assay buffer, and then washing cells thrice with 1 ml of
ice-cold assay buffer. Cells were lysed overnight by the addition 0.5 M NaOH
(0.5 ml/well). Lysates were pooled for each group, and two 100 µl aliquots were
counted per group. Radioactivity was measured by scintillation counting using a
Packard Tri-Carb Liquid Scintillation Counter (Gaithersberg, MD, USA). Basal
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45

Ca2+ entry was designated as that observed in vehicle treated cells.

45

Ca2+

entry in treatment groups was normalized to that observed in vehicle treated
controls.
2.13. DAT-mediated [3H]-DA uptake in rat striatal synaptosomes
In vitro [3H]-DA uptake was performed as previously described with minor
modifications [57]. Briefly, adult male Sprague-Dawley rats (200 – 250 g) were
anesthetized with CO2 and decapitated. Striata were rapidly dissected and
immediately placed into 10 volumes of ice-cold uptake buffer (120 mM NaCl, 3.9
mM KCl, 650 µM MgSO4, 510 µM CaCl2, 190 µM NaHPO4, 100 µM pargyline, 2
mg/ml glucose, 0.2 mg/ml ascorbic acid, 20 mM HEPES, pH 7.4, saturated with
95% O2/5% CO2) containing 0.32 M sucrose. Striatal tissue was homogenized in
a glass homogenization tube with a Teflon pestle. The homogenate was
centrifuged at 1,000 x g for 10 minutes at 4°C. The resulting supernatant was
collected and centrifuged at 16,000 x g for 20 minutes at 4°C. The resulting pellet
was washed twice with ice-cold uptake buffer and re-suspended in 10 ml of
uptake buffer (synaptosome preparation). Synaptosomes (100 µl) were added to
individual wells in a 96-well plate and incubated at 37°C for 10 minutes.
Lobinaline was dissolved in 100% DMSO, then diluted with uptake buffer (0.3 nM
– 3.0 mM). The final concentration of DMSO in uptake studies never exceeded
1.0%, which had no significant effect on radiotracer uptake using methods
outlined in the present study. Lobinaline (100 µl; final concentration, 0.1 nM – 1.0
mM) was co-incubated with synaptosomes for 10 minutes at 37°C prior to the
addition of [3H]-DA (100 µl). After the 10-minute co-incubation, [3H]-DA was
added to each well (final concentration, 15 – 30 nM) and uptake was allowed to
proceed for 5 minutes at 37°C. Uptake was terminated by placing 96-well plates
on ice, and then immediately harvesting synaptosomes onto 96-well GF/C filter
plates (PerkinElmer Inc.) by vacuum filtration, followed by three rapid washes
with ice-cold 50 mM Tris-HCl buffer (pH 7.4). After allowing filtration plates to dry
overnight, 35 µl of scintillation fluid (Microscint 20, Packard Inc.) was added to
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each well and the plate was kept in the dark for 2 hours. Subsequently,
radioactivity was measured by scintillation counting using a Packard TopCount®
NXT™ microplate scintillation counter. Total uptake was measured in the
presence of [3H]-DA alone. Non-specific uptake was determined in the presence
of 10 µM GBR-12909. Total specific uptake and specific uptake in the presence
of inhibitor was calculated by subtracting non-specific uptake from each,
respectively. Specific uptake in the presence of inhibitor was expressed as a
percentage of total specific uptake. [3H]-DA uptake studies with conducted with
extracts, fractions, or CHCl3 sub-fractions were conducted using the same
methods. The CHCl3 sub-fraction that most potently inhibited the DAT was
analyzed via GC-MS (see section 2.9) to determine the major constituent/s
present.
2.14. DPPH free radical scavenging assay
Lobinaline’s capacity to scavenge free radicals was examined using the
DPPH free radical scavenging assay. The DPPH assay was performed as
previously described with minor modifications [141]. Briefly, a DPPH stock
solution (600 µM) and stock solutions (1 mg/ml) of lobinaline, lobeline, and the
reference compound quercetin were prepared by dissolving compounds in
methanol. Stock solutions of DPPH and test compounds were prepared fresh on
the day of the experiment. The assay was performed in a 96-well plate format.
DPPH solution (final concentration, 300 µM), or DPPH solution and solutions of
pure compounds were (final concentration, 1 – 500 µg/ml) added to each plate in
quadruplicate. Plates were immediately covered and placed in the dark for 5
minutes. After 5 minutes, the reaction mixture’s absorbance at 517 nm was
measured using a Wallac 1420 VICTOR plate reader (PerkinElmer Inc., MA,
USA). DPPH free radical scavenging activity was calculated using the following
equation:
DPPH Free Radical Scavenging Activity (%) = ((Abs1 – Abs2) / Abs1) x 100
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,where Abs1 is the absorbance of the solution containing DPPH only and Abs2 is
the absorbance of the solution containing DPPH and pure compounds.
2.15. Fractional [3H] release from [3H]-DA preloaded striatal slices
The ability of lobinaline to evoke fractional [3H] release from [3H]-DA
preloaded striatal slices was examined as previously described, with minor
modifications [142, 143]. Briefly, coronal slices of rat striatum (500 µm, 6 – 8 mg)
were incubated in Krebs’ buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2 1.0
mM NaH2PO4, 1.3 mM CaCl2, 11.1 mM glucose, 25 mM NaHCO3, 0.11 mM
ascorbic acid, and 0.004 mM EDTA, pH 7.4, saturated with 95%O2/5%CO2) for
30 minutes in a metabolic shaker at 34°C. Afterward, slices were incubated in
Krebs’ buffer containing 0.1 µM [3H]-DA (6 – 8 slices/3 ml) for 30 minutes at
34°C. Subsequently, slices were rinsed and transferred to a glass superfusion
chamber maintained at 34°C. Slices were superfused with oxygenated Krebs’
buffer containing the monoamine oxidase (MAO) inhibitor pargyline (10 µM) and
the DAT inhibitor nomifensine (10 µM) at 1 ml/minute. The inclusion of a MAO
inhibitor reduced [3H] signal arising from [3H]-DA metabolites, and the DAT
inhibitor prevented the release of [3H]-DA via DAT reversal, promoting the
measurement of fractional [3H] release via exocytosis of [3H]-DA from vesicular
stores [143, 144]. Slices were superfused for 60 minutes, and then five 4-minute
samples (4 ml) were collected in scintillation vials to determine the level of basal
[3H] outflow ensuring baseline was stable.
In studies assessing the lobinaline’s ability to concentration-dependently
evoke fractional [3H] release, a single concentration of lobinaline (10, 100, or
1000 µM) was perfused through an individual superfusion chamber after
collection of basal samples. Slices treated with lobinaline were superfused with a
single concentration of the alkaloid for the remainder of the experiment. In each
experiment, one chamber was superfused with vehicle only throughout the entire
course of the experiment. After the addition of lobinaline, superfusate samples

34	
  

	
  
were collected at 4-minute intervals. A repeated-measures design was utilized for
superfusion studies to establish a concentration-response for lobinaline-evoked
fractional [3H] release.
After establishing a concentration-response for lobinaline in fractional [3H]
release studies, experiments were performed to determine whether MEC (10 µM)
could antagonize lobinaline-evoked fractional [3H] release. A repeated-measures
design was used for studies evaluating the effect of MEC on lobinaline-evoked
fractional [3H] release. Slices were perfused for 60 minutes prior to the collection
of two 4-minute samples to determine basal [3H] overflow ensuring baseline was
stable. After collection of basal samples, chambers were superfused with vehicle
or Krebs’ buffer containing MEC (10 µM) for 20 minutes. After being superfused
with vehicle or MEC for 20 minutes, lobinaline (100 µM) was added to a single
chamber for the remainder of the experiment. In each experiment performed, one
chamber was superfused with vehicle only throughout the entire course of the
experiment. Superfusate samples were collected in scintillation vials at 4-minute
intervals.
Upon completion of each superfusion experiment, slices were carefully
removed from superfusion chambers and solubilized with 1 ml of TS-2 in
scintillation vials. The volume and pH of solubilized striatal slices were adjusted
to match that of superfusate samples. Radioactivity in the samples collected
during superfusion studies was measured by liquid scintillation using a Packard
Tri-Carb Liquid Scintillation Counter (Gaithersberg, MD, USA). Fractional [3H]
release was calculated by expressing [3H] collected in superfusate samples as a
percentage of [3H] present in solubilized striatal slices upon completion of each
superfusion study. Fractional [3H] release evoked by various treatments was
compared to vehicle treated control slices.
2.16. In vivo electrochemical studies
In vivo electrochemical studies were conducted using previously described
methods to evaluate lobinaline’s ability to modulate DAT function in the dorsal
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striatum of anesthetized rats [46, 83]. Briefly, high-speed chronoamperometric
(HSC) measurements were performed using a FAST-16 system (Quanteon,
L.L.C., Nicholasville, KY, USA). Square wave pulses, 0.00 V to +0.55 V vs.
Ag/AgCl reference electrodes, were applied for 100 milliseconds at a frequency
of 5 Hz. Oxidation and reduction currents were integrated during the last 80
milliseconds of each pulse and averaged over 1 second. Carbon-fiber
microelectrodes (Quanteon, L.L.C., Nicholasville, KY, USA), constructed as
previously described, consisted of a single carbon-fiber (outer diameter, 30 – 33
µm) passed through and sealed in a glass capillary tube (exposed fiber length,
~150 µm). Nafion (5% solution, Aldrich Chemical Co., Milwaukee, WI) coating of
the exposed carbon-fiber tip (2 – 3 coats cured in a 200°C-oven, 5-minute cure
interval per coat) provided excellent selectivity for DA over other anionic
interferents (DA over ascorbic acid ≥ 100:1; DA over DOPAC ≥ 100:1), as
previously reported [145]. Microelectrodes were calibrated in vitro in phosphate
buffered saline (0.05 M) to generate calibration curves for DA (slope > 0.2 nA/µM
and L.O.D < 50 nM) for each microelectrode prior to in vivo studies. Electrode
responses to DA were linear (r2 ≥ 0.997). Lobinaline was evaluated in vitro prior
to in vivo studies to determine whether the alkaloid was electroactive. For in vivo
studies, micropipette-microelectrode assemblies were constructed using sticky
wax (Kerr, Orange, CA, USA) to affix double-barrel micropipettes (A-M System,
Sequim, WA) to the microelectrodes. The distance between micropipette and
electrode tips ranged from 250 – 350 µm. Care was taken to ensure parallel,
vertical

alignment

of

micropipettes

and

microelectrodes.

Double-barrel

micropipettes contained a solution of DA (200 µM in 0.9% saline, pH 7.4) in one
micropipette and lobinaline (1 mM in 0.9% saline solution containing 0.1%
DMSO, pH 7.4; vehicle containing DMSO did not affect DA dynamics) in the
second micropipette. Animals were anesthetized using isoflurane (1 – 3%) and
placed securely in a stereotaxic frame. Body temperature was maintained at
37°C throughout the experiment using a heating pad coupled to a rectal
thermometer. Ag/AgCl reference electrodes were implanted in the brain
parenchyma at a region remote to recording sites through a burr hole and
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secured using dental acrylic. Skin overlying the cranium of rats was reflected,
and the skull and dura overlying recording sites were removed bilaterally.
Micropipette-microelectrode assemblies were implanted in the striatum under
stereotactic control using the following coordinates: anterior-poster, +1.5 mm;
medial-lateral, ±2.2 mm; dorsal-ventral, -3.8 to -5.4 mm. The atlas of Paxinos and
Watson (2007) was used to determine coordinates for stereotaxic placement
[146]. Solutions of DA (ejection volume, ~100 nl) or lobinaline (ejection volume,
~250 nl) were pressure ejected using a Picospritzer III (Parker instrumentation)
and the volume ejected was monitored with a dissecting microscope equipped
with a 10 mm reticule [147]. After implantation, the micropipette-microelectrode
assembly was left undisturbed to achieve baseline (~30 minutes) before starting
the experiment. DA was then pressure ejected at 5-minute intervals until three
reproducible signals were obtained (±10%) at each recording site. Lobinaline was
then applied slowly (10 – 15 seconds) to minimize disturbance of electrochemical
signals. DA was ejected 1 minute following the lobinaline application, and then at
5-minute intervals thereafter (4 – 5 times). The micropipette-microelectrode
assembly was lowered 0.5 mm to obtain additional recordings (4 – 6 recordings
per hemisphere). Responses to DA were averaged from each animal and data
were analyzed using FAST analysis software (Version 6.0; Quanteon, L.L.C.,
Nicholasville, KY, USA). Two DA signal parameters were obtained: 1) the T80
(80% decay time from peak response), and 2) the clearance rate, the first order
rate of decay of the DA signal multiplied times the peak amplitude. The T80 and
the clearance rate reflect alterations in DAT function, rather than diffusion or
metabolism [83, 148]. Comparisons were made between amplitude matched DA
signals pre- and post-lobinaline application.
2.17. Assessment of lobinaline’s oral “druggability”
The oral “druggability” of a molecule is commonly evaluated using
Lipinski’s “Rule of Five” [149]. These criteria enable prediction of a lead
molecule’s potential as a drug candidate based on its physiochemical properties.
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Assessment of lobinaline’s druggability based on these criteria was assessed
using

data

readily

available

at

the

PubChem

website

(https://pubchem.ncbi.nlm.nih.gov/) [150, 151].
2.18. Statistical analysis
Statistical analyses, curve fitting, and graphical presentation of data were
performed using GraphPad Prism software (Version 6.0; GraphPad Software,
San Diego, CA, USA). The statistical significance of treatment-induced

45

Ca2+

entry in SH-SY5Y cells was determined using a one-tailed Student’s t-test. The
statistical significance of DAT inhibition caused by pretreatment of rat striatal
synaptosomes with the LCaq and the LCCHCl3 was determined with a one-tailed
Student’s t-test. ID50, IC50, and EC50 values for high-throughput DSS, [3H]-DA
uptakes studies, and DPPH free radical scavenging assays, respectively, were
calculated using nonlinear regression analysis to fit data to a variable slope,
sigmoidal dose-response curve. Ki values were calculated using the ChengPrusoff equation for radioligand binding studies using nonlinear regression
analysis to fit data to a one-site competition binding model, sigmoidal
concentration-response

curve.

Repeated-measures,

two-way

analysis

of

variance (ANOVA) was performed (lobinaline x time interaction) to determine
whether lobinaline evoked a significant, dose-dependent increase in fractional
[3H] release from [3H]-DA preloaded striatal slices. Repeated-measures, two-way
ANOVA was performed (treatment x time interaction) to determine whether
lobinaline-evoked fractional [3H] release was MEC-sensitive. Bonferroni’s posthoc analysis was used to determine time points at which fractional [3H] release
was statistically different from vehicle treated controls. DA signals from in vivo
electrochemical studies were obtained using Fast Analysis Software (Version
6.0; Quanteon, L.L.C., Nicholasville, KY, USA) and GraphPad Prism software
was used for graphical presentation of data. DAT inhibitors consistently increase
the T80, whereas the clearance rate may increase or decrease depending on
experimental conditions [148]. Thus, a paired one-tailed Student’s t-test and a
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paired two-tailed Student’s t-test were performed to determine the significance of
lobinaline’s effects on the aforementioned DA signal parameters, respectively. All
data are expressed as the mean ± the standard error of the mean (S.E.M.),
unless otherwise stated. A p-value < 0.05 was defined as statistically significant.

Copyright © Dustin Paul Brown 2015
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Table 2.1.
DDR values, anabasine, and nicotine content of select Nicotiana species
Species
Nicotine : Anabasine, % of total alkaloids1
DDR Value2
N. tabacum
94.8 : 0.3
9.5
N. undulate
95.3 : 1.3
6.7
N. velutina
2.8 : 8.1
2.9
1
Alkaloid content reported by Saitoh et al. (1984) [134]
2
DDR values reported by Littleton et al. (2005) [15]
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Chapter 3

Identification of Lobelia cardinalis and the isolation of lobinaline

3.1. Introduction
Plants are a rich source of nicotinic acetylcholine receptor (nicAchR)
ligands used as medicines, drug leads, and/or pharmacological probes [22]. In
plants, metabolites active at nicAchRs are believed to function as chemical
defenses against herbivorous insects [13, 14, 29]. Nicotine is a well-known
example of a naturally occurring insecticide present in Nicotiana tabacum
(tobacco) that, upon ingestion, targets and activates nicAchRs present in the
insect central nervous system (CNS) producing aversive stimuli and/or death [14,
29]. Nicotine also activates nicAchRs present in the human CNS, which underlies
its rewarding and neuroprotective properties [14, 152]. The latter effect has
generated interest in the development of nicAchR agonists as neuroprotective
agents [153-160]. Nicotine itself is undergoing evaluation in the NIC-PD trial
funded by the Michael J. Fox Foundation to assess its therapeutic efficacy in the
early stage of Parkinson’s disease (PD) patients (https://www.michaeljfox.org/)
[153].
The neuroprotective effects of nicAchR ligands are primarily a function of
agonist activity at α4β2- and α7-nicAchR subtypes [153, 154, 156-161].
Considering plants are known to synthesize nicAchR ligands of astonishing
complexity and diversity, the screening of plant extracts to discover novel
nicAchRs ligands with potential as neuroprotective drug leads seems logical [15,
22]. However, the majority of nicAchR ligands that have been isolated from plant
sources are either α4β2-nicAchRs selective agonists (e.g. cytisine), or selective
antagonists at α7-nicAchRs (e.g. methyllycaconitine) [22, 128, 132, 133].
Agonists selective for α4β2-nicAchRs are likely to induce dependence, whereas
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α7-nicAchR selective antagonism is associated with toxicity [15, 132, 162-164].
Therefore, development of a screen that enables rapid identification of plant
extracts, which contain metabolites with appropriate nicAchR selectivity is
necessary to efficiently discover novel neuroprotective drug leads from plant
sources [15].
In the present study, high-throughput pharmacological screening (HTPS)
was performed on a library of aqueous plant extracts prepared from ~1,000
species in an effort to discover novel nicAchR ligands with greater therapeutic
potential as neuroprotective agents, as compared to previously investigated
ligands. The “differential smart screen” employed in the present study, as
previously described by Littleton et al. (2005), measures a plant extract’s binding
activity at α4β2- and α7-nicAchRs, yielding a differential displacement ratio (DDR)
indicative of nicAchR selectivity [15]. The DDR was previously utilized to identify
plant extracts containing metabolites selective for α7-nicAchRs, although it can
be readily applied to identify extracts containing metabolites with equipotent
binding activity at α4β2- and α7-nicAchRs (see section 2.5) [15]. The latter may
fully exploit neuroprotection afforded by nicAchR agonists via activation of both
receptor subpopulations associated with nicotine’s neuroprotective effects [154,
158, 160, 161].
Several previously uninvestigated plant species were identified in the
HTPS as having activity meriting further investigation. Lobelia cardinalis was one
of these displaying activity indicative of the presence of metabolites with
equipotent binding activity at α4β2- and α7-nicAchRs. Furthermore, the extract
from L. cardinalis induced 45Ca2+ uptake via nicAchR activation in SH-SY5Y cells,
indicating the metabolite/s present functioned as an agonist/s [111]. Lobelia
alkaloids have previously been described as inhibitors of the dopamine
transporter (DAT), thus the extract from L. cardinalis was screened for this
activity [143, 165, 166]. Indeed, the extract significantly inhibited DAT-mediated
[3H]-dopamine (DA) uptake in rat striatal synaptosomes. This combination of
pharmacological

activities

is

potentially

of

considerable

value

for

the

development of neuroprotective agents targeted on the dopaminergic (DAergic)
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neurodegeneration that occurs in PD, and psychostimulant-induced DAergic
neurotoxicity [95-99, 102, 103, 153-160, 167].
Native Americans knew the potential medicinal value of L. cardinalis,
although the uses show no clear relation to the pharmacology described herein.
Formulations of the plant were consumed by tribes for a wide variety of
purposes, ranging from its use as an emetic, a remedy for the treatment of
typhoid, and even as a “love potion” [168]. In addition, a close relative of L.
cardinalis, L. inflata, is the source of lobeline [166]. Lobeline has been generated
interest as a treatment for neurodegenerative disorders, such as PD and
Alzheimer’s

disease,

as

well

as

neuropsychiatric

disease

including

psychostimulant dependence and attention deficit hyperactivity disorder [166].
Bioactive metabolites originating from species of the Genus Lobelia may hold
therapeutic potential for a variety of neurological disorders. Here, we describe the
putative identification of the major bioactive metabolite present in L. cardinalis,
lobinaline, and the subsequent isolation of the alkaloid.
3.2. Identification of L. cardinalis as a “species of interest” using the highthroughput DSS
In the present study, a library of aqueous plant extracts was screened to
identify extracts that contained nicAchR ligands with relatively equipotent binding
affinity at α4β2- and α7-nicAchRs. This was accomplished utilizing an innovative
HTPS previously described by Littleton et al. (2005), coined “differential smart
screening” (DSS) [15]. As described above, this translated into the prioritization
of extracts with a DDR value of ~3 in the DSS (see section 2.5). An extract’s
DDR value was calculated (see section 2.5) by dividing the percentage
displacement of [3H]-cytisine by that of [3H]-MLA at a concentration equal to the
ID50 for [3H]-epibatidine displacement [15]. The aqueous extract from L. cardinalis
(LCaq) displaced [3H]-epibatidine from rat cortical membranes (ID50 = 1:300, 333
µg/ml), and exhibited a DDR value of 2.96. Thus, L. cardinalis was designated as
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a “species of interest,” since its DDR value indicated the presence of a nicAchR
ligand(s) with relatively equipotent binding affinity at α4β2- and α7-nicAchRs.
3.3. The LCaq activates nicAchRs and inhibits the DAT
The LCaq activated nicAchRs and inhibited the DAT in functional studies
performed in vitro (Figure 3.1). In a variety of neuronal and non-neuronal cell
types, acute treatment with nicAchR agonists (e.g. NIC and DMPP) has been
reported to increase

45

Ca2+ entry [140, 169]. In contrast, basal levels of

intracellular Ca2+ are generally unaltered by treatment with nicAchR antagonists,
such as MEC or MLA [111, 140, 169, 170]. Here,
conducted

with

SH-SY5Y

cells

due

to

45

their

Ca2+ entry studies were
neuronal

properties,

catecholaminergic phenotype, and utility as an in vitro model of DAergic
neurotoxicity [123, 124]. Furthermore, SH-SY5Y cells express β2-subunit
containing and α7-nicAchRs, reported to mediate many of the neuroprotective
effects of nicAchR agonists, as well as α3β4-nicAchRs that are believed to
indirectly modulate the activity of the mesolimbic DAergic pathway [111, 153,
154, 156-161, 170]. Ca2+ entry elicited by nicAchR ligands and extracts was
measured using 45Ca2+, rather than calcium fluorimetry, to eliminate signal arising
from other sources of Ca2+, such as that released from intracellular stores via
Ca2+-induced Ca2+ release [111, 169]. In the SH-SY5Y cells, NIC (10.0 µM)
significantly increased
45

45

Ca2+ entry (374% increase above basal, p = 0.0001).

Ca2+ entry was unaffected by MEC (1.0 µM), a non-selective nicAchR

antagonist, in agreement with previous studies [111, 140, 143, 169-171]. The
LCaq (1.0 mg/ml) significantly increased

45

Ca2+ entry (137% increase above

basal, p < 0.001), and this effect was completely blocked by MEC.

45

Ca2+ entry

was significantly increased in SH-SY5Y cells concomitantly treated with the LCaq
and NIC (1.0 mg/ml and 10 µM, respectively; 232% increase above basal, p <
0.001), yet the effect was significantly less (p = 0.0143) than that observed in SHSY5Y cells treated with NIC alone. The NIC-evoked increase in Ca2+ entry in the
current study is consistent with previous studies reporting nicAchR agonist-
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evoked Ca2+ entry in SH-SY5Y cells, measured using fluorimetric techniques
[111]. These results suggest the LCaq likely contains a metabolite(s) that
functions as a nicAchR partial agonist. Consistent with this view, the LCaq
displays intrinsic activity at nicAchRs present on SH-SY5Y cells, but functions as
a nicAchR antagonist in the presence of a nicAchR full agonist (i.e. NIC) [170,
172, 173]. Furthermore, in rat striatal synaptosomes the LCaq significantly and
dose-dependently inhibited DAT-mediated [3H]-DA uptake. The LCaq significantly
inhibited DAT-mediated [3H]-DA uptake at concentrations of 74.1 µg/ml (35%
uptake, p < 0.001), 151.3 µg/ml (12% uptake, p < 0.001) and 3.3 mg/ml (2%
uptake, p < 0.001). The unique combination of pharmacological effects (i.e.
nicAchR partial agonism and DAT inhibition) merited further investigation of L.
cardinalis with the aim of identifying a metabolite or metabolites responsible for
the aforementioned activities.
3.4. Putative identification of a multifunctional alkaloid present in L. cardinalis
A crude methanolic extract prepared from air-dried aerial portions of L.
cardinalis was subject to bioassay-guided fractionation. Fractions obtained were
evaluated in the DSS and for their ability to inhibit the DAT in vitro. The CHCl3
fraction thus obtained displaced [3H]-epibatidine from rat cortical membranes
(ID50 = 1:60,000, 1.67 µg/ml), and exhibited a DDR value of 1.59 in the DSS,
indicative of the presence of a ligand(s) with comparable affinity at α4β2- and α7nicAchRs, as compared to nicotine or lobeline (DDR values of 13.00 and 6.27,
respectively) [15]. The CHCl3 fraction also caused a significant, dose-dependent
inhibition of DAT-mediated [3H]-DA uptake in rat striatal synaptosomes (Figure
3.2) at 33.3 µg/ml (38% uptake, p < 0.001) and 3.3 µg/ml (90% uptake, p =
0.0013). Thus, pHPLC sub-fractionation of the CHCl3 fraction was performed in
an effort to identify a multifunctional plant metabolite responsible for the
aforementioned activities. A single CHCl3 sub-fraction was the most effective at
displacing [3H]-MLA from rat hippocampal membranes, and was also the most
potent inhibitor of the DAT in rat striatal synaptosomes. These results indicated
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the presence of a putatively novel multifunctional plant metabolite. GC-MS
analysis of the CHCl3 sub-fraction revealed lobinaline, the major alkaloid present
in L. cardinalis, as the most abundant constituent (AUC = 70%) of the subfraction [80, 81, 135, 174, 175]. The identity of lobinaline, a complex
binitrogenous alkaloid, was confirmed based on previously reported structural
and MS data [135, 174, 175].
3.5. Isolation of lobinaline
The crude methanolic extract prepared from air-dried aerial portions of L.
cardinalis was fractionated to obtain the CHCl3 fraction. Acid-base extraction was
performed on the CHCl3 fraction, yielding lobinaline (purity ≥ 95%). The identity of
the alkaloid was confirmed based on previously reported MS data, and its purity
was determined by integration of the AUC of the chromatographic peak
corresponding to lobinaline on the GC trace [135]. Lobinaline (Figure 3.3) was
stored in the dark at -20°C prior to further experimentation.
3.6 Discussion
Plants are a rich source of multifunctional drug leads, as described in
recent reviews [13, 176, 177]. The complex alkaloid lobinaline was putatively
identified as the major bioactive metabolite present in L. cardinalis [80, 81, 135,
174, 175]. The alkaloid was presumably responsible for nicAchR agonism and
DAT inhibition caused by L. cardinalis extracts. NicAchR agonists and DAT
inhibitors attenuate DAergic neurotoxicity in animal models of PD and
psychostimulant abuse [95-99, 102-104, 119, 153-160, 167, 178-182]. Thus,
lobinaline may prove to be a particularly valuable lead for the development of
multifunctional

neuroprotective

therapeutics

aimed

to

prevent

DAergic

neurotoxicity if, indeed, it is responsible for the aforementioned pharmacological
effects.
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Initially, HTPS was conducted on a library of aqueous plant extracts from
~1,000 species in an effort to identify a novel nicAchR agonist with equipotent
binding affinity at α4β2- and α7-nicAchRs. Using the DSS previously described by
Littleton et al. (2005), the L. cardinalis aqueous extract (LCaq) produced a DDR
value of 2.96 signifying the extract contained a metabolite/s with similar binding
affinity at α4β2- and α7-nicAchRs, as described above (see section 2.5) [14, 15].
In SH-SY5Y cells, the LCaq (1.0 mg/ml) significantly increased

45

Ca2+ entry. The

LCaq-induced increase in 45Ca2+ entry was abolished by MEC (1.0 µM), indicating
the effect was mediated by nicAchR activation [111, 140, 143, 169-171].
Furthermore, the LCaq significantly reduced NIC-induced

45

Ca2+ entry in SH-

SY5Y cells. Collectively, these results indicated the LCaq contained a
metabolite/s that functioned as a nicAchR partial agonist with relatively
equipotent affinity for α4β2- and α7-nicAchRs [170, 172, 173]. This is in contrast to
“typical” nicAchR ligands from plant sources, the majority of which are α4β2nicAchR selective agonists (e.g. cytisine) or α7-nicAchR antagonists (e.g. MLA)
[22, 128, 132, 133]. Additionally, the extract inhibited DAT-mediated [3H]-DA
uptake in rat striatal synaptosomes. This was an intriguing observation since, to
the best of our knowledge, all plant metabolites reported to inhibit the DAT and
modulate nicAchRs act as antagonists at the latter [22, 143, 144, 183].
Bioassay-guided fractionation of the L. cardinalis methanolic extract,
followed by pHPLC sub-fractionation, indicated both activities resided in a single
CHCl3 sub-fraction. GC-MS analysis of the sub-fraction revealed lobinaline was
the major constituent present (AUC = 70%), the identity of which was confirmed
based on previously reported MS data [135]. Lobinaline, the alkaloid putatively
responsible for multifunctional pharmacological effects of L. cardinalis, was
subsequently isolated (purity ≥ 95%). Studies then were conducted to
characterize the pharmacology of lobinaline, confirming the multi-target effects of
the alkaloid.

Copyright © Dustin Paul Brown 2015
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A

B

Figure 3.1. Modulation of 45Ca2+ entry in SH-SY5Y cells and DATmediated [3H]-DA uptake in rat striatal synaptosomes by the LCaq. Data
expressed as the mean ± S.E.M. A) NIC (10.0 µM) and the LCaq (1.0
mg/ml) significantly increased 45Ca2+ entry in SH-SY5Y cells. The LCaq
significantly attenuated NIC-induced 45Ca2+ entry, and MEC (1.0 µM)
pretreatment completely abolished LCaq-induced 45Ca2+ entry. *** p <
0.001 vs. vehicle (VEH), Student’s one-tailed t-test; # p < 0.05 compared
to cells treated with NIC alone, Student’s one-tailed t-test. B) DATmediated [3H]-DA uptake is significantly and dose-dependently inhibited
by the LCaq. *** p < 0.001 vs. VEH, one-tailed Student’s t-test. n = 3 - 4.
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Figure 3.2. Modulation of DAT-mediated [3H]-DA uptake in rat
striatal synaptosomes. Data expressed as the mean ± S.E.M.
The L. cardinalis chloroform fraction (LCCHCl3) significantly and
dose-dependently inhibited the DAT. ** p < 0.01, *** p < 0.001
vs. vehicle (VEH), one-tailed Student’s t-test. n = 4.
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Figure 3.3. The structure of lobinaline. Red circles denote chiral centers.
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Chapter 4

Pharmacological characterization of lobinaline

4.1 Introduction
Lobinaline was putatively identified as the major bioactive metabolite
present in L. cardinalis. Here, the multifunctional pharmacology of the complex
decahydroquinoline alkaloid is described, as well as its potential therapeutic
applications. The alkaloid possesses a unique polypharmacological profile
functioning as a nicAchR agonist, DAT inhibitor, and free radical scavenger.
These pharmacological effects of lobinaline are previously unreported, and to the
best of our knowledge, the alkaloid is the only natural product with a combination
of the aforementioned activities. NicAchR agonists, DAT inhibitors, and free
radical scavengers attenuate DAergic neurotoxicity in animal models of PD and
psychostimulant abuse [95-99, 102-104, 119, 153-160, 167, 178-182]. Thus,
lobinaline may be a particularly valuable lead for the development of
multifunctional

neuroprotective

therapeutics

aimed

to

prevent

DAergic

neurotoxicity.
Here, the in vitro pharmacological characterization major bioactive
metabolite present in L. cardinalis, lobinaline, is described. The alkaloid’s effects
on DA uptake in vivo were examined by measuring the clearance of exogenous
DA locally applied in the striatum of isoflurane-anesthetized rats using Nafioncoated

carbon

fiber

microelectrodes

in

combination

with

high-speed

chronoamperometry (HSC) [46, 78, 83, 184-187]. Since excessive free radical
production contributes to DAergic neurotoxicity seen in PD and psychostimulant
abuse, lobinaline’s capacity to scavenge free radicals was evaluated in the 1,1diphenyl-2-picrylhydracyl (DPPH) free radical scavenging assay [97, 98, 104,
167, 188, 189]. All of the data presented suggest lobinaline is a potential lead
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compound for the development of multifunctional neuroprotective agents to
prevent DAergic neurotoxicity.
4.2. Lobinaline displaces radioligands selective for nicAchRs and the DAT
Lobinaline concentration-dependently inhibited [3H]-epibatidine, [3H]cytisine, and [3H]-MLA binding at nicAchRs (Ki = 16.2, 1.1, and 67.5 µM,
respectively; Figure 4.1 A – C). Radioligand binding studies with the
aforementioned nicAchR ligands were performed as described previously [15,
136]. Competition binding studies with [3H]-epibatidine and [3H]-cytisine were
conducted in rat cortical membranes. The former nicAchR ligand is relatively
non-selective at neuronal nicAchR subtypes, while the latter is selective for α4β2nicAchRs [22, 128, 130, 131]. Competition binding studies with the α7-nicAchR
selective ligand [3H]-MLA were conducted in rat hippocampal membranes [128,
132]. In contrast to nicotine and lobeline, lobinaline has similar affinity at α4β2and α7-nicAchRs (see Table 4.1 for comparison) [190, 191]. Lobinaline produced
a DDR value of 1.32, virtually identical to that produced by the CHCl3 fraction,
indicating lobinaline was the main metabolite responsible for the fraction’s
nicAchR binding activity. Lobinaline also inhibited binding of [3H]-GBR12935, a
highly selective DAT ligand, in rat striatal membranes (Ki = 2.5 µM; Figure 4.2)
[84, 86].
4.3. Lobinaline activates nicAchRs and inhibits the DAT in vitro
Lobinaline’s functional effect at nicAchRs was evaluated by assessing its
ability to modulate

45

Ca2+ entry in SH-SY5Y cells (Figure 4.3 A). In these

experiments, NIC (10.0 µM) significantly increased

45

Ca2+ entry (197% increase

above basal, p = 0.0008). Treatment of cells with MEC alone (1.0 µM) did not
affect

45

Ca2+ entry. At the concentration tested in the current study, lobinaline

(1.0 mM) significantly increased
0.0011). Lobinaline-induced

45

45

Ca2+ entry (42% increase above basal, p =

Ca2+ entry in SH-SY5Y cells was completely
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abolished by MEC. Concomitant treatment of SH-SY5Y cells with lobinaline and
NIC (1.0 mM and 10 µM, respectively) significantly increased

45

Ca2+ entry (116%

increase above basal, p < 0.001). Similar to the LCaq, concomitant treatment of
SH-SY5Y cells with lobinaline and NIC significantly reduced

45

Ca2+ entry (p =

0.0347), as compared to cells treated with NIC alone. The observation of
nicAchR activation by lobinaline, in combination with its ability to attenuate NICinduced

45

Ca2+ entry, is consistent with the view that lobinaline functions as a

partial agonist at nicAchRs expressed by SH-SY5Y cells [170, 172, 173]. In order
to assess lobinaline’s efficacy as an inhibitory modulator of the DAT, [3H]-DA
uptake was performed in rat striatal synaptosomes. DAT-mediated [3H]-DA
uptake was inhibited by lobinaline (IC50 = 12.0 µM; Figure 4.3 B). Based on
these results, and data obtained from binding studies, lobinaline functions as a
multifunctional alkaloid with unique pharmacological profile, acting as a nicAchR
partial agonist and an inhibitor of the DAT.
4.4. Lobinaline is a relatively potent DPPH free radical scavenger
Multiple lines of evidence indicate excessive free radical production
contributes to DAergic neurotoxicity seen in PD and psychostimulant abuse [97,
98, 104, 167, 188, 189]. The DPPH free radical scavenging assay is commonly
utilized to assess a molecule’s ability to quench free radicals [141]. Lobinaline
acted as a potent free radical scavenger (EC50 = 18.0 µM), as did quercetin (EC50
= 11.2 µM), a plant metabolite previously reported to potently scavenge DPPH
free radicals (Figure 4.4) [141]. In contrast, lobeline was a weak DPPH free
radical scavenger (EC50 = 228.8 µM). Although quercetin’s EC50 is greater than
previously reported (6.22 µM), this was expected given the concentration of
DPPH used in the present study (300 µM) was 6-fold greater than the former (50
µM) [141].
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4.5. Lobinaline dose-dependently evokes fractional [3H] release from [3H]-DA
preloaded rat striatal slices
The modulation of nicAchRs by lobinaline was also examined by
monitoring its ability to evoke fractional [3H] release from rat striatal slices
preloaded with [3H]-DA. Superfusion studies were performed in the presence of
pargyline (10.0 µM) and nomifensine (10.0 µM). The inclusion of a MAO inhibitor
reduced the contribution of [3H]-DA metabolites to the [3H] signal recorded, and
the use of a DAT inhibitor promoted measurement of [3H]-DA released from
vesicular stores, rather than efflux of [3H]-DA via reversal of the DAT [143, 144].
Lobinaline caused a significant, concentration-dependent increase in fractional
[3H] release from rat striatal slices preloaded with [3H]-DA (Figure 4.5 A).
Repeated measures, two-way ANOVA revealed a significant main effect of
concentration (F(3,26) = 15.5, p < 0.001), a significant main effect of time (F(11, 286)
= 4.9, p < 0.001), and a significant concentration x time interaction (F(33, 286) = 3.6,
p < 0.001). The lowest concentration of lobinaline that evoked a significant
increase in fractional [3H] release compared to vehicle was 100 µM. At
concentrations of 100 µM and 1000 µM, lobinaline-evoked fractional [3H] release
reached significance (p < 0.05 and p < 0.001, respectively) 8 minutes after
treatment (the second sample collected after lobinaline treatment). Fractional [3H]
release evoked by 1000 µM lobinaline reached a maximum (494% greater than
vehicle treated, p < 0.001) 8 minutes post-treatment. Fractional [3H] release
evoked by 100 µM lobinaline reached a maximum (186% greater than vehicle
treated, p < 0.001) 12 minutes post-treatment, and was no longer significantly
different from vehicle treated slices 16 minutes after treatment. In contrast,
fractional [3H] release evoked by 1000 µM lobinaline remained significantly
elevated above that of vehicle treated slices for the remainder of the experiment
(28 minutes).
After establishing lobinaline’s ability to concentration-dependently evoke
fractional [3H] release, studies were performed to evaluate the contribution of
nicAchR stimulation to lobinaline-evoked fractional [3H] release. Striatal slices
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preloaded with [3H]-DA were pretreated with MEC (10.0 µM) for 20 minutes prior
to the addition of lobinaline (100 µM). Fractional [3H] release from vehicle treated
striatal slices served as a control. MEC significantly attenuated lobinaline-evoked
fractional [3H] release indicating activation of nicAchRs contributes to fractional
[3H] release evoked by the alkaloid (Figure 4.5 B) [143]. Repeated measures,
two-way ANOVA revealed a significant main effect of treatment (F(2, 9) = 9.683, p
= 0.0057) and a significant main effect of time (F(13, 117) = 2.465, p = 0.0053). The
treatment x time interaction was not significant (F(26, 117) = 1.488, p = 0.0793). In
this set of experiments, the effect of lobinaline (100 µM) alone was generally in
agreement with initial studies, albeit the time course of its effect was slightly
prolonged. That is, lobinaline-evoked fractional [3H] release reached significance
8 minutes after treatment (160% greater than vehicle, p < 0.05), and was no
longer significantly different from vehicle treated slices after 24 minutes.
Additionally, the maximal increase in fractional [3H] release occurred 16 minutes
after lobinaline treatment and the maximum (262% greater than vehicle treated
controls, p < 0.001) was greater than that observed in initial studies. When
comparing fractional [3H] release from vehicle treated slices and slices pretreated
with MEC prior to lobinaline, no significant difference was observed at any time
point. These results indicate lobinaline’s effect was MEC-sensitive, providing
additional evidence that the alkaloid is a nicAchR agonist. This is in contrast to
lobeline, which evokes fractional [3H] release from rat striatal slices that is MECinsensitive, and was reported to antagonize nicAchRs [143, 144].
4.6. Lobinaline inhibits DA uptake in vivo in the striatum of isofluraneanesthetized rats
In vivo electrochemical studies were performed to evaluate modulation of
DA uptake in isoflurane-anesthetized rats. In agreement with in vitro [3H]-DA
uptake studies, local application of lobinaline in the dorsal striatum significantly
prolonged the clearance rate of exogenous DA. A representative trace of
exogenous DA clearance recorded pre- and post-lobinaline application is
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depicted in Figure 4.6 A. The alkaloid significantly increased the T80 (76.3 ± 39.5
sec., p = 0.0203) and significantly decreased the clearance rate (0.09 ± 0.05
µM/sec., p = 0.0459) 1-minute post-application, as compared to the T80 (33.7 ±
12.5 sec.) and clearance rate (0.13 ± 0.07 µM/sec.) pre-application (Figure 4.6 B
and C). The effects of lobinaline on the aforementioned DA signal parameters
are indicative of DAT inhibition. Lobinaline’s effects on DA clearance are short
acting, as they are no longer significant 3 – 5 minutes after lobinaline ejection.
Lobinaline’s effects on DA clearance are somewhat like those observed after
local application of nomifensine in the dorsal striatum of urethane-anesthetized
Sprague-Dawley rats, but were not as efficacious, which is consistent with in vitro
studies of nomifensine in synaptosomes [84, 148]. In vitro electrochemical
studies confirmed lobinaline itself was not electroactive by chronoamperometric
recordings used to measure endogenous DA (data not shown). In vivo, lobinaline
had no direct effects when locally applied from a micropipette (n = 10; data not
shown). Given lobinaline prolonged exogenous DA clearance and failed to cause
DA release, the alkaloid appears to act as a DAT inhibitor, rather than a DAT
substrate/releasing agent.
4.7. Lobinaline fits the criteria set forth by Lipinski’s “Rule of Five”
The oral “druggability” of lobinaline, based on its physiochemical
properties, was assessed according to Lipinski’s “Rule of Five” [149]. These data
are readily available the PubChem website (https://pubchem.ncbi.nlm.nih.gov/)
[150, 151]. Lobinaline did not violate any of the criteria set forth by Lipinski’s
“Rule of Five”: molecular weight = 386, hydrogen bond donors = 0, hydrogen
bond acceptors = 2, cLogP = 4.8, molar fractivity = 82.47. Additionally, based on
previously

reported

in

vivo

studies,

lobinaline

displays

appropriate

pharmacokinetics and low mammalian toxicity in mice relative to lobeline, the
most widely studied Lobelia alkaloid [81].
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4.8. Discussion
Plants are a rich source of multifunctional drug leads [13, 176, 177]. The
multifunctional alkaloid lobinaline was identified as the major bioactive metabolite
present in L. cardinalis [80, 81, 135, 174, 175]. The alkaloid possesses a unique
polypharmacological profile functioning as a nicAchR agonist, DAT inhibitor, and
free radical scavenger. These pharmacological effects of lobinaline are
previously unreported, and to the best of our knowledge, the alkaloid is the only
natural product with a combination of the aforementioned activities. NicAchR
agonists, DAT inhibitors, and free radical scavengers attenuate DAergic
neurotoxicity in animal models of PD and psychostimulant abuse [95-99, 102104, 119, 153-160, 167, 178-182]. Thus, lobinaline may be a particularly valuable
lead for the development of multifunctional neuroprotective therapeutics aimed to
prevent DAergic neurotoxicity.
Lobinaline inhibited binding of the α4β2-nicAchR selective ligand [3H]cytisine (Ki = 1.1 µM), and the α7-nicAchR selective ligand [3H]-MLA (Ki = 67.5
µM), in rat cortical and hippocampal membranes, respectively, and produced a
DDR value of 1.32 [22, 128, 132, 133]. Compared to other plant metabolites,
such as nicotine and lobeline, lobinaline is relatively non-selective with respect to
α4β2- and α7-nicAchRs (see Table 4.1 for comparison) [190, 191]. The plant
metabolite anabasine is also non-selective at α4β2- and α7-nicAchRs (Ki = 65 nM
and 58 nM at α4β2- and α7-nicAchRs, respectively) [22]. However, anabasine is
teratogenic, limiting its clinical utility [192]. In SH-SY5Y cells, lobinaline
significantly increased

45

Ca2+ entry, an effect that was blocked by MEC.

Lobinaline also significantly reduced NIC-induced

45

Ca2+ entry in SH-SY5Y cells.

The ability of lobinaline to activate nicAchRs and functionally antagonize the
effect of a nicAchR full agonist (i.e. NIC) suggests the alkaloid may be a nicAchR
partial agonist [170, 172, 173]. Lobeline, on the other hand, antagonizes
nicAchRs in a variety of experimental models [143, 144]. Based on these data,
lobinaline appears to be distinct from nicotine and lobeline in terms of its
selectivity and functional effects at nicAchRs. Electrophysiological studies (e.g.
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two-electrode voltage clamping) assessing lobinaline’s efficacy at nicAchRs are
necessary to confidently designate lobinaline as a nicAchR partial agonist.
Lobinaline was further evaluated in vitro for its ability to interact with and
modulate the DAT. In rat striatal membranes, binding of the highly selective DAT
ligand [3H]-GBR12935 was inhibited by lobinaline (Ki = 2.5 µM), and the alkaloid
dose-dependently attenuated DAT-mediated [3H]-DA uptake (IC50 = 12.0 µM) in
rat striatal synaptosomes [84, 86]. Lobeline also inhibits the DAT, but is less
potent (IC50 = 28.2 – 80.0 µM) than lobinaline [143, 190]. In contrast, nicotine is
inactive at the DAT in rat striatal synaptosomes [143]. However, in in vivo
electrochemical studies performed in rats, systemic administration of nicotine
enhanced DAT function [193]. The latter study suggests an intact neurological
system is required to examine modulation of DAT activity by nicotinic agonists.
As described above, lobinaline exerts pleiotropic pharmacological effects
relevant to the prevention and/or reduction of DAergic neurotoxicity seen in PD
and psychostimulant abuse, including nicAchR activation and DAT inhibitory
modulation [95, 98, 99, 102, 103, 153-157, 160, 167]. Since multiple lines of
evidence indicate excessive free radical production contributes to DAergic
neurotoxicity seen in the aforementioned pathologies, lobinaline was assessed
for its capacity to scavenge free radicals [97, 98, 104, 167, 188, 189]. In the
DPPH free radical scavenging assay, lobinaline acted as a potent scavenger of
free radicals (EC50 = 18.0 µM), as compared to quercetin (EC50 = 11.2 µM), a
natural product known for its free radical scavenging and antioxidant activity
[119, 141, 177, 182]. Lobeline’s capacity to scavenge DPPH free radicals was
relatively poor (EC50 = 228.8 µM). Given quercetin’s neuroprotective effects in
cellular and animal models of PD, lobinaline may exert similar effects warranting
future investigation of the alkaloid in models of PD [119, 182].
In superfusion studies, lobinaline caused a significant, dose-dependent
increase in fractional [3H] release from rat striatal slices preloaded with [3H]-DA.
The buffer used in superfusion studies contained a MAO inhibitor and a DAT
inhibitor to reduce signal arising from [3H]-DA metabolites and [3H]-DA release
via reversal of the DAT, respectively [143, 144]. At the highest concentration

58	
  

	
  
examined in the current study (1000 µM), lobinaline-evoked fractional [3H]
release remained significantly greater than control for the duration of the
experiment. This effect mirror’s that observed for high concentrations of lobeline
(10.0 – 1000 µM) under essentially identical experimental conditions [143]. In
contrast, nicotine’s effect on fractional [3H] release is transient, even at high
concentrations, likely due to desensitization of nicAchRs [143]. Subsequent
experiments revealed lobinaline-evoked fractional [3H] release was MECsensitive, providing additional evidence that the alkaloid is an agonist at
nicAchRs. Based on these observations, stimulation of nicAchRs underlies
lobinaline’s ability to evoke fractional [3H] release from [3H]-DA preloaded striatal
slices. Lobeline, on the other hand, is reported to antagonize nicAchRs, and
evokes fractional [3H] release that is MEC-insensitive and Ca2+-independent
[143].
Lobinaline’s ability to affect vesicular monoamine transporter type-2
(VMAT-2) activity, inhibition of which is believed to underlie lobeline’s effect in
similar superfusion studies, was not examined [143]. Furthermore, the [3H] signal
measured in studies examining lobeline-evoked fractional [3H] release from [3H]DA preloaded rat striatal slices was reported to arise predominantly from an
increase in [3H]-DOPAC release, rather than [3H]-DA [143]. The authors reached
this conclusion upon measuring lobeline-evoked endogenous DA and DOPAC
release from rat striatal slices via HPLC coupled with electrochemical detection
(HPLC-ECD). Lobinaline’s ability to modulate VMAT-2 and endogenous
DA/DOPAC release from rat striatal slices, measured using HPLC-ECD, remain
to be explored.
The effect of lobinaline on DAT function was examined in vivo in the
striatum of isoflurane-anesthetized rats using HSC coupled to local applications
of exogenous DA. This technique allows measurement of DA dynamics in vivo in
an intact neurological system with a high degree of spatial and temporal
resolution, and has been used extensively to characterize effects of DAT
inhibitors [46, 78, 148, 184, 194]. Consistent with in vitro [3H]-DA uptake studies,
lobinaline significantly prolonged the clearance rate of exogenous DA 1-minute
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post-application. Local application of the alkaloid in the dorsal striatum
significantly increased the T80 and significantly reduced the clearance rate when
compared to amplitude matched DA signals pre-lobinaline application. These
observations demonstrate lobinaline’s ability to inhibit DAT function in vivo,
although the alkaloid’s effects are transient and are no longer significant 3 – 5
minutes post-application. Alterations in the T80 and the clearance rate reflect
modulation of DAT activity, as has been characterized for other DAT inhibitors
[46, 148, 195]. Effects somewhat like those of lobinaline were observed following
local application of the DAT inhibitor nomifensine in the dorsal striatum of
Sprague-Dawley rats, albeit lobinaline was less efficacious, which is consistent
with in vitro studies of nomifensine in synaptosomes [84, 148]. In isofluraneanesthetized rats, lobinaline locally applied in the striatum had no direct effects.
DAT substrate-releasing agents, such as amphetamines, induce endogenous DA
release [196, 197]. Thus, lobinaline likely functions as a DAT inhibitor, rather than
a substrate, although the results are not conclusive. The transient nature of
lobinaline’s effects in vivo may result from the alkaloid’s relatively low affinity
and/or potency at the DAT. Conformational changes resulting from lobinaline’s
interaction with the DAT and mechanism/s underlying lobinaline’s effects on
DAergic neurotransmission and DAT function in vivo remain to be thoroughly
elucidated.
The multifunctional pharmacological effects of lobinaline are somewhat
expected in view of the structural complexity and functional groups present in the
decahydroquinoline alkaloid. For example, lobinaline meets all criteria of the
“refined” pharmacophore proposed by Inamdar (2011) for DAT inhibitors: 1)
ionizable nitrogen, 2) aromatic ring, 3) hydrogen bond acceptor, and 4) two
hydrophobic groups [198]. Although these requirements are not absolute, an
ionizable nitrogen within ~6 Å of a phenyl moiety is present in the vast majority of
DAT inhibitors [198, 199]. Illustrating this point, the lack of a phenyl and/or benzyl
substituent in nicotine and anabasine seems to be a reasonable explanation for
their inability to inhibit DAT, especially given their structural similarity to the
competitive DAT inhibitor/substrate 1-methyl-4-phenlypiperidinium [22, 151, 200].
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On the other hand, structural features common to lobinaline and the alkaloids
anabasine and anabaseine likely explain lobinaline’s selectivity and activity at
select nicAchR subtypes. The 3-(2-piperidyl)pyridine alkaloids anabasine and
anabaseine, the latter having a 1,2-unsaturated piperidyl group, are nicAchR
agonists with similar affinity for α4β2- and α7-nicAchRs [22, 200]. Although
lobinaline lacks a pyridyl functional group, the aromatic character of its phenyl
substituents in the vicinity of the 1,2-dehydropiperidine functional group may
suffice to create a physiochemical environment adequate to engender similar
interactions with nicAchRs. The agonist activity lobinaline displays at nicAchRs is
of note, given other decahydroquinolines studied to date antagonize nicAchRs,
possibly due to the lack of a tetrahydropiperidyl substituent in those previously
investigated [201, 202].
A question becomes apparent when considering the pharmacological
actions of lobinaline, and the amount of energy that is likely required to
synthesize a molecule of its complexity: What benefit does lobinaline afford to the
plant? One explanation relates to the effects of nicAchR agonists and DAT
inhibitors on insect behavior. Both classes of compounds have been reported to
function as naturally occurring insecticides, nicotine and cocaine representing
examples of the former and latter [14, 29, 30]. Additionally, modulating two
molecular targets may be more effective, due to synergistic effects. Targeting
nicAchRs and the DAT also ensures protection against herbivorous insects
resistant to one mode-of-action, or the other. Thus, having a “shotgun” approach
to fend off herbivorous threats is potentially “safer” for the plant. Furthermore,
lobinaline’s ability to function as an antioxidant should reduce oxidative stress
arising from excessive exposure to ultraviolet radiation, or free radical species
that are generated during normal metabolism [13]. All in all, synthesis of a
multifunctional molecule is potentially a more efficient strategy, given a single
biosynthetic pathway and resulting metabolite addresses each of the challenges
plants encounter, outlined above. Given evolution favors efficiency and
effectiveness, natural selection would likely favor the retention and optimization
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of multifunctional molecules, such as lobinaline, and their respective biosynthetic
pathways.
Only one other molecule which activates nicAchRs and inhibits the DAT
has been reported, a synthetic analogue of cocaine, cocaine methiodide (CMI)
[22, 183, 203]. However, the clinical utility of CMI is severely limited due its toxic
peripheral effects [203]. Previously, a limited number of in vivo studies were
performed with lobinaline [81]. Intravenous administration of lobinaline in cats
and rabbits was reported to lower blood pressure, whereas respiration was
unaffected by the alkaloid [81]. The authors reported minimal lethal doses of 800
and 300 mg/kg for lobinaline and lobeline, respectively, following subcutaneous
administration in mice [81]. These initial studies indicate the alkaloid’s
pharmacokinetic (PK) and toxicity profile are acceptable for a drug lead,
especially considering complications arising from PK and toxicity reportedly
underlie failure of ~30% of NCEs in clinical development [204, 205]. Additionally,
lobinaline does not violate criteria outlined by Lipinski’s “Rule of Five,” a common
assessment used to predict a molecule’s oral “druggability” based on its
physiochemical properties [149]. Thus, lobinaline holds considerable value as a
potential lead molecule for the development of therapeutics with its combination
of effects. One hurdle that may stall optimization of the alkaloid via traditional
medicinal chemistry is the lack of a method for the total synthesis of lobinaline,
limiting access to a pure starting material [8, 20, 206]. Although tracer studies
examining lobinaline biosynthesis in planta indicate phenylalanine and lysine are
the likely precursors of the alkaloid, a method for the total synthesis of lobinaline
remains elusive [80]. Also the presence of five chiral centers in lobinaline would
necessitate the separation of enantiomers likely to arise during chemical
optimization, creating additional challenges and costs [8]. To address this
problem, our group is currently developing a novel plant-based drug discovery
platform that favors evolution of plant biosynthetic pathways yielding molecules
with desirable interactions at a protein which is a therapeutic molecular target.
Proof-of-application studies are being conducted using the hDAT as the
molecular target, and L. cardinalis as the candidate plant species.
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Lobinaline, or congeners with similar pharmacological effects represent
promising multifunctional drug leads to prevent DAergic neurotoxicity seen in PD
or psychostimulant abuse. For example, DAT inhibitors prevent uptake of
endogenous and exogenous neurotoxic substrates of the transporter thought to
contribute to DAergic neuron loss in PD, and DAT inhibitors alleviate specific
parkinsonian symptoms in rodent and nonhuman primate models of PD [95-101].
NicAchR agonists selective for α4β2- or α7-nicAchRs are neuroprotective in
cellular and animal models of PD, and reduce drug-induced dyskinesia caused
by therapeutics used to treat PD [153-160, 207]. In models of psychostimulant
abuse, α4β2- and α7-nicAchR selective agonists, as well as DAT inhibitors,
attenuate neurotoxicity caused by amphetamines [99, 102-104, 153, 154, 156,
159, 160, 167]. In animal models of cocaine and amphetamine abuse, “atypical”
DAT inhibitors (e.g. JHW-007) reduce psychostimulant self-administration and
display low abuse liability [59, 60, 65, 66, 70, 79]. DAergic neurotoxicity caused
by psychostimulants and neurotoxic DAT substrates utilized to model PD is
attenuated by pre-treatment with antioxidants, including ubiquinol (coenzyme
Q10) and flavonoids (e.g. baicalein) [119, 178-182]. Thus multifunctional
molecules, such as lobinaline, which activate α4β2- and α7-nicAchRs, inhibit the
DAT, and function as free radical scavengers may be superior DAergic
neuroprotectants that act via a single mechanism of action. This notion is
supported by recent reviews indicating multifunctional leads have a higher
probability of displaying efficacy with minimal side effects [177, 204, 208].
Furthermore, high affinity binding is not required for multifunctional drugs
presumably due to synergistic and/or additive effects arising from their multitarget activities, and this relative lack of potency at a single molecular target may
reduce adverse effects [177, 204, 208]. Collectively, the data presented herein
indicate lobinaline’s potential as a lead to develop multifunctional neuroprotective
therapeutics for neurological disorders involving DAergic neurodegeneration
and/or psychostimulant abuse.

Copyright © Dustin Paul Brown 2015
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B

C

Figure 4.1. Lobinaline displaces nicAchRselective radioligands. Data are expressed as
the mean ± S.E.M. Concentration-dependent
inhibition of A) [3H]-epibatidine (Ki = 16.2 μM)
and B) [3H]-cytisine (Ki = 1.1 µM) binding at
nicAchRs by lobinaline in rat cortical
membranes.
C)
Concentration-dependent
inhibition of [3H]-MLA binding (Ki = 67.5 µM) at
nicAchRs in rat hippocampal membranes. n =
3 – 4.
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Table 4.1.
NicAchR selectivity of lobinaline, lobeline, and nicotine at α4β2- and α7nicAchRs
Ki µM
NicAchR Selectivity
Compound α4β2-nicAchR
α7-nicAchR
(-fold difference)5
DDR value
Lobinaline
1.1
67.5
63
1.32
Lobeline3
4.0 x 10-3
6.26
1565
6.276
Nicotine4
9.6 x 10-4
1.448
1508
13.006
3
Ki’s previously reported by Hojahmat et al. (2010) [209]
4
Ki’s previously reported by Rueter et al. (2006) [191]
5
Selectivity based on comparison of Ki’s
6
DDR values previously reported by Littleton et al. (2005) [15]
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Figure 4.2. Lobinaline displays affinity for the DAT. Data
expressed as the mean + S.E.M. A.) Lobinaline concentrationdependently displaces [3H]-GBR12935 (Ki = 2.5 µM) from rat
striatal membranes. n = 4.
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B

Figure 4.3. Lobinaline (LBNA) activates nicAchRs and
inhibits the DAT. Data expressed as the mean ± S.E.M. A)
NIC (10.0 µM) and LBNA (1.0 mM) significantly increase
45
Ca2+ entry in SH-SY5Y cells. LBNA significantly attenuates
NIC-induced 45Ca2+ entry, and MEC (1.0 µM) pretreatment
completely abolishes LBNA-induced 45Ca2+ entry. ** p <
0.01, *** p < 0.001 vs. vehicle (VEH), Student’s one-tailed ttest. # p < 0.05 vs. cells treated with NIC alone, Student’s
one-tailed t-test. n = 3 – 4. B.) Lobinaline dose-dependently
inhibits the DAT (IC50 = 12.0 µM). n = 3 – 4.
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Figure 4.4. DPPH free radical scavenging activity.
Data expressed as the mean ± S.E.M. Quercetin (u)
and lobinaline (n) are potent DPPH free radical
scavengers (EC50 = 11.2 and 18.0 µM, respectively).
Lobeline ( ) is a relatively poor scavenger of DPPH
free radicals (EC50 = 228.8 µM). n = 3 - 5.
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Figure 4.5. Time course of lobinaline-evoked fractional [3H] release from [3H]-DA
preloaded rat striatal slices. Data expressed as the mean ± S.E.M. A) Lobinaline
significantly, and dose-dependently increased fractional [3H] release at 100 µM
( ) and 1,000 µM ( ) vs. vehicle treated controls ( ). Fractional [3H] release was
not significantly increased by 10 µM ( ) lobinaline. Lobinaline was added
immediately after the collection of the fifth sample, as indicated by the arrow. * p
< 0.05, *** p < 0.001, 100 µM lobinaline vs. vehicle treated slices; ## p < 0.01,
### p < 0.001, 1,000 µM lobinaline vs. vehicle treated slices; Two-way ANOVA,
Bonferroni’s post-hoc test. n = 4 – 10 rats. B) Effect of MEC on the time course of
lobinaline-evoked fractional [3H] release from [3H]-DA preloaded rat striatal slices.
Fractional [3H] release was significantly increased by 100 µM lobinaline ( ).
Fractional [3H] release from striatal slices pretreated with 10 µM MEC prior to the
addition of 100 µM lobinaline ( ) was not significantly different from vehicle
treated slices ( ). MEC was added immediately after the collection of the second
sample (small arrow). Lobinaline was added immediately after collection of the
seventh sample (large arrow). * p < 0.05, *** p < 0.001, 100 µM lobinaline vs.
vehicle treated slices; Two-way ANOVA, Bonferroni’s post-hoc test. n = 4.
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Figure 4.6. Effects of lobinaline (LBNA) on exogenous DA clearance in
isoflurane-anesthetized rats measured using HSC. Data are expressed as the
mean ± S.E.M. A) Representative trace of exogenous DA clearance pre- (solid
line) and post-LBNA (dashed line) application. B) LBNA significantly increased (p
= 0.0203) the T80 1-minute post application (76.3 ± 39.5 sec.), as compared to
the T80 pre-application (33.7 ± 12.5 sec.). * p < 0.05, pre- vs. post-lobinaline
application, paired one-tailed Student’s t-test. C) LBNA significantly decreased
(p = 0.0459) the clearance rate 1-minute post-application (0.09 ± 0.05 µM/sec.),
as compared to the clearance rate pre-application (0.13 ± 0.07 µM/sec.). * p <
0.05, pre- vs. post-LBNA application, paired two-tailed Student’s t-test. n = 6.
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Chapter 5

Hairy root methodology

5.1. Chemicals and supplies
Methanol, hexane, and chloroform were purchased from Sigma Aldrich
(St. Louis, MO, USA). [3H]-GBR12935 (S.A. = 40 Ci/mmol) and [3H]-DA (S.A. =
60 Ci/mmol) were purchased from American Radiolabeled Chemicals, Inc. (St.
Louis, MO, USA). All other chemicals and materials were purchased from Fisher
Scientific (Pittsburgh, PA, USA), unless otherwise stated. In all instances, the use
of water (preparation of media, aqueous solutions, etc.) refers to the use of MilliQ® H2O (Millipore, Billerica, Massachusetts, USA). Sterile water refers to Milli-Q
H2O sterilized by autoclaving at 120°C for 20 minutes.
5.2. Selection of candidate plant species
The selection of the candidate plant species for proof-of-concept studies
aimed to demonstrate the use target-directed biosynthesis to optimize a plant’s
pharmacological genotype/phenotype was identified based on the following
characteristics: 1) biological activity of interest, 2) bioactivity arising from a
structurally complex metabolite that was not amenable to pharmacological
optimization via traditional approaches used by medicinal chemist, 3) amenable
to genetic transformation using well-established methodology to generate stable
transgenic cultures, and 4) transgenic cultures generated from the candidate
species which are readily maintained in vitro. In the present study, this translated
to each of the following, respectively: 1) inhibitory modulation of the DAT, 2)
bioactivity arising due to a metabolite having for which no published method for
total synthesis exists which possessed a high degree of structural complexity
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rendering total synthesis unfeasible, 3) amenable to A. rhizogenes-mediated
genetic transformation, and 4) resultant transgenic hairy root cultures having a
rapid rate of growth using conventional in vitro methodology for plant cell culture.
These characteristics were required and/or desirable to increase the feasibility of
successfully demonstrating proof-of-concept.
5.3. Bacterial and plant cell culture media formulations
All bacterial cultures were grown using lysogeny broth (LB; pH 7.0),
prepared as previously described [210]. LB media was autoclaved at 121°C for
20 minutes. Solid LB medium was prepared by adding a gelling agent (agar, 15
g/l) prior to autoclaving. Autoclaved media was placed in a water bath, allowed to
reach 55°C, and then filter sterilized (0.45 µm pore size) solutions of antibiotics
were added as required. The following LB media compositions were used during
the course of the study: liquid LB supplemented with kanamycin (50 mg/ml) or
ampicillin (100 mg/ml), and solid LB supplemented with kanamycin (50 mg/ml) or
ampicillin (100 mg/ml). Solid LB used to isolate transformed E. coli bacterial
colonies carrying pGEM-T vectors was prepared using instructions provided with
the p-GEMT Easy Vector System (Promega, Madison, WI, USA). Transformed A.
rhizogenes strains carrying pCambia1301-based binary vectors were selected
solidified LB supplemented with kanamycin, whereas strains carrying the binary
vector pKYLX80 or pPCVICE4hpt were selected on solidified LB containing
ampicillin.
In vitro plant growth media was prepared using hormone-free half-strength
Murashige and Skoog salts containing B vitamins (½ MS), supplemented with
sucrose (30 g/l) and MES hydrate (0.5 g/l), adjusted to a pH of 5.8. Solid media
was prepared by adding Gelrite (3.875 g/l) prior to autoclaving. All media was
sterilized by autoclaving at 121°C for 20 minutes. After autoclaving and allowing
media to cool to 55°C in a water bath, filter sterilized (0.45 µm pore size)
solutions of antibiotics (cefotaxime) and selection agents (MPTP or MPP+) were
added to achieve required media formulations. The following media were used
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during the course of experimentation: antibiotic-free liquid ½ MS, liquid ½ MS
supplemented with cefotaxime (800 mg/ml), antibiotic-free solid ½ MS, solid ½
MS supplemented with cefotaxime (800 mg/ml or 400 mg/ml), and solid ½ MS
supplemented with cefotaxime (400 mg/ml) and MPTP or MPP+ (final
concentration, 100 µM).
5.4. Binary vectors and the construction of pCambia1301-hDAT
Binary vectors mobilized into A. rhizogenes for the purpose of hairy root
induction, including their respective reporter genes, genes of interest, and
selectable marker genes, are summarized in Table 6.1. Human brain total
reference RNA obtained from Ambion RNA Company (Life Technologies, Grand
Island, NY, USA) was used to isolate cDNA via reverse transcription. Full-length
cDNA coding for the hDAT (1.8-kb pairs) was PCR amplified (forward primer: 5’AAGCTTATGAGTAAGAGCAAATGCTC-3’; reverse primer: 5’-TCTAGACTACACCTTGAGCCAGTGGC-3’), and cloned into the p-GEMT Easy Vector System
(Promega, Madison, WI, USA) using methods provided by the manufacturer.
HindIII and XbaI restriction enzyme sites were added to the 5’-end of the forward
and reverse primers, respectively (underlined above). Authenticity of the gene
was confirmed via sequencing. Full-length cDNA encoding the hDAT was subcloned into the binary vector pKYLX80 downstream of the CaMV 35S promoter
using a directional cloning strategy using the restriction enzymes HindIII and
Xba1, thus creating pKYLX80-hDAT. The CaMV 35S promoter, multiple cloning
site, and rbcs 3’ terminator sequence was restricted from pKYLX80 using EcoR1
and Cla1, then sub-cloned into the multiple cloning site of pBluescript SKcreating a modified pBluescript SK- (mpBluescript SK-). The CaMV 35S promoter
and cDNA encoding the hDAT were excised from pKYLX80-hDAT with EcoR1
and Xba1 restriction enzymes, and ligated into mpBluescript SK- upstream of the
rbcs 3’ terminator, creating hDATmpBluescript SK-. The expression cassette
consisting of the CaMV 35S promoter, full length cDNA coding for the hDAT, and
the rbcs 3’ terminator was excised from hDATmpBluescript SK- using EcoR1 and
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Sal1 restriction enzymes, and ligated into the binary vector pCabmia1301,
ultimately obtaining pCambia1301-hDAT. The presence of the hDAT expression
cassette in pCambia1301-hDAT was confirmed via PCR amplification (forward
primer:

5’-ATGAGTAAGAGCAAATGCTCCGTGGG-3’;

reverse

primer:

5’-

CTACACCTTGAGCCAGTGGCGGAG-3’).
5.5. Agrobacterial strains and transformation
In the present study, A. rhizogenes strain R1000 (AR1000) was used to
generate hairy roots. Competent cells of AR1000 were transformed with binary
vectors using the freeze-thaw method, as previously described [210]. AR1000
carrying pCambia1301, pCambia1301-hDAT, pKM24GFP, or pPCVICE4hpt was
thus obtained (AR1000-C, AR1000-hDAT, AR1000-GFP, and AR1000-ATM,
respectively). Agrobacterial strains were stored at -80°C in 60% glycerol. Fresh
agrobacterial stocks retrieved from storage at -80°C and grown overnight were
used for all plant transformation experiments. Fresh agrobacterial stocks were
prepared every 6 months to conserve the viability and integrity of bacterial strains
their respective vectors.
5.6. Plant growth conditions
In vitro grown plant cultures were maintained in a plant growth chamber at
25°C ± 2°C on a 12-hour light/dark cycle under commercially available
fluorescent lights (light intensity, 45 µmol ! m-2 ! sec-1). All in vitro grown plants,
wild-type roots, and hairy root cultures were maintained under aseptic conditions.
In vitro grown plants, wild-type roots, and hairy root cultures were subcultured
onto fresh medium every 4 – 6 weeks, unless otherwise stated.
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5.7. Germination of L. cardinalis seedlings and induction hairy roots: primary
hairy root induction
L. cardinalis seeds obtained from the Prairie Moon Nursery (Winona, MN,
USA) were surface sterilized with an aqueous 30% bleach solution for 15
minutes, washed three times with sterile water, then stored at 4°C in 10 volumes
of sterile water. Under aseptic conditions, sterilized seeds were aspirated into a
sterile 9-inch pipette, plated onto antibiotic-free solid ½ MS, and then placed in a
plant growth chamber. Care was taken to distribute the seeds evenly over the
surface of the medium. Seeds generally germinated within 4 – 8 weeks.
Hairy roots were generated using methods previously described for L.
erinus, with minor modifications [211, 212]. Briefly, AR1000-hDAT was grown
overnight to an OD600 of ~0.6 in liquid LB supplemented with kanamycin (100
mg/ml). The following day, the bacterial suspension was centrifuged at 4,000 x g
for 8 minutes. The resulting pellet was re-suspended 25 ml of antibiotic-free liquid
½ MS. Plant tissue explants used for hairy root induction consisted of hypocotyl
segments (length, ~1.5 cm) prepared by excising and discarding cotyledons and
radicles from 4 – 6 week old seedlings grown in vitro under aseptic conditions.
Explants were placed in antibiotic-free liquid ½ MS containing agrobacteria,
punctured three times with a sterile hypodermic needle, and allowed to soak for
20 minutes in presence of agrobacteria. Explants were then removed from the
solution containing agrobacteria, blotted on sterile filter paper, placed on
antibiotic-free solid ½ MS, and kept in the dark in a plant growth chamber for a 3day co-cultivation period. Afterward, explants were transferred to a 50 ml conical
tube containing 40 ml of liquid ½ MS supplemented with cefotaxime (1,000
mg/ml) for 30 minutes. The conical tubes were gently shaken (~30 seconds) at 5minute intervals. Explants were then removed, blotted on sterile filter paper,
placed on solid ½ MS supplemented with cefotaxime (800 mg/ml), and
subcultured onto fresh medium every 3 – 5 days for 2 weeks. Next, explants
were transferred to and maintained on solid ½ MS supplemented with cefotaxime
(400 mg/ml), and subcultured onto fresh medium every 1 – 2 weeks. Hairy roots
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emerged from explants within 4 – 6 weeks. Upon reaching a length ≥ 1.5 cm,
hairy roots were excised and maintained on solid ½ MS supplemented with
cefotaxime (400 mg/ml). Control hairy roots were induced using essentially
identical methods, with the exception of being transformed with AR1000-C. Hairy
roots generated directly from L. cardinalis hypocotyls herein are referred to as
primary hairy roots (1°HRs). Two populations of 1°HRs were thus obtained: 1)
transgenic primary hairy roots expressing the hDAT (hDAT-1°HRs) and 2) control
primary hairy roots (Ctrl-1°HRs).
5.8. β-glucuronidase (GUS) histochemical staining assay
Successful transformation of L. cardinalis hairy roots induced with
AR1000-C or AR1000-DAT was confirmed using the GUS histochemical staining
assay, as previously described [210]. Briefly, a stock solution of GUS staining
buffer (50 mM Na3PO4, 0.5 mM K3Fe(CN)6, 0.5 mM K4Fe(CN)6, 10 mM EDTA,
and 0.05% Triton X-100 dissolved in 150 ml of water, pH 7.0) was prepared and
15 ml aliquots of the stock were stored at -20°C. For GUS staining, a 15 ml
aliquot of stock GUS staining buffer was thawed, diluted with water (final volume,
100 mL), and then 35 mg of 5-bromo-4-chloro-3-indolyl-β-D-glucuronide (X-Gluc)
dissolved in 150 µl of DMF was added to the diluted stock buffer. Hairy roots
(length, ~3 – 4 cm) were divided into equal halves with a sterile surgical blade.
Hairy root apices were maintained on solid ½ MS supplemented with cefotaxime
(400 mg/ml). Basal portions of hairy roots were incubated in GUS staining buffer
containing X-Gluc for a 24-hour period at 37°C. The formation of a blue
precipitate indicated successful integration of T-DNA. Hairy root apices
corresponding to basal portions that tested positive for GUS reporter gene
expression were maintained for use in later studies.
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5.9. Conformation of cDNA encoding the hDAT in hDAT-1°HRs
Total RNA was isolated from Ctrl- and hDAT-1°HRs that tested positive for
GUS reporter gene expression. RNA (1 µg) from each sample was reversely
transcribed and subsequently amplified using a cDNA synthesis kit from
Invitrogen and 0.5 mmol of both sense and antisense primers specific to the
hDAT gene sequence. Ten-fold dilutions (initial concentration, 100 ng) of
pCambia1301-hDAT plasmid DNA was used as positive control (standard).
Standards and samples were simultaneously PCR amplified for 30 cycles in a
thermocycler. After amplification, the PCR products were run in agarose gelbased electrophoresis and visualized after ethidium bromide staining. The
amplified PCR products were analyzed under UV light in a Gel-Doc system. The
following primer sequences were used for PCR amplification: forward, 5’ATGAGTAAGAGCAAATGCTCCGTGGG-3’; reverse, 5’-CTACACCTTGAGCCAGTGGCGGAG-3’. hDAT-1°HRs that tested positive for cDNA encoding the hDAT
were maintained for use in later studies.
5.10. [3H]-GBR12935 binding in transgenic L. cardinalis hairy root membranes
Radioligand binding studies were conducted in 1°HR membrane
preparations with the highly selective DAT ligand [3H]-GBR12935 [84, 86].
Membranes were prepared as previously described, with minor modifications
[213]. Briefly, plant tissue from Ctrl- or hDAT-1°HRs that tested positive for cDNA
encoding the hDAT was flash frozen with liquid nitrogen and lyophilized. Freezedried tissue was ground to a fine powder and homogenized in 10 volumes of
buffer (0.1 M Na2HPO4, 0.5 M mannitol, 50 mM ascorbic acid, 5 mM EDTA, 40
mM 2-mercaptoethanol, 0.5 M PMSF, 10 µg/ml leupeptin, 4.4 µg/ml aprotenin
and 2.5 µg/ml bacitracin). The resulting homogenates were centrifuged at 10,000
x g for 15 minutes at 4°C, the resulting pellet was discarded, and the supernatant
was centrifuged at 50,000 x g for 30 minutes at 4°C. The resulting pellet was
resuspended in buffer (20 mM HEPES, 20 mM NaCl, 1 mM MgCl2, 1 mM EDTA,
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30% glycerol, 0.2 mM PMSF, 10 µg/ml leupeptin, 4.4 µg/ml aprotenin, 2.5 µg/ml
bacitracin), washed 3 times, then pelleted again at 50,000 x g for 30 minutes at
4°C. The resulting membrane isolates (final tissue concentration, 3.3 µg/ml) were
incubated with [3H]-GBR12935 (final concentration, 0 – 250 nM) in assay buffer
(50 mM Na2PO4, 120 mM NaCl, 10 µM ZnCl, adjusted to pH 7.4) for 2 hours in a
96-well plate format (final reaction volume, 300 µL). Experiments were performed
at room temperature. After reaching equilibrium, membranes were harvested
onto 96-well GF/B filter plates (PerkinElmer Inc., Waltham, MA, USA) by vacuum
filtration, and rapidly washed three times with ice-cold 50 mM Tris-HCl buffer (pH
7.4). Filter plates were pretreated with a solution of 0.1% polyethyleneimine 1
hour prior to harvesting membranes to reduce non-specific binding. Filter plates
were allowed to dry overnight. The following day, 35 µL of scintillation fluid
(Microscint 20, Packard Inc.) was added to each well and plates were placed in
the dark for two hours. Afterward, radioactivity was measured by scintillation
counting (2 minutes per well) using a Packard TopCount® NXT™ microplate
scintillation counter. Total binding was measured in the presence of radioligand
alone, and non-specific binding was measured in the presence of excess
GBR12909 (final concentration, 10 µM). Specific binding was calculated by
subtracting non-specific binding from total binding. hDAT-1°HRs that tested
positive for hDAT protein expression were maintained for use in subsequent
experiments.
5.11. [3H]-DA uptake studies in L. cardinalis 1°HRs
Radiotracer uptake studies were performed with apices from Ctrl- or
hDAT-1°HRs. Briefly, excised 1°HR apices (n = 20 per group; total mass,
~100mg) were incubated in uptake buffer (120 mM NaCl, 3.9 mM KCl, 650 µM
MgSO4, 510 µM CaCl2, 190 µM NaHPO4, 100 µM pargyline, 2 mg/ml glucose,
0.2 mg/ml ascorbic acid, 20 mM HEPES, pH 7.4), uptake buffer containing the
highly selective DAT inhibitor GBR12909 (final concentration, 100 µM), or Na+free uptake buffer at 37°C for 15 minutes prior to the addition of [3H]-DA (final
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concentration, 20 – 30 nM) [84-88]. Initial experiments were performed at a
single time point, terminating uptake 4 minutes after the addition of [3H]-DA.
Experiments examining the time-dependence of [3H]-DA uptake were performed
by incubating Ctrl- or hDAT-1°HRs in uptake buffer at 37°C for 15 minutes, after
which [3H]-DA was added. Uptake in time course studies was terminated 1 – 30
minutes after the addition of [3H]-DA. In a final set of experiments, Ctrl- or hDAT1°HRs were incubated in uptake buffer, or uptake buffer containing GBR12909
(final concentration, 10 µM or 100 µM) for 15 minutes at 37°C, after which [3H]DA was added, and uptake was allowed to proceed for 5 or 25 minutes. The final
concentration of [3H]-DA was consistent in all uptake studies. Uptake in all
experiments was terminated by washing 1°HR apices thrice with ice-cold uptake
buffer after the removal of solution containing [3H]-DA. After removing the last
wash, 1°HR apices were flash frozen with liquid nitrogen, lyophilized, and ground
to a fine powder. Ground hairy root tissue was extracted with 300 µl of uptake
buffer containing cellulase enzyme (1,500 units/ml) for 24 hours, then centrifuged
at 20,0000 x g for 20 minutes at 4°C. Aliquots (100 µl) from the supernatants of
various treatment groups were added to scintillation fluid and radioactivity was
measured by scintillation counting using a Packard Tri-Carb Liquid Scintillation
Counter (Gaithersberg, MD, USA). Data were expressed as the rate of uptake
per unit mass of hairy root tissue per unit time (CPM/mg tissue/minute).
5.12. 6-OHDA- and MPTP/MPP+-induced cytotoxicity
Wild-type roots (WT-Rs), Ctrl-1°HRs, and hDAT-1°HRs were exposed to
cytotoxic DAT substrates, 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP), which are neurotoxins used to model PD [43,
89-92, 114, 214]. The oxidative metabolite of MPTP, 1-methyl-4-phenylpyridinium
(MPP+), is a cytotoxic DAT substrate [89, 90]. Hairy root apices (n = 5 per
treatment group; total mass, ~ 120 mg total) were placed in conical tubes
containing 5 ml of liquid ½ MS (vehicle), or liquid ½ MS containing MPTP or 6OHDA (final concentration, 100 µM and 50 µM, respectively), and then incubated
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at room temperature for 24 hours in the dark. Cell viability was normalized to that
of WT-Rs. In a separate set of experiments, Ctrl- or hDAT-1°HR apices were
placed in conical tubes containing 5 mL of liquid ½ MS (vehicle) or liquid ½ MS
containing GBR12909 (final concentration, 10 µM or 100 µM) for 1 hour prior to
being treated with MPTP or 6-OHDA, as described above. In the latter
experiments, only hDAT-1°HR apices were treated with GBR12909 and/or
neurotoxins. Cell viability was normalized to that of vehicle treated Ctrl-1°HRs.
After the 24-hour treatment period, root apices were stained with trypan
blue to visualize dead or dying cells, as previously described with modifications
[215]. Briefly, treatment solutions were removed and discarded, then root apices
were washed 3 times with liquid ½ MS. The final wash was removed, replaced
with 5 ml of trypan blue stain (0.4%), and the staining solution was vacuum
infiltrated for 30 minutes. Root apices were then incubated at 90°C for 2 hours,
the trypan blue staining solution was then removed, and replaced with an
aqueous solution (5 ml) of chloral hydrate (final concentration, 2.5 g/ml). Roots
were incubated in the solution of choral hydrate at room temperature overnight in
the dark. The following day, root apices were placed on a microscope slide and
visualized at 32x magnification using a dissecting microscope. Images were
captured with a digital camera affixed to the microscope. Trypan blue staining
intensity was quantified with ImageJ software and converted to an index of cell
viability.
5.13. Sequential hairy root transformation: induction of secondary hairy roots
Sequential transformation of hairy roots was accomplished using
essentially the same protocol as that described to induce 1°HRs (see section
5.7), with the exception that 1°HRs served as a source of explants. Explants
(length, ~1.5 – 2 cm) excised from Ctrl-1°HRs that tested positive for GUS
reporter gene expression (see section 5.8) were co-cultured with AR1000-GFP.
Secondary hairy roots (2°HRs) emerged ~2 – 4 weeks later at cut surfaces and
wound sites on the lateral surfaces of explants created with a sterile hypodermic
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needle. Individual hairy roots were tested for both GFP and GUS reporter gene
expression via florescent microscopy (equipment, wave length of excitation, etc.)
and histochemical staining, respectively. Initially, 2°HRs were evaluated for GFP
reporter gene expression, since GUS staining would preclude GFP imaging. The
transformation frequency was determined by dividing the total number of 2°HRs
emerging from the each 1°HR explant by the number of 2°HRs that tested
positive for both GUS and GFP reporter gene expression.
5.14. Induction and selection of transgenic gain-of-function hairy roots
functionally expressing the hDAT
Explants (length, ~1.5 – 2 cm) obtained from hDAT-1°HRs functionally
expressing the hDAT were co-cultured with AR1000-ATM for 3 days, using
methods for sequential hairy root induction described above. Following the cocultivation period, hairy root explants were soaked in liquid ½ MS supplemented
with cefotaxime (1,000 mg/ml) for 30 minutes, blotted on sterile filter paper, and
placed on solid ½ MS supplemented with cefotaxime (800 mg/ml). Explants were
subcultured every 3 days onto fresh medium for 1 week. Nodules indicating the
initiation of 2°HR formation began form at cut surfaces and wound sites on the
lateral surfaces of explants ~2 weeks after co-culture. Explants were then
transferred to selection medium, solid ½ MS supplemented with cefotaxime (400
mg/ml) and a neurotoxin/selection agent, MPTP or MPP+ (final concentration,
100 µM). During the first month of selection, explants were subcultured onto
fresh selection medium weekly. Subsequently, explants were subcultured onto
fresh selection medium every 4 – 6 weeks. Fully differentiated secondary gain-offunction transgenic hairy roots expressing the hDAT which were resistant to the
selection agent (toxin resistant secondary hairy roots, TR-2°HRs) emerged 4 – 6
weeks later, and were excised from hDAT-1°HR explants after reaching a length
≥ 1.5 cm. Excised TR-2°HRs were maintained on selection medium ≥ 4 months
prior to being transferred to solid ½ MS supplemented with cefotaxime (400
mg/ml) only. TR-2°HRs that were initially selected on medium containing MPTP
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were transferred to and maintained on selection medium containing MPP+ for ≥ 4
months prior to be transferred to solid ½ MS supplemented with cefotaxime (400
mg/ml) only. MPP+ was used as a selection agent, rather than MPTP, in later
studies since differences in MPTP susceptibility could have arisen due to
variations in 2°HRs’ ability to oxidize MPTP to MPP+. Selection with MPP+ also
prevented resistance that could have arisen from mutations leading synthesis of
oxidase inhibitors and/or reduction of oxidase activity. Therefore, MPP+ selection
was more selective for the survival of TR-2°HRs having mutations leading to
increased hDAT inhibitory modulation. A separate population of secondary gainof-function transgenic hairy roots expressing the hDAT was generated, but was
not selected on medium containing a cytotoxic DAT substrate (ATMhDAT2°HRs).
5.15. Hairy Root Populations and Tissue collection
Four hairy root populations were established: Ctrl-1°HRs (n = 68), hDAT1°HRs (n = 77), ATMhDAT-2°HRs (n = 72), and RHRs (n = 109). Root apices
(length, ~1.5 cm) were placed on fresh medium to propagate individual cultures
when hairy root populations were subcultured. All remaining tissue from
individual hairy root cultures was placed in 15 ml conical tubes labeled with the
corresponding population and hairy root number, then stored at -20°C prior to
use in subsequent experiments.
5.16. Preparation of hairy root MeOH extracts and the isolation of lobinaline
Tissue samples collected from individual hairy roots were removed from
storage at -20°C, immediately freeze-dried, ground to a coarse powder, and
extracted with 3 volumes of methanol overnight in the dark. The following day,
samples were centrifuged at 10,000 RPM for 30 minutes. Equal volumes of the
resulting supernatants were aliquoted into two pre-weighed, labeled 1.5 ml
conical tubes, dried using a CentriVap, and the masses conical tubes containing
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dried extract were determined. The mass of a dried extract was calculated by
subtracting the mass of the conical tube and from that of a conical tube
containing dried extract. One aliquot from each individual hairy root was
assessed in pharmacological assays. The other was subject to gas
chromatographic-mass spectrometric (GC-MS) analysis. Lobinaline was isolated
as previously described (see section 3.5). Lobinaline thus obtained was analyzed
using GC-MS methods described below (see section 5.18), and the purity of the
alkaloid was determined by integrating the area under the curve (AUC) of
lobinaline’s chromatographic peak (GC-MS run in TIC mode; purity ≥ 95%). The
identity the alkaloid was confirmed based on previously reported MS
fragmentation data for lobinaline [135]. Dried methanolic (MeOH) hairy root
extracts and lobinaline were stored at -20°C prior to further experimentation.
5.17. Pharmacological analysis of hairy root MeOH extracts: inhibition of DATmediated [3H]-DA uptake
The DAT inhibitory activity of MeOH extracts from individual hairy roots
was examined by performing [3H]-DA uptake in rat striatal synaptosomes. In vitro
[3H]-DA uptake was performed as previously described with minor modifications
[57]. Briefly, adult male Sprague-Dawley rats (200-250 g) were anesthetized with
CO2 and decapitated. Striata were rapidly dissected and immediately placed into
10 volumes of ice-cold uptake buffer (120 mM NaCl, 3.9 mM KCl, 650 µM
MgSO4, 510 µM CaCl2, 190 µM NaHPO4, 100 µM pargyline, 2 mg/ml glucose,
0.2 mg/ml ascorbic acid, 20 mM HEPES, pH 7.4, saturated with 95% O2/5% CO2)
containing 0.32 M sucrose. Striatal tissue was homogenized in a glass
homogenization tube with a Teflon pestle. The homogenate was centrifuged at
1,000 x g for 10 minutes at 4°C. The resulting supernatant was collected and
centrifuged at 16,000 x g for 20 minutes at 4°C. The resulting pellet was washed
twice with ice-cold uptake buffer and re-suspended in 10 ml of uptake buffer
(synaptosome preparation). Synaptosomes (100 µl) were added to individual
wells in a 96-well plate and incubated at 37°C for 10 minutes. Hairy root MeOH
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extracts were dissolved in uptake buffer containing 1.0% DMSO. Lobinaline was
dissolved in 100% DMSO, then diluted with uptake buffer (0.3 nM – 3 mM). The
final concentration of DMSO in uptake studies never exceeded 1.0%, which had
no significant effect on radiotracer uptake using methods outlined in the present
study. Hairy root MeOH extracts (100 µl; final concentration 200 or 100 µg/ml) or
lobinaline (100 µl; final concentration, 0.1 nM – 1 mM) were co-incubated with
synaptosomes for 10 minutes at 37°C prior to the addition of [3H]-DA (100 µl).
After the 10-minute co-incubation, [3H]-DA was added to each well (final
concentration, 15 – 30 nM) and uptake was allowed to proceed for 5 minutes at
37°C. Uptake was terminated by placing 96-well plates on ice, and then
immediately harvesting synaptosomes onto a 96-well GF/C filter plates
(PerkinElmer Inc.) by vacuum filtration, followed by three rapid washes with icecold 50 mM Tris-HCl buffer (pH 7.4). After allowing filtration plates to dry
overnight, 35 µl of scintillation fluid (Microscint 20, Packard Inc.) was added to
each well and the plate was kept in the dark for 2 hours. Subsequently,
radioactivity was measured by scintillation counting using a Packard TopCount®
NXT™ microplate scintillation counter. Total uptake was measured in the
presence of [3H]-DA alone. Non-specific uptake was determined in the presence
of 10 µM GBR-12909. Total specific uptake and specific uptake in the presence
of extract or lobinaline was calculated by subtracting non-specific uptake from
each, respectively. Specific uptake in the presence of inhibitor was expressed as
a percentage of total specific uptake. Each extract’s inhibitory activity at the DAT
was expressed as lobinaline equivalents, extrapolated from the lobinaline doseresponse curve. DAT inhibitory activity (mean ± S.E.M) of each hairy root
population was calculated. The frequencies of “highly active DAT inhibitors,”
designated as hairy roots whose extract produced DAT inhibition ≥ 2 S.D. above
mean DAT inhibition observed for the hDAT-1°HR population, were calculated for
ATMhDAT- and TR-2°HR populations.
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5.18. GC-MS analysis of hairy root MeOH extracts
MeOH extracts from individual hairy roots were analyzed via GC-MS. GCMS analyses were performed using a Hewlett Packard 6890 Gas Chromatograph
interfaced to a Hewlett Packard 5973 Series Mass Selective Detector, an Agilent
Technologies 7683 Series Injector, and a Hewlett Packard 7683 Series
Autosampler. ChemStation Software (Version 1.02.06) and the Wiley Spectral
Database (Version 4.0) were used for instrument control, data analysis, and
structural elucidation. Separation was performed on a HP-5MS column ((5%phenyl)-methylpolysiloxane; 30.0 m x 320 µm x 0.25 µm). Ultra-high purity helium
(flow rate of 1.2 ml/minute) served as the carrier gas. Sample volumes of 1 µl
were injected in split mode (split ratio, 10.0:1; split flow 12.3 ml/minute) at an inlet
pressure of 1.60 psi. The inlet temperature was held at 250°C. The oven was
operated using the following parameters: initial temperature, 80°C; 80°C, 2
minute hold; 10°C/minute to 160°C, 1 minute hold; 60°C/minute to 275°C, 12
minute hold; 60°C/min. to 60°C, 0 minute hold; total runtime, 28.50 minutes. The
transfer line temperature was held at 280°C. Lobinaline content of each extract
was quantified. A concentration-response curve for lobinaline was generated by
dissolving the alkaloid in methanol (concentrations prepared, 10 µg/ml, 25 µg/ml,
50 µg/ml, 100 µg/ml, 250 µg/ml, 500 µg/ml, and 1,000 µg/ml), and then analyzing
duplicate samples at each concentration. The abundances of the peak
corresponding

to

m/z

=

186

in

the

MS

extracted

from

lobinaline’s

chromatographic peak were averaged at each concentration. Data were
analyzed using linear regression, and response to lobinaline over this
concentration range displayed excellent linearity (r2 = 0.9965, x-intercept = 1.8
µg/ml). Lobeline was dissolved in methanol (final concentration, 10 – 1000
µg/ml), and subject to GC-MS analysis using the same chromatographic
conditions to identify and determine the retention time of it’s chromatographic
peaks (two prominent peaks were observed, presumably due to decomposition of
lobinaline in the instrument prior to reach the MSD). In the present study,
chromatographic peaks indicating the presence of lobeline were not detected in
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any of the MeOH extracts prepared from L. cardinalis hairy roots. Dried MeOH
extracts obtained from individual hairy roots were resuspended in methanol (final
concentration, 4 mg/ml), and then each sample was analyzed in duplicate. The
peak abundance (m/z = 186) in the MS extracted from the lobinaline’s
chromatographic peak was averaged for each individual hairy root. The
concentration of lobinaline present was calculated from the lobinaline calibration
curve. The mean lobinaline content of each hairy root population was calculated.
The frequencies of “lobinaline overproducers,” designated as hairy roots whose
extract’s lobinaline content was ≥ 2 S.D. above the mean lobinaline content
observed for the hDAT-1°HR population, were calculated for ATMhDAT- and TR2°HR populations.
Qualitative examination of GC traces from individual hairy roots from each
population was carried out to determine whether the “fingerprint” of metabolites
(i.e. chromatographic peaks) present in extracts within a given population were
consistent and reproducible. Qualitative analysis of GC traces from ATMhDAT2°HRs and TR-2°HRs was also performed to identify of chromatographic peaks
that were present, which were undetectable in 1°HR populations. When possible,
structural elucidation of metabolites present in increased yields and/or “novel”
metabolites was carried out using the software described above.
5.19. Data Analysis
Statistical analyses, curve fitting, and graphical presentation of data were
performed using GraphPad Prism software (Version 6.0; GraphPad Software,
San Diego, CA, USA). Bmax and Kd values for [3H]-GBR12935 binding in hDAT1°HR membranes were calculated using nonlinear regression analysis to fit
radioligand binding data to a one-site saturation binding model. One-way
analysis of variance (ANOVA) followed by Tukey’s post-hoc analysis was
performed to determine whether hDAT expression significantly increased [3H]-DA
uptake in hDAT-1°HRs, and to determine whether GBR12909 or Na+-free
conditions significantly affected radiotracer uptake in Ctrl- and hDAT-1°HRs at 4-
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minutes. Two-way ANOVA was performed (time x phenotype interaction) to
determine if hDAT expression significantly increased [3H]-DA uptake in time
course studies. Bonferroni’s post-hoc analysis was used to determine time points
at which the magnitude of [3H]-DA uptake in Ctrl- and hDAT-1°HRs was
significantly different. One-way ANOVA followed by Dunnett’s post-hoc analysis
was performed to determine the time points at which [3H]-DA uptake in Ctrl- or
hDAT-1°HRs was significantly different than that measured in respective groups
at 1-minute. Two-way ANOVA (time x phenotype interaction) followed by
Bonferroni’s post-hoc analysis was performed to determine whether [3H]-DA
uptake measured at 5- and 25-minutes was significantly increased by hDAT
expression, and to determine if uptake at 25-minutes was significantly greater
than that observed at 5-minutes in Ctrl- and hDAT-1°HRs. Two-way ANOVA
(treatment x phenotype interaction) followed by Bonferroni’s analysis was
performed to determine whether GBR12909 significantly inhibited [3H]-DA uptake
in Ctrl- and hDAT-1°HRs at 5- and 25-minutes. One-way ANOVA followed by
Tukey’s post-hoc analysis was performed to determine whether susceptibility to
cytotoxic DAT substrates was significantly affected by hairy root phenotype
and/or hDAT expression. One-way ANOVA followed by Tukey’s post-hoc
analysis was performed to determine whether GBR12909 significantly attenuated
toxicity caused by cytotoxic DAT substrates in hDAT-1°HRs. One-way ANOVA
followed by Tukey’s post-hoc analysis was performed to determine whether the
mean inhibitory DAT activity and the mean lobinaline content of hairy root
populations were significantly different. Two-tailed Chi-Square analysis and
Fisher’s exact test were performed to determine whether ATM combined with
selection significantly increased the frequency of “highly active DAT inhibitors”
and/or “lobinaline overproducers” when compared to the use of ATM alone. All
data are expressed as the mean ± the standard error of the mean (S.E.M.),
unless otherwise stated. A p-value < 0.05 was defined as statistically significant.

Copyright © Dustin Paul Brown 2015
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Table 5.1. Binary vectors mobilized into A. rhizogenes
Reporter genes,
Vector
Selectable marker gene*
genes of interest
GUS reporter
pCamiba1301
KanR, kanamycin resistance
gene
GUS reporter
pCambia1301gene
KanR, kanamycin resistance
hDAT
cDNA encoding
the hDAT
pKM24GFP
GFP
KanR, kanamycin resistance
pPCVICE4hpt

CaMV 35S
enhancer tetramer

AmpR, ampicillin resistance

*Selectable marker genes used to isolate transformed bacterial colonies
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Figure 5.1. Expression of foreign genes in plant cells via A. rhizogenesmedicated genetic transformation. A. rhizogenes carrying the root inducing
plasmid (Ri-plasmid) is capable of transforming plant cells leading the induction
of hairy roots. Transfer DNA (T-DNA) present in the Ri-plasmid is transferred
and integrated into the genome of host plant species, which encodes genes
responsible for hairy root formation. The Ri-plasmid is isolated and genes of
interest (GOI), along with a maker gene, are cloned into the borders of the TDNA. The Ri-plasmid, containing GOI and a marker gene within the borders of
the T-DNA, is transformed into A. rhizogenes. Transformation of plant seedlings
with A. rhizogenes harboring the newly constructed Ri-plasmid leads to the
induction hairy roots, which arise from a single transformed plant cell. The
resulting hairy root is comprised of cells that are clonal in nature, each
expressing the GOI and the marker gene, which is utilized to confirm successful
transformation. In the present study, L. cardinalis hypocotyl explants were
transformed with AR1000-hDAT, harboring the binary vector pCambia 1301hDAT, leading to the induction of hDAT-1°HRs.
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Figure 5.2. Lobinaline calibration curve. Data expressed as the mean ± S.E.M.
The lobinaline concentration-response displayed excellent linearity (r2 = 0.9965)
over the concentration range examined (10 – 1000 µg/ml). Each concentration
was prepared in duplicate. X-intercept = 1.8 µg/ml.
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Chapter 6

Functional Expression of the hDAT in transgenic L. cardinalis hairy roots

6.1. Introduction
Lobinaline is structurally complex binitrogenous alkaloid present in L.
cardinalis, which inhibits the DAT, albeit with low potency (IC50 = 12.0 µM). There
is no published method for the total synthesis of lobinaline, and the alkaloid is
obtained in low yields when purified from plant material, preventing access to
sufficient quantities of lobinaline required for pharmacological optimization via
traditional approaches [8, 20, 206]. In order to generate a library of L. cardinalis
plant cell cultures whose pharmacological profile was genomically optimized, the
human dopamine transporter (hDAT) was functionally expressed in transgenic L.
cardinalis hairy “primary” root cultures (hDAT-1°HRs). Here, “primary” refers to
hairy roots induced directly from wild-type plant, L. cardinalis, in contrast to
“secondary” hairy roots generated directly from hairy root explants via sequential
transformation.
The purpose of expressing the hDAT protein in transgenic plant cells was
two-fold. One, to enable the selection of gain-of-function mutant transgenic plant
cells expressing the hDAT on selection medium containing cytotoxic DAT
substrates, which was predicted to favor mutants with increased yields of
lobinaline and/or “novel” DAT inhibitors. Two, to favor biosynthesis of “novel”
DAT ligands whose structure was optimized to interact with a specific human
target protein. The former was desirable since mutants with increased yields of
lobinaline could be utilized for the production of the alkaloid, whereas mutants
with “novel” DAT inhibitors served as a repository of leads for the development of
novel DAT ligands. The latter should theoretically enable one to redirect plant
evolution favoring biosynthesis of molecules meant to interact with a human
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target protein. This is in contrast to naturally occurring plant metabolites, which
evolved to interact with molecular targets present in organisms more frequently
encountered by plants, such as microbes or herbivorous insects [13, 14].
6.2. Candidate plant species: Lobelia cardinalis
L. cardinalis was selected as the candidate species for proof-of-concept
studies using target-directed biosynthesis. Lobinaline (see Figure 3.3), the major
alkaloid present in L. cardinalis, inhibits the DAT and scavenges free radicals
(see sections 4.3 and 4.4, respectively). However, there is no published method
for the total synthesis of the complex decahydroquinoline alkaloid, rendering
lobinaline a poor candidate for pharmacological optimization via traditional
methods used by medicinal chemist. In preliminary studies, L. cardinalis was
readily transformed using A. rhizogenes-mediated genetic transformation. The
resulting hairy root cultures displayed a rapid rate of growth and were easily
maintained in vitro on solid ½ MS medium. These characteristics of the L.
cardinalis, L. cardinalis hairy root cultures, and lobinaline were ideal for proof-ofconcept studies using target-directed biosynthesis to optimize the plant’s
pharmacological activity at the hDAT. Here, optimized activity at the hDAT refers
to: 1) increased yields of lobinaline and/or 2) biosynthesis of “novel” metabolites
that are more potent DAT inhibitors.
6.3. Construction of pCambia1301-hDAT and the establishment of L. cardinalis
primary hairy root cultures
Full-length cDNA encoding the hDAT (1.8-kb) was PCR amplified from
human brain total reference RNA (Figure 6.1), sequenced and authenticity
confirmed. Subsequently, the cDNA coding for the hDAT was ligated into an
expression cassette downstream of the constitutively active CaMV 35S promoter
and upstream of the rbcs 3’ terminator sequence (Figure 6.2). AR1000-hDAT
was obtained by transforming AR1000 with pCambia1301-hDAT, created by sub-
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cloning the hDAT expression cassette within the T-DNA borders of the binary
vector pCambia1301.
Hairy roots were generated from hypocotyl segments of L. cardinalis
seedlings. Initial studies were performed to determine whether hairy roots could
be induced from L. cardinalis hypocotyl explants using AR1000-C. Ctrl-1°HRs
were successfully obtained. The transformation frequency for L. cardinalis
hypocotyl explants was ~53% (46 out of 86 explants produced Ctrl-1°HRs that
tested positive for GUS reporter gene expression). A total of 129 Ctrl-1°HRs, as
confirmed GUS reporter gene expression, were generated from the 46 explants
(mean Ctrl-1°HRs per explant, 2.8). Images of Crtl-1°HRs subject to GUS
histochemical staining clearly demonstrate the presence of a blue precipitate
(Figure 6.3), indicative of successful transformation. Subsequently, hypocotyl
explants were transformed with AR1000-hDAT generating hDAT-1°HRs, and
successful integration of T-DNA was confirmed based on GUS reporter gene
expression. A schematic summarizing the approach utilized to induce Ctrl- and
hDAT-1HRs is depicted in Figure 6.4.
6.4. hDAT-1°HRs tested positive for cDNA encoding the hDAT and hDAT protein
expression
The expression of the cDNA encoding the hDAT was examined in hDAT1°HRs by RT-PCR. As shown in Figure 6.5 A, a 1.8-kb PCR amplification
product was clearly visible in the sample from hDAT-1°HRs (lane 4), whereas the
band was absent in the sample from Ctrl-1°HRs (lane 3). Radioligand binding
studies were conducted to determine if the hDAT protein was expressed by
hDAT-1°HRs that tested positive for cDNA encoding the transporter. Ctrl- or
hDAT-1°HR membranes were incubated with varying concentrations of [3H]GBR12935 (0 – 250 nM), a highly selective DAT ligand [84, 86]. In hDAT-1°HR
membranes, specific binding was saturable (Kd = 2.8 ± 0.7 nM, Bmax = 22.9 ± 1.0
fmol/mg tissue), and displayed excellent fit (r2 = 0.9687) to a one-site binding
model (Figure 6.5 B). The Kd value for [3H]-GBR12935 at the hDAT in plant cell
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membranes corresponded well with that reported for the radioligand at the DAT
in rat striatal membranes (Kd ~1 – 6 nM) [84, 86]. However, the Bmax value
determined for hDAT-1°HR membranes was substantially lower than that
reported for rat striatum (56.9 ± 3.5 pmol/µg tissue) [216]. In Ctrl-1°HR
membranes, a non-specific increase in binding was observed. The hDAT-1°HR
lines that tested positive for cDNA encoding the hDAT and hDAT protein
expression were maintained for use in subsequent experiments.
6.5. [3H]-DA Uptake in 1°HRs: the hDAT expressed in hDAT-1°HRs is functional
Radiotracer uptake studies were performed to determine if the hDAT was
functional when expressed in transgenic plant cells. Initially, [3H]-DA uptake was
measured at a single time point (4 minutes; Figure 6.6 A). The rate of [3H]-DA
uptake was significantly greater in hDAT-1°HRs, as compared to Ctrl-1°HRs (5.9
± 0.5 and 2.8 ± 0.3 DPM/mg tissue/minute, respectively; p = 0.0008). In hDAT1°HRs, the rate of [3H]-DA uptake was significantly reduced by GBR12909 (100
µM) or under Na+-free conditions (3.1 ± 0.2 and 2.4 ± 0.4 DPM/mg tissue/minute,
p = 0.0018 and p = 0.0002, respectively), both of which reduced the rate of
radiotracer uptake to that observed in Ctrl-1°HRs. The rate of [3H]-DA uptake in
Ctrl-1°HRs was unaffected by GBR12909 pretreatment or under Na+-free
conditions. Next, the time course of [3H]-DA uptake was examined in Ctrl- and
hDAT-1°HRs (Figure 6.6 B). Two-way ANOVA revealed a significant effect of
phenotype (p < 0.001), a significant effect of time (p < 0.001), and a significant
time x phenotype interaction (p < 0.001). The magnitude of [3H]-DA uptake in
Ctrl- and hDAT-1°HRs was significantly different at 4-minutes (16.8 ± 0.9 and
24.7 ± 1.1 CPM/mg tissue, respectively, p = 0.0257), and remained significant
thereafter. Of note, [3H]-DA uptake in Ctrl- and hDAT-1°HRs was time-dependent
and saturable, albeit the Vmax was significantly lower (p = 0.0006) in Ctrl-1°HRs
(Vmax = 94.1 ± 2.7 CPM/mg tissue/minute), as compared to hDAT-1°HRs (Vmax =
131.8 ± 2.6 CPM/mg tissue/minute). A one-way ANOVA followed by Dunnett’s
post-hoc analysis was performed to determine the time points at which [3H]-DA
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uptake was significantly greater than that measured at 1-minute in Ctrl- or hDAT1°HRs. In Ctrl- and hDAT-1°HRs, the magnitude of [3H]-DA uptake at 5-minutes
(25.6 ± 0.1 and 36.0 ± 1.0 CPM/mg tissue, respectively) was significantly greater
(p < 0.001 and p = 0.0007, respectively) than that measured at 1-mintue (15.6 ±
0.4 and 18.6 ± 0.8 CPM/mg tissue, respectively). These data indicate that both
Ctrl- and hDAT-1°HRs express transporters with the capacity for [3H]-DA uptake,
in agreement with previous studies reporting transporter-mediated biogenic
amine uptake in plants [217, 218]. However, hDAT expression significantly
increased [3H]-DA uptake in hDAT-1°HRs demonstrating that the transporter was
functional in transgenic plant cells. Additionally, the increase in [3H]-DA uptake in
hDAT-1°HRs was abolished by GBR12909 or under Na+-free conditions
indicating that hDAT expressed in plant cells retains its sensitivity to
pharmacologic and ionic manipulations known to influence DAT function in
mammalian cells [54, 84-88].
To confirm hDAT-1°HR’s increased capacity for [3H]-DA uptake was
attributable to hDAT expression beyond 4-minutes, radiotracer uptake was
measured in Ctrl- and hDAT-1°HRs pretreated with vehicle or GBR12909 (100
µM) at two time points (5- and 25-mintues; Figure 6.6 C). Two-way analysis of
variance revealed a significant effect of time (p < 0.001), and a significant effect
of phenotype (p < 0.001), and a significant time x phenotype interaction (p <
0.001). [3H]-DA uptake measured at 5- and 25-mintues in hDAT-1°HRs was
significantly greater (p < 0.001) than that observed in all of the corresponding
Ctrl-1°HR treatment groups at 5- and 25-minutes. In Ctrl- and hDAT-1°HRs, the
magnitude of [3H]-DA uptake was significantly greater (p < 0.001) at 25-minutes,
as compared uptake measure in corresponding treatment groups at 5-mintues.
An additional two-way ANOVA revealed a significant effect of phenotype (p < 0.
001), a significant effect of treatment (p < 0.001), and a significant phenotype x
treatment interaction (p < 0.001). GBR12909 pretreatment did not affect [3H]-DA
uptake in Ctrl-1°HRs at either time point. In contrast, [3H]-DA uptake in hDAT1°HRs was significantly decreased (p < 0.001) by GBR12909 at 5- and 25minutes (19.9 ± 0.1 and 76.2 ± 1.6 CPM/mg, respectively), as compared to
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vehicle pretreated hDAT-1°HRs (36.0 ± 1.0 and 127.2 ± 1.1 CPM/mg tissue,
respectively). At 5- and 25-minutes, the magnitude of [3H]-DA uptake in hDAT1°HRs pretreated with GBR12909 was reduced to that observed in Ctrl-1°HRs.
These data indicate that hDAT expression enhances [3H]-DA uptake in hDAT1°HR’s, although radiotracer uptake occurs via two components: 1) hDATmediated uptake, which is Na+-dependent and GBR12909-sensitive, and 2) Na+independent transporter-mediated uptake that was GBR-insensitive. The latter,
which was observed in Ctrl- and hDAT-1°HRs, is consistent with previous studies
in rice and Arabidopsis demonstrating Na+-independent biogenic amine uptake
via system L amino acid transporters [217-219].
6.6. Differential cytotoxic effects of MPTP and 6-OHDA in Ctrl- and hDAT-1°HRs
L. cardinalis wild-type roots (WT-Rs), Ctrl- and hDAT-1°HRs were treated
with MPTP or 6-OHDA (final concentration, 100 and 50 µM, respectively; 24-hour
treatment) to determine whether hairy root phenotype and/or hDAT expression
altered root’s susceptibility to cytotoxic DAT substrates. MPTP’s oxidative
metabolite, MPP+, is a cytotoxic DAT substrate [89, 90]. In initial studies, cell
viability was normalized to that of WT-Rs treated with cytotoxins (Figure 6.7).
MPTP significantly reduced cell viability in hDAT-1°HRs (54.1% decrease, p <
0.0001), as compared to WT-Rs. MPTP reduced cell viability in Ctrl-1°HRs
(15.8% decrease), as compared to WT-Rs, but the effect was not significant (p =
0.2762). Cell viability in MPTP-treated hDAT-1°HRs was also significantly
reduced (38.3% decrease, p = 0.0016), as compared to Ctrl-1°HRs. In contrast,
6-OHDA significantly decreased cell viability in Ctrl-1°HRs (32.8% reduction, p =
0.0060) and hDAT-1°HRs (58.4% reduction, p < 0.001), as compared to WT-Rs.
Cell viability in hDAT-1°HRs exposed to 6-OHDA was significantly reduced
(25.7% reduction, p = 0.0034), as compared to Ctrl-1°HRs. These findings
indicated hairy root phenotype alone increased susceptibility to 6-OHDA, and
vulnerability to 6-OHDA was augmented by hDAT expression. On the other hand,
MPTP susceptibility was only significantly increased by hDAT expression. Thus,
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hDAT expression increased susceptibility to MPTP and 6-OHDA, but MPTP was
more selective for hDAT-1°HRs. These findings are consistent with studies
reporting DAT-independent 6-OHDA-induced toxicity, whereas MPTP is highly
selective for DAT-expressing cells [89, 90, 214].
Subsequent experiments examining GBR12909’s ability to attenuate
MPTP- and 6-OHDA-induced cytotoxicity in Ctrl- and hDAT-1°HRs ensued
(Figure 6.8). GBR12909 is a potent, selective DAT inhibitor which prevents
MPTP toxicity in mammalian cells expressing the DAT [84-90, 124]. Cell viability
was normalized to that of Ctrl-1°HRs treated with vehicle alone (i.e. no exposure
to MPTP or 6-OHDA). Prior to being exposed to MPTP or 6-OHDA (final
concentration, 100 and 50 µM, respectively; 24-hour treatment), hDAT-1°HRs
were pretreated (1 hour) with vehicle or GBR12909 (final concentration, 10 or
100 µM). MPTP and 6-OHDA significantly reduced cell viability (p = 0.0003 and p
< 0.001, respectively) in vehicle pretreated hDAT-1°HRs (51.3% and 52.0%
reduction, respectively), as compared to vehicle treated Ctrl-1°HRs. In hDAT1°HRs, GBR12909 dose-dependently attenuated MPTP-induced cytotoxicity. Cell
viability was increased by 10 µM GBR12909 (25.3% increase, p = 0.0619), and
was significantly increased by 100 µM GBR12909 (38.0% increase, p = 0.0088),
as compared to vehicle pretreated hDAT-1°HRs. In fact, cell viability in hDAT1°HRs pretreated with 100 µM GBR12909 was not significantly different from that
of Ctrl-1°HRs. However, GBR12909 pretreatment failed to attenuate cytotoxicity
caused by 6-OHDA in hDAT-1°HRs. Similar to PC12 cells, cytotoxicity caused by
6-OHDA in 1°HRs is not entirely dependent on the DAT, nor is it abolished by
selective DAT inhibition [214]. In contrast, MPTP-induced cytotoxicity was
selective for transgenic plant cells expressing the hDAT, and was dosedependently attenuated by GBR12909, in agreement with previous reports in
mammalian models [84-90, 124].
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6.7. Discussion
The hDAT was functionally expressed in transgenic L. cardinalis hDAT1°HRs via A. rhizogenes-mediated genetic transformation. The expression and
function of the hDAT protein in transgenic plant cells was confirmed by
performing radioligand binding and radiotracer uptake studies, respectively.
Expression of the hDAT in transgenic plant cells increased their susceptibility to
the DAergic neurotoxins MPTP, which is oxidized to the cytotoxic DAT substrate
MPP+, and 6-OHDA [43, 89-91, 214]. Cytotoxicity caused by MPTP in hDAT1°HRs was attenuated by the highly selective DAT inhibitor GBR12909 [84-88].
Initially, full-length cDNA coding for the hDAT was reverse transcribed
from human brain total reference RNA, PCR amplified, and cloned into the vector
p-GEMT. Authenticity of the gene was confirmed via sequencing. Full-length
cDNA encoding the hDAT was sub-cloned into the expression cassette depicted
in Figure 6.2, which was mobilized into the T-DNA borders of the binary vector
pCambia1301, creating pCambia1301-hDAT. A. Rhizogenes strain R1000 was
transformed

with

pCambia1301-hDAT,

thus

obtaining

AR1000-hDAT.

Subsequently, hypocotyl explants from L. cardinalis seedlings were transformed
with AR1000-hDAT, inducing the formation of hDAT-1°HRs. Successful
transformation of hDAT-1°HRs was confirmed using the GUS histochemical
assay.
Radioligand binding studies were performed in 1°HR membranes
determine if the hDAT protein was expressed in transgenic plant cells.
Membranes preparations from Ctrl- and hDAT-1°HRs were incubated with the
highly selective DAT ligand [3H]-GBR12935 [84, 86]. Binding in hDAT-1°HRs was
saturable and consistent with binding to a single site, whereas a non-specific
increase in [3H]-GBR12935 binding was observed in controls, confirming that the
hDAT protein was expressed in hDAT-1°HR cells. The affinity of [3H]-GBR12935
at the hDAT in hDAT-1°HRs (Kd = 2.7 ± 0.7 nM) corresponded well with that
reported for the radioligand at the DAT in rat striatal membranes (Kd ~1 – 6 nM)
[84, 86]. These data indicated that the hDAT cDNA was effectively translated,
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transcribed, and the hDAT protein was trafficked to the cell membrane where it
assumed a structural conformation similar to that in mammalian cells, thereby
enabling similar ligand-transporter interactions [213]. However, the expression
level of the hDAT protein expression (Bmax = 22.9 ± 1.0 fmol/mg tissue) in hDAT1°HRs was substantially lower than that reported in rat striatal tissue (Bmax = 56.9
± 3.5 pmol/µg tissue), likely due to differences in codon preference, protein
trafficking, and/or protein turnover [213, 216]. A significant increase in [3H]-DA
uptake was observed in hDAT-1°HRs, as compared to Ctrl-1°HRs, indicating the
transporter was functional. The hDAT expressed in transgenic plant cells also
retained its sensitivity to pharmacologic and ionic manipulations known to
influence DAT function in mammalian cells [54, 84-88]. Uptake of [3H]-DA was
saturable and time-dependent in Ctrl- and hDAT-1°HRs, indicating the presence
of endogenous transporters with the capacity for [3H]-DA uptake. GBR12909 and
Na+-free conditions reduced radiotracer uptake in hDAT-1°HRs to that observed
in Ctrl-1°HRs, suggesting the endogenous transporter is structurally distinct from
the hDAT and Na+-independent. This is consistent with studies performed in rice
and Arabidopsis, wherein biogenic amine uptake was mediated by a Na+independent system L amino acid transporter [217-219].
Expression of the hDAT protein in hDAT-1°HRs significantly increased
toxicity caused by the DAergic neurotoxins MPTP and 6-OHDA [43, 89-92, 114,
214]. Cell viability in Ctrl-1°HRs was significantly reduced by 6-OHDA, but not
MPTP, indicating toxicity caused by 6-OHDA was not dependent on hDAT
expression. This is consistent with 6-OHDA’s ability to induce cytotoxicity
extracellularly in PC12 cells [214]. The highly selective DAT inhibitor GBR12909
dose-dependently attenuated MPTP-induced cytotoxicity in hDAT-1°HRs, but did
not reduce toxicity caused by 6-OHDA [84-88]. Again, this is in agreement with
previous reports of DAT-independent toxicity caused by 6-OHDA, whereas
MPTP toxicity is highly dependent on DAT expression and is attenuated by DAT
inhibitors [89, 90, 214, 220]. Alternatively, endogenous transporters present in
the hairy roots may be capable of transporting 6-OHDA. Since [3H]-DA uptake
attributed to an endogenous transporter/s was not inhibited by GBR12909, the
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DAT inhibitor would not be expected attenuate 6-OHDA’s cytotoxic effects. On
the other hand, the endogenous transporter/s putatively present in Ctrl- and
hDAT-1°HRs may lack the capacity to efficiently translocate MPP+. In the latter
case, toxicity caused by MPTP’s oxidative metabolite MPP+, would be highly
dependent on DAT-mediated transport in hDAT-1°HRs, explaining GBR12909’s
ability to attenuate its cytotoxic effects. Based on these observations, gain-offunction mutations that increase biosynthesis of lobinaline and/or “novel” DAT
inhibitors in hDAT-1°HRs should confer resistance to MPTP only. Therefore,
MPTP was chosen as a selection agent for future studies.

Copyright © Dustin Paul Brown 2015
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Figure 6.1. Full-length cDNA encoding the
hDAT cloned into the multiple cloning site of
the vector p-GEMT. Sample DNA was PCR
amplified with hDAT specific primers. Lane 1
– ladder; Lane 2 – empty p-GEMT vector;
Lane 3 – p-GEMT vector containing fulllength cDNA encoding the hDAT; A 1.8-kb
band (indicated by the white arrow) is clearly
visible in the sample from p-GEMT containing
full-length cDNA coding for the hDAT
indicating the presence of cDNA coding for
the hDAT, which is absent in the sample from
empty p-GEMT vector. The hDAT cDNA was
sequenced and authenticity confirmed.
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Figure 6.2. Diagram of the hDAT expression cassette. Full-length cDNA
encoding the hDAT was flanked by the constitutively actively CaMV 35S
promoter (35S P) at it’s 5’-end and the rbcs terminator at it’s 3’-end. The
expression cassette was sub-cloned into the T-DNA borders of the binary
vector pCambia-1301, creating pCambia1301-hDAT.
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Figure 6.3. L. cardinalis hypocotyl explant
successfully transformed with AR1000-C. Hairy
roots can been seen emerging the explant which
tested positive for the GUS reporter gene, as
indicating by the formation of blue precipitate
following GUS histochemical staining.
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Figure 6.4. Induction of Ctrl- and hDAT-1°HRs. A) An empty binary
vector (pCambia1301) was mobilized into A. rhizogenes strain AR1000
creating AR1000-C. L. cardinalis seedlings were transformed with
AR1000-C inducing the formation of Ctrl-1°HRs. B) The binary vector
pCambia1301-hDAT, carrying the hDAT expression cassette within the
borders of its transfer DNA (T-DNA), was mobilized into A. rhizogenes
strain AR1000 creating AR1000-hDAT. L. cardinalis seedlings were
transformed with AR1000-hDAT inducing the formation of hDAT-1°HRs.
The GUS reporter gene was present in pCambia1301 and
pCambia1301-hDAT enabling the conformation of successful
transformation using the GUS histochemical staining assay. T-DNA
refers to DNA present in A. rhizogenes’ root inducing plasmid that is
transferred and integrated into the plant genome, which also encodes
genes responsible for the induction of hairy roots. A hairy root arises
from a single transformed plant cell and consists of cells that are clonal
in nature, each expressing the gene/s present within the T-DNA borders.
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Figure 6.5. Detection of cDNA encoding the hDAT and the hDAT protein in L.
cardinalis hDAT-1°HRs. A) DNA samples PCR amplified with hDAT specific
primers (Lane 1 – ladder; Lane 2 – pCambia1301-hDAT; Lane 3 – sample from
Ctrl-1°HRs; Lane 4 – sample from hDAT-1°HRs). A 1.8-kb band representing
the full-length cDNA encoding the hDAT is clearly visible in samples from
hDAT-1°HRs (small arrow; Lane 4) and pCambia1301-hDAT (large arrow; Lane
2), but is absent in the sample from Ctrl-1°HRs (Lane 3). B) Radioligand binding
was performed in Ctrl- and hDAT-1°HRs (dashed line with open circle markers
and solid line with gray circle markers, respectively) with the highly selective
DAT ligand [3H]-GBR12935. In hDAT-1°HR membranes, specific binding was
saturable (Kd = 2.773 ± 0.7304 nM, Bmax = 22.87 ± 0.9704 fmol/mg tissue) and
displayed excellent fit to a one-site binding model (r2 = 0.8956). In Ctrl-1°HR
membranes, only a non-specific increase in binding was observed.
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Figure 6.6. [3H]-DA uptake in L.
cardinalis 1°HRs. A) [3H]-DA uptake
performed at a single time point in Ctrl(white fill) and hDAT-1°HRs (gray fill).
[3H]-DA uptake in vehicle (VEH)
pretreated
hDAT-1°HRs
was
significantly greater than that in VEH
pretreated
Ctrl-1°HRs.
GBR12909
(GBR) pretreatment and Na+-free
conditions significantly reduced uptake
in hDAT-1°HRs. GBR pretreatment and
Na+-free conditions did not affect uptake
in Ctrl-1°HRs. *** p < 0.001 vs. VEH
treated Ctrl-1°HRs, +++ p < 0.001 vs.
GBR pretreated hDAT-1°HRs, p < 0.001
vs.
hDAT-1°HRs under
Na+-free
conditions; One-way ANOVA, Tukey’s
post-hoc test. B) Time course of [3H]-DA
uptake in Ctrl- (dashed line) and hDAT1°HRs (solid line). [3H]-DA uptake was
significantly greater in hDAT-1°HRs, as
compared to Ctrl-1°HRs by 4 minutes.
[3H]-DA uptake in Ctrl- and hDAT1°HRs was significantly greater than
that observed within the same group at
1 minute, and thereafter. * p < 0.05, ** p
< 0.01, *** p < 0.001 vs. Ctrl-1°HRs;
Two-way ANOVA, Bonferroni’s post-hoc
test. ^^^ p < 0.001 vs. Ctrl-1°HRs at 1
minute, ### p < 0.001 vs. hDAT-1°HRs
at 1 minute; One-way ANOVA,
Dunnett’s post-hoc test. C) [3H]-DA
uptake Ctrl- and hDAT-1°HRs at 5- and
25 minutes pretreated with VEH (no
lines) or GBR (diagonal lines). [3H]-DA
uptake in hDAT-1°HRs was significantly
greater than that observed in Ctrl1°HRs, and was significantly reduced
by GBR pretreatment. [3H]-DA uptake in
all treatment groups at 25-minutes was
significantly greater than that observed
at 5-minutes in corresponding treatment
groups. *** p < 0.001 vs. Ctrl-1°HRs,
+++ p < 0.001 vs. GBR, ^^^ p < 0.001
vs. corresponding group; Two-way
ANOVA, Bonferroni’s post-hoc test. n =
3.
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Figure 6.7. MPTP- and 6-OHDA-induced cytotoxicity in L.
cardinalis roots. Representative images of MPTP treated A) WTRs, B) Ctrl-, and C) hDAT-1°HRs stained with trypan blue. D)
MPTP significantly reduced cell viability in hDAT-1°HRs, but not
Ctrl-1°HRs, as compared to WT-Rs. MPTP significantly reduced
cell viability in hDAT-1°HRs, as compared to Ctrl-1°HRs. D) 6OHDA significantly reduced cell viability in Ctrl- and hDAT-1°HRs,
as compared to WT-Rs. Cell viability was significantly reduced by
6-OHDA in hDAT-1°HRs, as compared to Ctrl-1°HRs. ** p < 0.01,
*** p < 0.001 vs. WT-Rs; ++ p < 0.01 vs. Ctrl-°HRs; One-way
ANOVA, Tukey’s post-hoc test. n = 5.
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Figure 6.8. GBR-12909 dose-dependently attenuates toxicity caused by
MPTP, but not 6-OHDA, in L. cardinalis hDAT-1°HRs. A – C)
Representative images of vehicle treated Ctrl-1HRs (A), and hDAT-1°HRs
pretreated with vehicle (B), or 100 µM GBR12909 (C) prior to being exposed
to MPTP, then stained with trypan blue. D) MPTP significantly reduced cell
viability in vehicle pretreated hDAT-1°HRs (gray fill) and hDAT-1°HRs
pretreated with 10 µM GBR 12909, as compared to vehicle treated Ctrl1°HRs. Cell viability in hDAT-1°HRs pretreated with GBR12909 prior to
MPTP exposure was not significantly different than that of vehicle treated
Ctrl-1°HRs. Cell viability measured after exposure to MPTP was significantly
increased hDAT-1°HRs pretreated with 100 µM GBR12909, as compared to
vehicle pretreated hDAT-1°HRs. E) 6-OHDA significantly reduced cell
viability in all hDAT-1°HR treatment groups, as compared to vehicle treated
Ctrl-1°HRs, and GBR12909 failed to attenuate toxicity caused by 6-OHDA in
hDAT-1°HRs. ** p < 0.01, *** p < 0.001 vs. vehicle treated Ctrl-1°HRs; ++ p
< 0.01 vs. MPTP treated hDAT-1°HRs following pretreatment with vehicle.
One-way ANOVA, Tukey’s post-hoc test. n = 5.
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Chapter 7

Sequential hairy root transformation (proof-of-concept): induction of gainof-function hairy roots, initial pharmacological, and chemical assessments

7.1. Introduction
The hDAT was functionally expressed in transgenic L. cardinalis hDAT1°HRs via A. rhizogenes-mediated genetic transformation. Expression of the
transporter in hDAT-1°HRs increased their susceptibility to the selective DAergic
neurotoxin MPTP. Given DAT inhibition attenuated MPTP-induced cytotoxicity in
hDAT-1°HRs,

gain-of-function

mutations

which

increase

biosynthesis

of

lobinaline and/or “novel” DAT inhibitor should confer resistance to MPTP.
However, intact transgenic plants are traditionally regenerated from hairy roots
prior to further genomic modification. Regeneration can be particularly time
consuming in plants species, such as L. cardinalis, for which a standardized
regeneration protocol has not been developed. In order to circumvent the need
for regeneration, a novel method to induce hairy roots directly from hairy root
explants was developed, referred to as sequential hairy root transformation.
Subsequently, hDAT-1°HR explants were sequentially transformed with AR1000ATM harboring the activation tagging vector pPCVICE4hpt, inducing the
formation of gain-of-function transgenic hairy roots expressing the hDAT [16, 19,
221]. One population of ATMhDAT-2°HRs was generated under selection on
medium containing MPP+, such that only individuals having beneficial gain-offunction mutations engendering MPP+-resistance should survive. The resultant
population of TR-2°HRs was enriched with mutants with mutants overproducing
lobinaline and/or putatively “novel” inhibitors of the hDAT. Additionally, TR-2°HRs
were identified which survived selection via mechanisms other than DAT
inhibition.
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7.2. Sequential Transformation of L. cardinalis hairy roots: secondary hairy root
induction
In the present study, a novel method was developed to accelerate the
generation of gain-of-function transgenic hairy roots expressing the hDAT.
Essentially, hairy roots are induced directly from hairy root explants, herein
referred to as sequential transformation, leading the induction of 2°HRs. The
proof-of-application was demonstrated using AR1000-C and AR1000-GFP. L.
cardinalis hypocotyl explants were transformed with AR1000-C, and the resultant
Ctrl-1°HRs that tested positive for GUS reporter gene expression were
transformed with AR1000-GFP. In Figure 7.1 A, 2°HRs can be seen emerging
from a transformed Ctrl-1°HR explants. As shown in Figure 7.1, 2°HRs
expressing GFP (Figure 7.1 B) and the GUS reporter gene (Figure 7.1 D), via
integration of T-DNA from AR1000-C and AR1000-GFP, respectively, were
successfully obtained. On average, ~25 2°HRs were obtained from each Ctrl1°HR explant with a transformation frequency of ~32% (12 out of 37 tested
positive for both reporter genes). In theory, the process could be repeated to
induce successive hairy root “generations”, thus generating secondary, tertiary,
quaternary, etc. hairy roots. To the best of our knowledge, this is the first report
of sequential hairy root transformation.
7.3. Generation of secondary gain-of-function transgenic hairy roots expressing
the hDAT
Explants from hDAT-1°HRs were transformed with AR1000-ATM. Nodules
signifying the initiation of developing secondary gain-of-function transgenic hairy
roots expressing the hDAT (ATMhDAT-2°HRs) became visible on transformed
explants within ~2 weeks. Explants were then placed on selection medium
containing MPP+ (final concentration, 100 µM). Nodules were allowed to initiate
before placing explants on selection medium to allow adequate time for
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alterations in gene expression, resulting from the integration of the CaMV 35S
enhancer tetramer, to manifest at the cellular level prior to selection. Therefore,
only nodules representing developing ATMhDAT-2°HRs with beneficial gain-offunction mutations conferring MPP+-resistance were able to survive, differentiate,
and form mature hairy roots (Figure 7.2, schematic of selection process and
predicted mechanism/s underlying MPP+-resistance). Explants from hDAT-1°HRs
transformed with AR1000-ATM and emerging activation tagged 2°HRs on
medium lacking or containing MPP+, as well as TR-2°HRs emerging from hDAT1°HR explants, are depicted in Figure 7.3 A – C. ATMhDAT-2°HRs resistant to
MPP+ (MRGFhDAT-2°HRs) were maintained on selection medium for 4 months
to ensure genotype/phenotypes stability. A total of ~1500 hDAT-1°HR explants
were transformed with AR1000-ATM, which should theoretically yield ~12,000
activation tagged 2°HRs. However, only 120 TR-2°HRs were obtained, equating
to a survival rate of 1.0% in the presence of MPP+. After maintaining TR-2°HRs
on selection medium for ≥ 4 months, TR-2°HRs were transferred to growth
medium lacking MPP+. Only tissue from TR-2°HRs that had been removed from
selection medium for ≥ 2 months was used to prepare methanolic (MeOH)
extracts. Of note, 11 TR-2°HRs failed to survive after being removed from
medium containing MPP+, and were not included in pharmacological or chemical
analyses as they did not pass the 2 month “washout” period. MPP+ could
detected in MeOH extracts prepared from TR-2°HR tissue collected up to 6
weeks after removal from selection medium. Thus, the 2-month “washout” period
was essential to avoid confounds arising from the presence of MPP+ in TR-2°HR
extracts. A second population of ATMhDAT-2°HRs was generated (n = 72), but
was not selected on medium containing MPP+.
7.4. Pharmacological analysis of hairy root MeOH extracts: evaluation of DAT
inhibition in vitro
In vitro [3H]-DA uptake studies in rat striatal synaptosomes were
performed to measure the DAT inhibitory activity of hairy root extracts. Four
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populations were examined: 1) Ctrl-1°HRs (n = 68), 2) hDAT-1°HRs (n = 77), 3)
ATMhDAT-2°HRs (n = 72), and 4) TR-2°HRs (n = 109). The DAT inhibitory
activity of each hairy root extract was expressed as lobinaline equivalents,
extrapolated from lobinaline’s DAT inhibition dose-response curve. The DAT
inhibitory activity of each population were (summarized in Table 7.1; n, mean,
S.E.M., min., and max.) as follows (mean ± S.E.M): Ctrl-1°HRs, 2.9 ± 0.3 µg/ml;
hDAT-1°HRs, 2.3 ± 0.2 µg/ml; ATMhDAT-2°HRs, 3.6 ± 0.3 µg/ml; TR-2°HRs
2,632 ± 791 µg/ml. The mean DAT inhibitory activity of the Ctrl-1°HR, hDAT1°HR, and ATMhDAT-2°HR populations were not significantly different. However,
the mean DAT inhibitory activity of the TR-2°HR population was significantly
greater than that of Ctrl-1°HR, hDAT-1°HR, and ATM-hDAT-2°HR populations (p
= 0.0024, p = 0.0015, and p = 0.0019, respectively). Additionally, the frequency
of “highly active DAT inhibitors” in the TR-2°HR population (64.2%) was
significantly greater (p < 0.001) than that of the ATMhDAT-2°HR population
(12.5%). Frequency distributions of each population are depicted in Figure 7.4.
These data indicate that hDAT expression does not increase DAT inhibitory
activity of hairy root extracts. Although ATM alone was capable of generating
mutants with increased inhibitory activity at the DAT (max. = 11.9 µg/ml), the
frequency at which such mutants were generated was not sufficient to
significantly increase the mean DAT inhibitory activity of the ATMhDAT-2°HR
population. As predicted, the TR-2°HR population displayed a significant
increase in the frequency of mutants with increased inhibitory activity at the DAT,
thereby significantly increasing the mean DAT inhibition of the population.
Furthermore, TR-2°HR cultures were obtained which displayed a remarkable
increase in DAT inhibitory activity, exceeding that which could be expressed as
lobinaline equivalents. Therefore, the activity of 10 TR-2°HRs was expressed as
the maximum amount of lobinaline equivalents which could be extrapolated from
lobinaline’s DAT inhibition dose-response curve (i.e. 28,496 µg/ml). A single TR2°HR mutant’s extract did not produce DAT inhibition of sufficient magnitude, and
was expressed as the minimum amount of lobinaline equivalents that could be
extrapolated from lobinaline’s DAT inhibition dose-response curve (i.e. 1.2 x 10-4
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µg/ml). DAT inhibitory activity of extracts from individuals of all other populations
could be expressed as lobinaline equivalents. These observations indicate that
target-directed biosynthesis is a feasible approach to optimize a plant’s
pharmacological activity at a specific molecular target.
7.5. GC-MS analysis of hairy root extracts
Hairy root MeOH extracts were analyzed via GC-MS to quantify lobinaline
content and to acquire a chromatographic “fingerprint” of the metabolite profile of
each hairy root. The lobinaline content of each population are as follows: 1) Ctrl1°HRs, 41.3 ± 1.9 µg/mL; hDAT-1°HRs, 38.3 ± 1.8 µg/mL; ATMhDAT-2°HRs,
56.5 ± 1.8 µg/mL; TR-2°HRs 59.2 ± 2.5 µg/mL (summarized in Table 7.2; n,
mean, S.E.M, min., and max.). The mean lobinaline content of the Ctrl- and
hDAT-1°HR populations was not significantly different. In contrast, the mean
lobinaline content of ATMhDAT- and TR-2°HR populations was significantly
greater than that of the Ctrl- (p < 0.001 and p < 0.001, respectively) and hDAT1°HR (p < 0.001 and p < 0.001, respectively) populations. Although the mean
lobinaline content of ATMhDAT- and TR-2°HR populations were not significantly
different, the frequency of “lobinaline overproducers” in the TR-2°HR population
(33.9%) was significantly greater (p = 0.0267) than that of the ATMhDAT-2°HR
population (18.1%). Frequency distributions of each population are depicted in
Figure 7.5. Qualitative analysis of the GC traces acquired from Ctrl- and hDAT1°HRs revealed an excellence correspondence between the chromatographic
peaks present and their relative abundances when comparing traces within and
between populations. An overlay of representative GC traces obtained from Ctrland hDAT-1°HRs can be seen in Figure 7.6. These findings indicate that hDAT
expression does not significantly increase lobinaline biosynthesis. Greater
variation was observed in GC traces acquired from ATMhDAT- and TR-2°HRs
with regards to the chromatographic peaks present (see below) and their relative
abundances. The use of ATM alone did generate ATMhDAT-2°HRs with a
marked increased in lobinaline content (max. = 92.9 µg/ml), however the
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frequency at which such mutants were generated was insufficient to significantly
increase the mean of the population. As predicted, the frequency of “lobinaline
overproducers” was significantly increased in the TR-2°HR population, thus
leading to a significant increase in the mean lobinaline content of the population.
The lobinaline content of 14 TR-2°HRs was greater than the maximum of the
ATMhDAT-2°HR population. The frequency of “lobinaline overproducers” and the
maximum increase in lobinaline biosynthesis (max. = 117.0 µg/ml) was greater in
the TR-2°HR population, owing to the use of selection favoring mutants of
interest. These observations indicate that target-directed biosynthesis is a
feasible approach to genetically optimize medicinal plants to increase yields of
therapeutically valuable, structurally complex bioactive plant metabolites.
7.6. Discussion
Agrobacterium-mediated ATM creates stable gain-of-function mutations in
plant cells via integration of an enhancer tetramer into the plant genome,
activating genes 10-kb upstream and downstream of the integration site [14, 18].
Activation tagging has previously been demonstrated as a means to increase the
yields of bioactive plant metabolites and/or cause synthesis of putatively “novel”
metabolites with similar bioactivity [14, 15]. However, the use of ATM requires
the generation and maintenance of thousands of mutants to saturate the plant
genome, and subsequent preparation and screening of extracts from each
culture [14, 15]. As such, ATM alone is inefficient, timely, and laborious if used
for the purpose of drug discovery [14, 15]. Target-directed biosynthesis
circumvents these limitations by generating gain-of-function mutants under
selection conditions favoring the survival of individuals of interest. First, a human
target protein is functionally expressed in transgenic plant cells, corresponding to
hDAT-1°HRs expressing the hDAT in the current study. Next, gain-of-function
mutants functionally expressing the human target protein are generated on
selection medium such that survival is dependent upon enhanced activity at the
human target protein, described below.
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Traditionally, after obtaining transgenic plant cell cultures, intact plants are
regenerated and the T3 progeny is obtained to ensure plants are homozygous for
the transgene before inducing additional mutations in the transgenic plants.
However, the process can problematic when time constraints are an issue,
especially if the plant species is difficult to regenerate and/or has a long life cycle.
Since there is no standardized regeneration protocol for L. cardinalis hairy roots,
and the plant takes a minimum of ~3 months to mature and produce seed, a
considerable amount of time would have been invested to obtain the T3 progeny.
In order to circumvent the need to regenerate and obtain T3 progeny prior to
activation tagging, a novel method referred to as sequential hairy root
transformation was developed, wherein hairy roots are induced directly from
hairy roots. Proof-of-concept was demonstrated by transforming Ctrl-1°HR
explants, which expressed the GUS reporter gene, with AR1000-GFP, inducing
the formation of GUS/GFP-2°HRs. The GUS/GFP-2°HRs expressed both
reporter

genes,

as

confirmed

via

fluorescence

microscopy

and

GUS

histochemical staining, respectively. To the best of our knowledge, this is the first
report of sequential hairy root transformation, a feasible approach rapidly obtain
transgenic plant cell cultures expressing multiple transgenes. In theory, hairy
roots could be sequentially transformed repeatedly, inducing successive hairy
root “generations” introducing additional transgenes with each round of
transformation. This possibility remains to be explored in future studies.
One goal of the current study was to obtain gain-of-function hairy root
cultures with mutations leading to increased inhibitory modulation of the hDAT
predicted to arise via increased biosynthesis of lobinaline and/or “novel” DAT
inhibitors of greater potency. Activation tagged hDAT-1°HR explants were placed
on selection medium containing the cytotoxic DAT substrate MPP+ once nodules
representing the initiation of ATMhDAT-2°HRs became visible [89, 90]. As such,
only nodules representing ATMhDAT-2°HRs with beneficial gain-of-function
mutations conferring resistance to MPP+ should survive selection. Given
GBR12909 prevented toxicity caused by MPTP in hDAT-1°RHs, gain-of-function
mutations that increase inhibitory activity at the hDAT should confer resistance to
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the toxin. MPP+ was utilized as a selection agent, rather than its precursor
MPTP, given resistance to the latter could have arisen due to mutations that
decreased MPTP oxidation. Monoamine oxidase inhibitors and DAT inhibitors
attenuate MPTP-induced cytotoxicity, whereas the former do not reduce toxicity
caused by MPP+ [89, 90, 124]. Thus, selection on medium containing MPP+
should theoretically engender greater selectivity for mutations that enhance
inhibitory activity at the hDAT. However, MPP+-resistance could potentially arise
via other mechanisms. The selective DAergic neurotoxin MPP+, which is used to
model PD, is generally accepted to cause neurotoxicity as follows: 1) MPP+ is
transported to the cell interior by the DAT, 2) MPP+ inhibits complex-I of the
electron transport chain, 3) mitochondrial dysfunction leads to depletion of ATP
and excessive free radical production, and 4) resultant caspase activation leads
to initiation of apoptotic signaling, ultimately culminating in cell death [92]. Gainof-function mutations that directly and/or indirectly interfere with any of the
aforementioned steps preceding cell death should confer resistance to MPP+,
given pharmacological agents acting at any of these stages attenuate toxicity
caused by MPP+ in mammalian cells [89, 90, 92, 107-126].
Indeed, 109 TR-2°HRs were obtained which expressed the hDAT, yet
were MPP+-resistant. In order to obtain this quantity of TR-2°HRs, ~1500 hDAT1°HR explants were activation tagged, which should have theoretically produced
~12,000 ATMhDAT-2°HRs, equating to a survival rate of 1.0%. Three other
populations of L. cardinalis hairy roots were generated: Ctrl-1°HRs, hDAT-1°HRs,
and ATMhDAT-2°HRs. Extracts prepared from every individual of each
population were evaluated for their ability to inhibit DAT-mediated [3H]-DA uptake
in rat striatal synaptosomes. Additionally, extracts were subject to GC-MS
analysis to quantify their lobinaline content, examine GC traces for the present of
“novel” chromatographic peaks undetectable in controls, and to identify peaks
present in controls that may have been up-regulated in other experimental
groups, as described below.

Copyright © Dustin Paul Brown 2015
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Figure 7.1. Sequential hairy root transformation in L. cardinalis. A) GUS/GFP2°HRs (arrowheads) emerging from a Ctrl-1°HR explant (arrow) transformed
with AR1000-GFP. B) GFP expression in a GUS/GFP-2°HR. C) Background
observed in Ctrl-1°HRs. D) GUS/GFP-2°HRs that tested positive for GFP
expression, which express the GUS reporter gene, as indicated by the
formation of blue precipitate.

117	
  

	
  

Predicted Outcome: A) Survival of mutants that “overproduce” inhibitors of
DAT or B) molecules that interfere with toxins intracellular mechanisms of cell
death

Toxin

DAT

1

DAT

3

2

A
BA DAT A	
  

Cell Death

Figure 7.2. Schematic of the selection process and mechanisms predicted to
confer resistance to MPP+.
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Figure 7.3. Activation tagged hDAT-1°HR explants and emerging
activation tagged 2°HRs on medium containing and lacking MPP+. A) On
medium lacking MPP+, hDAT-1°HR explants and ATMhDAT-2°HRs
thrive. B) On selection medium containing MPP+, all hDAT-1°HR
explants, and the vast majority of activation tagged 2°HRs, fail to survive.
C) If sufficient quantities of hDAT-1°HR explants are activation tagged
and placed on selection medium containing MPP+, TR-2°HRs that
express the hDAT, yet are resistant to MPP+ (indicated by arrows), can
be obtained. However, hDAT-1HR explants never survived selection.
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Table 7.1.
DAT inhibitory activity of hairy root populations*
Population
n
Mean
S.E.M.
Min.
Ctrl-1°HRs
68
2.9
0.3
0.2
hDAT-1°HRs
77
2.3
0.2
1.1 x 10-2
ATMhDAT-2°HRs
72
3.6
0.3
0.3
TR-2°HRs
109
2,632
791
1.2 x 10-4
*DAT inhibitory activity expressed as lobinaline equivalents (µg/ml)
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Max.
10.7
9.0
11.9
28496
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Figure 7.4. Frequency distributions of the hairy root populations' DAT inhibitory
activity. As depicted above, Ctrl-1°HR, hDAT-1°HR, and ATMhDAT-2°HRs
frequency distributions were not significantly different. However the frequency of
individuals that were "highly active inhibitors of the DAT" was significantly
increased in the X-2°HR population.
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Table 7.2
Lobinaline content of hairy root populations*
Population
n
Mean
S.E.M
Ctrl-1°HRs
68
41.3
1.9
hDAT-1°HRs
77
38.3
1.8
ATMhDAT-2°HRs
72
56.5
1.8
TR-2°HRs
109
59.2
2.4
*Lobinaline content expressed as (µg/ml)
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Min.
13.7
11.0
12.2
9.9

Max.
70.3
76.8
92.9
117.0
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Figure 7.5. Frequency distributions of the hairy root populations' lobinaline
content. The frequency of "lobinaline overporducers" in Ctrl- and hDAT-1°HR
populations was not significantly different. The frequency of "lobinaline
overproducers" present in the ATMhDAT- and X-2°HR populations was
significanly greater than that of Ctrl- or hDAT-1°HRs. Additionally , the
frequency of "lobinaline overproducers " present in the X-2°HR population was
significantly greater than that of the ATMhDAT-2°HR population.
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A

B

Figure 7.6. Overlay of a representative GC trace from a Ctrl- (green trace) and
a hDAT-1°HR (black trace). A) An overlay of a representative GC trace from a
Ctrl- and hDAT-1°HR reveals major differences with regards to the
chromatographic peaks present and their relative abundances. B) Closer
examination reveals no difference in the relative abundance of lobinaline in
Ctrl- and hDAT-1°HRs. This was also confirmed quantitatively for Ctrl- and
hDAT-1°HR populations. The green and black striped arrow in each of the GC
traces indicates the chromatographic peak corresponding to lobinaline.
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Chapter 8

Characterization of gain-of-function subpopulations

8.1. Introduction
In previous studies, a population of MPP+-resistant gain-of-function mutant
transgenic secondary hairy roots expressing the human dopamine transporter
(TR-2°HRs) was generated. After analyzing extracts from MPP+-resistant TR2°HRs for their ability to in inhibit the DAT, and via GC-MS, it became apparent
that the TR-2°HR population consisted of multiple “subpopulations”, summarized
in Table 8.1. The selection agent utilized in the present study, MPP+, is generally
accepted to cause cytotoxicity by the following steps: 1) DAT-mediated MPP+
uptake to the cytosol, 2) mitochondrial dysfunction arising from inhibition of
complex-1 by MPP+, 3) consequential depletion of ATP and excess free radical
production, 4) activation of caspases and associated apoptotic signaling
cascades, and 5) ensuing cell death [92]. As such, molecules that inhibit the
DAT, preserve mitochondrial function, prevent ATP depletion, prevent free
radical damage, or prevent activation of caspases attenuate MPP+-induced
cytotoxicity [89, 90, 92, 107-126]. The various “subpopulations” of TR-2°HRs,
and their respective mechanisms of MPP+-resistance, are described in greater
detail below.

Copyright © Dustin Paul Brown 2015
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Table 8.1
TR-2°HR Subpopulations
Number
Mechanism of Resistance
n, (frequency)
1
DAT inhibition
42, (38.5%)
2
Increased biosynthesis of cytoprotective lipids
33, (30.3%)
3
Increased biosynthesis of cytoprotective metabolites 24, (22.0%)
4
Induction of cytoprotective genes
10, (9.2%)
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Chapter 9

TR-2°HR Subpopulation-1: increased inhibitor modulation of the hDAT

9.1. Introduction
The DAT transporter is exclusively expressed on DAergic neurons in the
CNS, and has been implicated as a “gateway” allowing neurotoxins to access the
intracellular compartment of nigrostriatal neurons [43, 50, 52, 95, 97, 98, 220,
222-224]. Upon gaining entry to the interior of DAergic neurons, selective
DAergic neurotoxins have been reported to cause cell death by a variety of
mechanisms, such as inhibition of mitochondrial function and inducing excessive
free radical production [43, 50, 52, 92, 95, 97, 98, 220, 222-224]. Given DATmediated uptake plays a pivotal role in the selective vulnerability of DAergic
neurons to the neurotoxin MPP+, it is not surprising that numerous DAT inhibitors
have been reported to attenuate MPP+-induced cytotoxicity in vitro and in vivo
[50, 52, 89, 90, 95, 97, 98, 220, 222-224]. As such, increased inhibition of the
hDAT was predicted to be the primary mechanism underlying MPP+-resistance in
in the TR-2°HR population. Pharmacological analysis of TR-2°HRs’ methanolic
(MeOH) in [3H]-DA uptake studies revealed that DAT inhibition was the primary
mechanism underlying MPP+ resistance in the TR-2°HR population.
9.2. Criteria indicating that MPP+-resistance was the result of beneficial gain-offunction mutations that increased inhibitory modulation of the DAT
The designation of TR-2°HRs to Subpopulation-1 (mechanism of survival,
increased inhibitory modulation of the hDAT) was made based on the following
criteria: 1) DAT inhibitory modulation of TR-2°HR extract could not be expressed
as lobinaline equivalents and/or 2) the TR-2°HR’s extract produced DAT
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inhibition greater than three standard deviations above the mean of the
ATMhDAT-2°HR population (see Table 9.1). DAT inhibition produced by the TR2°HRs’ extracts was attributed to a “novel” DAT inhibitor if the extract’s activity
could not be expressed as lobinaline equivalents.
9.3. TR-2°HR Subpopulation-1: DAT inhibitory activity is attributable to lobinaline
and putatively “novel” inhibitors of the DAT
The majority of TR-2°HRs (n = 42, frequency = 38.5%) were resistant to
MPP+ via increased inhibitory modulation of the DAT, and therefore were
designated to Subpopulation-1. In Subpopulation-1, 22 TR-2°HRs’ extracts
exhibited increased DAT inhibition that was attributed to lobinaline, as indicated
by a corresponding increase in DAT inhibition and lobinaline content. However,
20 TR-2°HRs in Subpopulation-1 displayed a marked increase in DAT inhibitory
activity that was not accompanied by a corresponding increase in lobinaline. In
fact, DAT inhibition produced by extracts from 10 TR-2°HRs could not be
expressed as lobinaline equivalents. These observations, and the presence of
chromatographic peaks in GC traces acquired from the latter TR-2°HRs’ extracts,
which were absent/undetectable in controls, suggested the extracts contained
“novel” metabolites that where presumably highly potent DAT inhibitors.
9.4. Discussion
In the present study, L. cardinalis TR-2°HRs expressing the hDAT were
generated on medium containing the cytotoxic DAT substrate MPP+ [89, 90]. As
predicted, the presence of beneficial gain-of-function mutations that increased
DAT inhibitory activity were the primary explanation for MPP+-resistance in the
TR-2°HR population. The underlying reasons for this were two-fold: 1) L.
cardinalis has the biosynthetic machinery necessary to synthesize DAT inhibitors
and 2) DAT inhibitors are known to ameliorate the cytotoxic effects of MPP+ in
vitro and in vivo [75, 89, 90, 94, 124]. Increased yields of lobinaline explained

128	
  

	
  
DAT inhibition produced by roughly half (n = 22) of the TR-2°HRs designated to
Subpopulation-1. A representative GC trace obtained from an TR-2HR whose
DAT inhibitory activity was explained by increased yields of lobinaline is depicted
in Figure 9.1. However, the quantity of lobinaline present in the remaining TR2°HRs was not sufficient to account for DAT inhibition produced by their extracts,
indicating the presence of putatively “novel” DAT inhibitors of greater potency.
Lobinaline is a complex binitrogenous decahydroquinoline alkaloid present
in L. cardinalis that inhibits the DAT, activates nicAchRs, and scavenges free
radicals (see Chapter 4). Considering MPP+ treatment increases free radical
production, which contributes to its cytotoxic effects, lobinaline should attenuate
the deleterious effects of the toxin via two mechanisms: 1) preventing uptake of
the MPP+ via inhibition of the hDAT, and 2) scavenging free radicals produced by
MPP+ that may have gained access to the cell interior through hDAT proteins
unoccupied by lobinaline. The potential cytoprotective effects of lobinaline in
models of neurodegeneration in mammalian cells utilizing MPTP/MPP+ remain to
be explored in future studies.
In Subpopulation-1, roughly half (n = 20) of the TR-2°HRs’ extracts
inhibitory activity at the DAT was not attributed to lobinaline. In fact, the potency
of 10 TR-2°HRs’ extracts produced DAT inhibition equivalent to the positive
control GBR12909, a highly potent and selective DAT inhibitor [84-88]. DAT
inhibition produced by extracts from the aforementioned hairy roots could not be
expressed as lobinaline equivalents. Therefore, their activity was expressed as
the maximum amount of lobinaline equivalents that could be extrapolated from
the lobinaline dose-response curve. GC trace acquired via analysis of TR-2°HRs’
extracts for which lobinaline was not responsible for DAT inhibition are depicted
in Figure 9.2 and Figure 9.3. These TR-2°HRs represent a “library” of
genomically optimized plant cultures whose evolution was redirected to favor
biosynthesis of DAT inhibitors meant to interact with the hDAT. This is in contrast
to DAT inhibitors that occur naturally in plants, which evolved to target the DAT
and/or other monoamine transporters present in organisms other than humans.
Given the TR-2°HRs putatively contain “novel” DAT inhibitors that evolved to
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interact with the human target protein, leads isolated form the cultures may
require less optimization than those found in nature. This is particularly
advantageous from a drug discovery perspective, since their extracts known to
contain highly potent DAT inhibitors whose structure may require only minor
modifications, thus streamlining their discovery and development.
Pharmacological and chemical analysis of extracts from TR-2°HR
designated to Subpopulation-1 demonstrated that the technology is a viable
option to increase yields of bioactive metabolites present in the wild-type plant.
Furthermore, target-directed biosynthesis represents a means to tap a plant’s
inherent biosynthetic capacity to generate “novel” bioactive metabolites active at
a specific human target protein, here the hDAT. If lobinaline proves to be a
valuable therapeutic, and/or derivatives of lobinaline prove to be valuable
therapeutics, TR-2°HRs which overproduce lobinaline could be used as a
production system to obtain bulk quantities of the complex alkaloid. The hairy
roots containing novel DAT inhibitors represent a repository of metabolites that
could be mined to identify “novel” DAT inhibitors and/or leads for the
development of novel DAT inhibitors. Given natural products are often more
“druggable” than synthetics, target-directed biosynthesis may prove to be an
effective approach to generate leads with greater potential to be successfully
developed as therapeutics. It’s also advantageous in that leads generated using
this system “evolve” in an aqueous environment, akin to that of human cells. This
is in contrast to synthetics, which “evolve” in organic solution, which may partly
contribute to lower druggability of the synthetic molecules.

Copyright © Dustin Paul Brown 2015
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Table 9.1
DAT inhibitory modulation of the ATMhDAT-2°HR population*
Mean
Standard Deviation (S.D.)
Mean + 3x S.D.
3.6
2.5
11.3
*DAT inhibition expressed as lobinaline equivalents (µg/ml)
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A

B

Figure 9.1. Overlay of a representative GC trace from a hDAT-1°HR (black
trace) and a TR-2°HR (green trace) overproducing lobinaline. A) An overlay of a
representative GC trace from a hDAT-1°HR and a TR-2°HR with increased
yields of lobinaline clearly shows a marked increase in the latter, as compared
the former. B) A closer examination demonstrates the pronounced increase in
lobinaline content in the TR-2°HR, as compared to a representative hDAT1°HR. The black and green arrows indicate the chromatographic peak
corresponding to lobinaline in the GC traces from a hDAT-1°HR and a TR2°HR, respectively.
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Figure 9.2. Overlay of GC traces from a representative hDAT-1°HRs (black
trace) and a TR-2°HR with increased yields of a putatively “novel” DAT inhibitor
(blue trace). A) An overlay of a representative GC trace from a hDAT-1°HR and a
TR-2°HR with increased yields of a putatively “novel” DAT inhibitor demonstrates
a marked increase in the latter (blue arrow), as compared the former (black
arrow). B) A closer examination demonstrates the pronounced increase in the
TR-2°HR, as compared to a representative hDAT-1°HR.
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Figure 9.3. Overlay of GC traces from a representative hDAT-1°HRs and a TR2°HR with increased yields of a putatively “novel” DAT inhibitor. A) An overlay
of a representative GC trace from a hDAT-1°HR and a TR-2°HR with increased
yields of a putatively “novel” DAT inhibitor demonstrates a marked increase in
the latter (green arrow), as compared the former (black arrow). B) A closer
examination demonstrates the pronounced increase in the TR-2°HR, as
compared to a representative hDAT-1°HR.
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Chapter 10

Subpopulation-2: Increased biosynthesis of cytoprotective lipids

10.1. Introduction
Lipids are hydrophobic molecules that serve diverse physiological
functions in eukaryotic cells [225]. For example, lipids are the primary structural
components of cellular membranes, serve as substrates that can be metabolized
to produce energy in the form of ATP, function as intracellular and extracellular
signaling molecules, and modulate gene expression [225]. The four primary
classes of lipids are fatty acids, triglycerides, phospholipids, and steroids [225].
A variety of naturally occurring lipids have been demonstrated to attenuate
the cytotoxicity caused by a variety of insults [75, 94, 226, 227]. As described
above, MPP+-resistance in TR-2°HRs was predicted to arise from increased
inhibitory modulation of the hDAT and/or increased biosynthesis of cytoprotective
metabolites that prevent MPP+-induced cytotoxicity intracellularly. A variety of
lipids have been reported to attenuate cytotoxicity caused by cytotoxic substrates
of the DAT, such as squalene, lanosterol, and polyunsaturated fatty acids [93,
94, 227]. In the TR-2°HR population, increased biosynthesis of cytoprotective
lipid was the second most common mechanism explaining MPP+-resistance, as
described below.
10.2. Criteria indicating MPP+-resistance was attributable to increased
biosynthesis of cytoprotective lipids
The designation of TR-2°HRs to Subpopulation-2 (mechanism of survival,
increased biosynthesis of cytoprotective lipids) was made based on the following
criteria: 1) DAT inhibitory modulation produced by the TR-2°HRs’ extracts was
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less than three standard deviations above the mean of the ATMhDAT-2°HR
population (see Table 9.1) and 2) chromatic peaks in the TR-2°HRs’ GC traces
were “positively identified” as lipids previously reported to attenuate cytotoxicity
caused by cytotoxic DAT substrates. Here, “positive identification” refers to the
identification of lipids based on the MS spectra extracted from their
corresponding chromatographic peak (quality of match ≥ 99%).
10.3. Subpopulation-2: increased biosynthesis of squalene, polyunsaturated fatty
acids, and/or sterols engenders resistance to MPP+
MPP+-resistance arose from increased biosynthesis of cytoprotective
lipids in 33 TR-2°HRs (frequency = 30.3%). In TR-2°HRs designated to
Subpopulation-2, squalene was the most common lipid present in increased
quantities (n = 23, 69.70%), followed by linoleic acid (n = 21, 63.64%). In
Subpopluation-2, both squalene and linoleic were present in increased yields in 9
TR-2°HRs (frequency = 27.27%). Each of these lipids has previously been
reported to attenuate the deleterious effects of cytotoxic DAT substrates [93, 94,
227].
10.4. Discussion
A heterogeneous population of L. cardinalis gain-of-function mutant
transgenic hairy roots expressing the hDAT was generated on medium
containing MPP+. Upon completing pharmacological and chemical analysis of
TR-2°HRs extracts, it became evident that MPP+-resistance in a large portion of
the population arose from increased biosynthesis of cytoprotective lipids. In fact,
increased biosynthesis of cytoprotective lipids was the second most frequent
mechanism underlying MPP+-resistance in TR-2°HRs.
Squalene was the most frequently observed lipid present in increased
quantities in extracts from TR-2°HRs designated to Subpopulation-2. MPP+ is
commonly utilized to model DAergic neurotoxicity observed in PD, and the hDAT
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was expressed in TR-2°HRs such that their phenotype resembled that of DAergic
neurons at a fundamental level in that DAT expression is restricted to DAergic
neurons [43, 52]. Thus, a literature search was performed to determine whether
squalene was reported to exert cytoprotective effects in models of PD. Indeed,
previous studies demonstrated that squalene attenuated DAergic neurotoxicity
observed in the 6-OHDA model of PD in rats [93]. This finding supported the
hypothesis that cytoprotective metabolites that prevent the cytotoxic effects of
selective DAergic neurotoxins would also exert similar effects in mammalian
cells. The neuroprotective effects of squalene in the 6-OHDA model of PD were
attributed to its ability to stabilize cell membranes, scavenge singlet oxygen
radicals, and reduce inflammation [93, 228]. Lastly, squalene is a precursor for
the biosynthesis of plant phytosterols and sterols present in human cells [227,
229]. Given lanosterol exerts cytoprotective effects in in vitro and in vivo models
of PD, increased yields of squalene may led to greater levels of phytosterols that
exert effects analogous to lanosterol in plant cells (i.e. induction of mitochondrial
uncoupling proteins) [227].
Linoleic acid has previously been reported to abolish the cytotoxic effects
of MPP+ in PC12 cells [94]. Polyunsaturated fatty acids (PUFAs), such as
arachidonic acid, attenuate H2O2- and glutamate-induced cytotoxicity in
hippocampal slices [94]. PUFAs also reduce cell death caused by ischemia and
ethanol in the cardiac myocytes and gastrointestinal epithelia cells, respectively
[94]. Furthermore, PUFAs have been reported to inhibit the DAT [74, 75].
Elongation of hydrocarbon tail and a higher degree of unsaturation increases the
inhibitory potency of PUFAs [75]. The inhibitory action of PUFAs is dependent
upon the presence of a terminal carboxylic acid group, given esters of PUFAs fail
to inhibit DAT function [75]. Given PUFAs are reported to inhibit DAT, and exert
antioxidant, anti-inflammatory, and anti-apoptotic effects, their ability to inhibit
cytotoxicity caused by MPP+ is not surprising [74, 75, 94, 226]. Additionally,
MPTP toxicity was reduced in mice via dietary supplementation with PUFAs
[226].
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Resistance to MPP+ in TR-2°HR Subpopulation-2 arose from beneficial
gain-of-function mutations which increased the biosynthesis of cytoprotective
lipids. Both squalene and linoleic acid were present in increased quantities in TR2°HRs, each of which has been reported to exert neuroprotective effect in
models of PD [93, 94]. The ability of cytoprotective lipids to prevent the cell death
caused by MPP+ in plant cells, in addition to their cytoprotective effects in
mammalian models of PD, supports the hypothesis that cytoprotective
metabolites will protect human and plant cells challenged with similar insults [93,
94]. As such, similar approaches could be utilized to drive the production of
cytoprotective metabolites for the treatment of other human diseases. For
example, the generation of gain-of-function mutants plant cell resistant to 3nitropropionic acid, which is utilized to model Huntington’s disease (HD), would
be predicted to favor biosynthesis of metabolites with therapeutic applications in
HD [230-233]. The utilization of target-directed biosynthesis may potentially
revitalize plant-based drug discovery and accelerate the discovery of
therapeutics and/or “druggable” leads for the treatment of numerous human
diseases.
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Figure 10.1. Overlay of a representative GC trace from a hDAT-1°HR (black
line) and a TR-2°HR (green line) overproducing squalene. A) An overlay of a
representative GC trace from a hDAT-1°HR and a TR-2°HR with increased
yields squalene demonstrates the marked increase in the latter, as compared
the former. B) A closer examination demonstrates the pronounced increase
squalene content in the TR-2°HR, as compared to a representative hDAT1°HR. The black and green arrows indicate the chromatographic peak
corresponding to squalene in the GC traces from a hDAT-1°HR and a TR2°HR, respectively. C) The structure of squalene.	
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Figure 10.2. Overlay of a representative GC trace from a hDAT-1°HR (black
trace) and a TR-2°HR (blue trace) overproducing linoleic acid. A) An overlay of a
representative GC trace from a hDAT-1°HR and a TR-2°HR with increased yields
linoleic acid demonstrates the marked increase in the latter, as compared the
former. B) A closer examination demonstrates the pronounced increase in the
TR-2°HR, as compared to a representative hDAT-1°HR. The black and blue
arrows indicate the chromatographic peak corresponding to squalene in the GC
traces from a hDAT-1°HR and a TR-2°HR, respectively. C) The structure of
linoleic acid.
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Figure 10.3. Overlay of a representative GC trace from a hDAT-1°HR (black
trace) and a TR-2°HR (blue trace) overproducing linoleic acid and squalene. A)
An overlay of a representative GC trace from a hDAT-1°HR and a TR-2°HR
with increased yields linoleic acid and squalene demonstrates the marked
increase in the latter, as compared the former. B) A closer examination
demonstrates the pronounced increase in the TR-2°HR, as compared to a
representative hDAT-1°HR. The black and blue arrows indicate the
chromatographic peaks corresponding to linoleic acid and squalene
(chromatographic peaks indicated by arrows on the left and right, respectively)
in the GC traces from a hDAT-1°HR and a TR-2°HR, respectively.
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Chapter 11

Subpopulation 3: Increased biosynthesis of putatively “novel”
cytoprotective metabolites
11.1. Introduction
Numerous phytochemicals and other small molecule natural products
(SMNPs) have been investigated for their ability to attenuate MPP+-induced
cytotoxicity in vitro and in vivo [108, 109, 112, 113, 115-118, 120-122, 125].
MPP+-induced DAergic neurotoxicity is widely accepted as a useful tool to model
PD [92, 123, 124]. The efficacy of phytochemicals and SMNPs at preventing
DAergic neuron loss in models of PD has spiked interest in their use as potential
therapeutics and/or drug leads for the development of anti-PD therapeutics, as
covered in recent reviews [234, 235]. Chrysotoxine, salvianolic acid B, lycopene,
and neoechinulin A, amongst other SMNPs, have been reported reduce
cytotoxicity caused by MPP+ (select phytochemicals and SMNPs reported to
reduce MPP+-induced cytotoxicity are summarized Table 11.1) [108, 109, 112,
113, 115-118, 120-122, 125]. The cytoprotective effects of the aforementioned
plant metabolites were not reported to occur via inhibition of the DAT, nor have
they been reported to inhibit the DAT [108, 109, 112, 113, 115-118, 120-122,
125]. In fact, salvianolic acid B was reported to lack inhibitory activity at the DAT,
and was shown to increase Nrf2 expression and glial-cell derived neurotrophic
factor (GDNF) release [122]. Therefore, it is conceivable that TR-2°HRs’
resistance to MPP+ may have arisen due to increased biosynthesis
cytoprotective

metabolites

that

exert

effects

similar

to

those

of

the

abovementioned phytochemicals. Extracts from TR-2°HRs designated to
Subpopulation-3 did not display a marked increased in DAT inhibitory
modulation, and GC-MS analysis of their extracts indicated no discernable
increase in cytoprotective lipids. However, GC-MS analysis of extracts from TR-
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2°HRs designated to Subpopulation-3 revealed the presence of chromatographic
peaks that were detectable in trace amounts and/or were undetectable in
controls, and were predicted to represent putatively “novel” cytoprotective
metabolites.
11.2. Criteria indicating MPP+-resistance was attributable to increased
biosynthesis of “novel” cytoprotective metabolites
The designation of TR-2°HRs to Subpopulation-3 (mechanism of survival,
increased biosynthesis of “novel” cytoprotective metabolites) was made based on
the following criteria: 1) DAT inhibitory modulation produced by the TR-2°HRs’
extracts was less than three standard deviations above the mean of the
ATMhDAT-2°HR population (see Table 9.1), 2) chromatographic peaks
representing cytoprotective lipids were not identified in the TR-2°HRs’ GC traces,
and 3) prominent chromatographic peaks were present in the TR-2°HRs’ GC
traces that were only detectable in trace amounts and/or were undetectable in
controls.
11.3. Subpopulation 3: increased biosynthesis of “novel” cytoprotective
metabolites putatively underlies resistance to MPP+
Increased biosynthesis of putatively “novel” cytoprotective metabolites that
prevent MPP+ intracellularly, rather than preventing DAT-mediated toxin uptake
or via increased biosynthesis of cytoprotective lipids, was the third most
frequently observed mechanism underlying MPP+-resistance (n = 24, frequency
= 22.0%). Chemical structures were not assigned to the putatively “novel”
cytoprotective metabolites present TR-2°HRs designated to Subpopulation-3.
The inability to assign chemical structures the aforementioned metabolites
presumably arose from the utilization of a GC-MS method aimed to separate and
identify alkaloids, specifically those structurally related to lobinaline. Considering
“novel” metabolites present in the TR-2°HRs were predicted to have structures
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related to lobinaline, the method employed for GC-MS analysis was developed
accordingly with the aim of separating and identifying such alkaloids.
11.4. Discussion
A population of L. cardinalis TR-2°HRs was generated, which consisted of
mutants resistant to MPP+ despite expressing the hDAT. The most common
mechanism explaining resistance to the cytotoxin in the TR-2°HRs was increased
inhibitory modulation of the hDAT, followed by increased biosynthesis of
cytoprotective lipids. However, TR-2°HRs were identified which did not display
increased inhibitory activity at the DAT, nor did their extracts contain increased
amounts of cytoprotective lipids previously reported to attenuate MPP+-induced
cytotoxicity. Chemical analysis of the aforementioned TR-2°HR extracts via GCMS led to the identification of chromatographic peaks that were absent and/or
present in trace amounts in controls. The peaks were predicted to indicate the
presence of putatively “novel” cytoprotective metabolites that conferred
resistance to MPP+.
Structural elucidation of the putatively “novel” cytoprotective metabolites
via analysis of the MS extracted from their corresponding chromatographic peaks
proved unavailing. However, the GC-MS method employed in the current study
was developed to enable the detection, separation, and structural identification of
lobinaline (see Figure 3.3) and lobinaline-like alkaloids. Considering alkaloids
structurally related to lobinaline, which were active at the DAT, were predicted to
be the primary metabolites present in TR-2°HRs, the GC-MS method utilized was
logical. If an alternate GC-MS method was utilized the quantification of lobinaline
present in hairy root extracts may not have been achieved, which would have
prevented the attribution of DAT inhibition to lobinaline and/or a novel DAT
inhibitor/s. However, the GC-MS method utilized generated data essential for one
develop hypotheses pertaining to the class of metabolites present in the TR2°HR extracts, thus allowing the future utilization of analytical instrumentation
necessary for structural elucidation.
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In future studies, analytical instrumentation that is less likely to
decompose metabolites prior to reaching the mass selective detector (MSD),
which also acquires superior MS data, could be utilized in combination with MS
libraries of greater breadth. For example, flavonoids are decomposed when
analyzed via GC-MS prior to reaching the MSD, precluding structural elucidation
[236]. Liquid chromatographic techniques (i.e. HPLC or UPLC) coupled to
tandem mass spectroscopy (LC-MS/MS) may prove to be an effective alternative
to elucidate the structures of unidentified metabolites present in TR-2°HRs [236].
The TR-2°HRs represent a repository of putatively “novel” small molecule natural
products (SMNPs) with a high probability of exerting cytoprotective effects
awaiting to be mined for such metabolites if reasonable manpower and resources
are dedicated to this task. Given squalene and linoleic acid were present in TR2°HRs designated to Subpopulation-2, each of which protects TR-2°HR and
neuronal cells from similar insults, this is truly a possibility of high likelihood [93,
94].
That said, a coumarin-like compound (8-methyloctahydrocoumarin) was
amongst the hits that arose in the while performing library searches of the MS
data, albeit the quality of the match was low (quality of match, 41%). This may
indicate that increased biosynthesis of molecules similar to coumarins and/or
flavonoids, which share a degree of structural similarity, and are reported to
attenuate MPP+-induced cytotoxicity, led to MPP+-resistance in TR-2°HRs
designated to Subpopulation-3 [112, 114, 116, 117, 119]. Especially considering
L. cardinalis contains complex flavonoid-anthocyanin glycosides, and both
flavonoids and anthocyanins have been shown to attenuate MPP+-induced
cytotoxicity [112, 114, 116, 117, 119, 237]. Although other classes of metabolites
cannot be ruled out, increased biosynthesis of flavonoid- or anthocyanin-like
metabolites

is

a

plausible

explanation

underlying

MPP+-resistance

in

Subpopulation-3.
A wide variety of phytochemicals and SMNPs have been identified that
attenuate the deleterious effects of cytotoxic DAT substrates in mammalian
systems in vitro and in vivo [108, 109, 112, 113, 115-118, 120-122, 125]. Most of
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the aforementioned natural products reduce MPP+-induced formation of reactive
oxygen species, prevent opening of the mitochondrial permeability transition
pore, reduce the Bax/Bcl-2 ratio, and decrease caspase-3 activity, all effects
which reduce MPP+-induced apoptosis [108, 109, 112, 113, 115-118, 120-122,
125]. Lycopene, salvianolic acid B, sulforaphane, and carnosic acid cause Nrf2
translocation to the nucleus, which is believed to function as a master regulator
of antioxidant systems within cells responsible for the induction of detoxification
and antioxidant enzymes [108, 113, 118, 122, 238]. Furthermore, Nrf2 signaling
activated by salvianolic acid B increases GDNF release in vitro, and increases
GNDF levels in vivo [122]. GDNF exerts neuroprotective effects in a wide variety
of in vitro and in vivo models, and is particularly effective at restoring DAergic
function in animal models of PD [122].
Homologs of Nrf2’s upstream regulator, Keap1, have been identified in
plants [238-241]. It is conceivable that phytochemicals such as salvianolic acid B,
sulforaphane, and carnosic acid, which activate Nrf2, bind to homologs of Keap1
in plant cells, but disrupt the Keap1-Nrf2 interaction in animal cells thereby
allowing Nrf2 translocation to the nucleus. Considering plant homologs of Keap1
have been identified, plants and animals may share similar signaling pathways to
induce the expression of antioxidant defenses [13, 239]. Subpopulation-3 may be
enriched with TR-2°HRs containing molecules that activate plant cells’
antioxidant defense systems, thereby providing protection from toxicity caused by
MPP+. Supporting this notion, an isothiocyanate (2-heptane isothiocyanate) was
the top match identified after performing a library search on the MS extracted
from a chromatographic peak present in increased abundance in an TR-2°HR’s
extract present in Subpopulation-3. Isothiocyanates that occur naturally in plants,
sulforaphane representing a prime example, have been shown activate Nrf2
thereby exerting neuroprotective effects [118, 241, 242]. Subpopulation-3 could
essentially be viewed as a chemical repository that likely contains SMNPs
capable of promoting Nrf2 translocation to the nucleus, thereby exerting
cytoprotective and neuroprotective effects.
Copyright © Dustin Paul Brown 2015
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Table 11.1
Phytochemicals and other SMNPs shown to reduce the toxic effects of
cytotoxic DAT substrates and/or selective DAergic neurotoxins*
Cytotoxin,
SMNP
Source
model
Mechanism of Action
system

1

Chrysotoxine

2

Kaempferol

Dendrobium
species

Glycine max

6-OHDA,
SH-SY5Y
cells

Reduce ROS formation
Preserve ΔΨm
Attenuate increase in [Ca2+]i
Prevent cytochrome c
release
Reduce Bax/Bcl-2 ratio
Prevent caspase-3
activation
Reduce p38 MAPK and
ERK1/2 phosphorylation
Inhibit NF-κB translocation
Prevent iNOS up-regulation
Reduce NO production

Rotenone,
SH-SY5Y
cells

Reduce ROS formation
Preserve ΔΨm
Restore ΔΨm (<12 posttreatment)
Reduce lipid peroxidation
Induce mitophagy

Lycopene3

Solanum
lycopersicum

MPP+,
SH-SY5Y
cells

Reduce ROS formation
Reduce lipid peroxidation
Preservation of
mitochondrial morphology
Prevent opening of mPTP
Prevent ATP depletion
Prevent reduction in mtDNA

Neoechinulin A4

Eurotium
rubrum

MPP+,
PC12
cells

Reduce free radical levels
Reduce activation of
caspase-3
Increase NADH production
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Table 11.1 (continued)
Phytochemicals and other SMNPs shown to reduce the toxic effects of
cytotoxic DAT substrates and/or selective DAergic neurotoxins*

Osthole

Cnidium
monnieri

5

6

S-Allylcysteine

7

Salvianic acid A

Salvianolic acid B8

Allium
sativum

Salvia
miltiorrhiza

Salvia
miltiorrhiza

MPP+,
PC12
cells

Reduce ROS formation
Induction of SOD activity
Induction of catalase
activity
Reduce lipid peroxidation
Reduce Bax/Bcl-2 ratio
Reduce caspase-3 activity

MPP+,
C57BL/6J
mice

Reduce ROS formation
Reduce lipid peroxidation
Enhance CuZn-SOD
activity
Enhance glutathione
reductase activity

MPP+,
SH-SY5Y
cells

Reduce ROS formation
Reduce Bax/Bcl-2 ratio
Preserve ΔΨm
Inhibit cytochrome c
release
Reduce caspase-3 activity

MPP+,
neuronmicroglia
cultures

Reduce glial TNF-a release
Reduce IL-1b release
Reduce NO production
Increase GDNF mRNA
Increase GDNF release

MPP+,
mouse
midbrain
neuronglia
cultures

Increase Nrf2 expression
Increase Nrf2 translocation
Reduce glial TNF-a release
Reduce IL-1b release
Reduce NO production
Increase GDNF mRNA
Increase GDNF release

MPTP,
C57BL/6J
mice

Reduce glial TNF-a release
Reduce IL-1b release
Reduce NO production
Increase GDNF content
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Table 11.1 (continued)
Phytochemicals and other SMNPs shown to reduce the toxic effects of
cytotoxic DAT substrates and/or selective DAergic neurotoxins*
Tetrahydroxystilbene
glucoside9
Licopyranocoumarin10
Glycyrurol10

Polygonum
multiflorum

MPP+,
SH-SY5Y
cells

Reduce ROS formation
Preserve ΔΨm
Reduce Bax/Bcl-2 ratio
Reduce capase-3 activity

Glycyrrhiza
species

MPP+,
PC12
cells

Reduce ROS formation
Preserve ΔΨm
Attenuate JNK activity

*The list provided is non-exhaustive and is intended to provide select examples
of phytochemicals and other SMNPs that reduce MPP+- and/or 6-OHDAinduced cytotoxicity
Small molecule natural product, SMNP; 6-hydroxydopamine, 6-OHDA; 1methyl-4-phenylpyridinium, MPP+; reactive oxygen species, ROS;
mitochondrial membrane potential, ΔΨm; inducible nitric oxide synthase,
iNOS; nitric oxide (NO), mitochondrial permeability transition pore; adenosine
triphosphate, ATP; mitochondrial DNA, mtDNA; superoxide dismutase, SOD;
copper-zinc superoxide dismutase, CuZn-SOD
1
Song et al. (2013) [109]
2
Filomeni et al. (2012) [116]
3
Yi et al. (2013) [113]
4
Kajimura et al. (2008) [115]
5
Liu et al. (2010) [117]
6
Rojas et al. (2011) [120]
7
Wang et al. (2015) [121]
8
Zhou et al. (2014) [122]
9
Sun et al. (2011) [125]
10
Fujimaki et al. [112]
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Figure 11.1. Overlay of GC traces from a representative hDAT-1°HR extract
(black trace) and a TR-2°HR with increased yields of a putatively “novel”
cytoprotective metabolite/s (blue trace), in this case a coumarin-like metabolite.
A) An overlay of a representative GC trace from a hDAT-1°HR and a TR-2°HR
with increased yields of a putatively “novel” cytoprotective metabolite
demonstrates the marked increase in the latter (blue arrows), as compared the
former (black arrows). B) A closer examination demonstrates the pronounced
increase in the TR-2°HR, as compared to a representative hDAT-1°HR.	
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Chapter 12

Subpopulation 4: Mechanism of MPP+-resistance undetermined
12.1. Introduction
The DAT has been implicated to play a role in DAergic neurodegeneration
seen in PD, functioning as a “gateway” allowing cytotoxic substances to access
the cytosol of nigrostriatal neurons [50, 52, 95, 97, 98, 220, 222-224]. Cytotoxic
substrates of the DAT include endogenous and exogenous compounds, such as
salsolinol and MPP+, respectively [95]. Upon accessing the cytosol of DAergic
neurons, the aforementioned compounds cause cell death by disrupting
mitochondrial function, increasing free radical production, and/or depleting ATP
levels, ultimately inducing apoptosis and/or necrosis [50, 52, 92, 95, 97, 98, 110,
220, 222-224]. In the present study, the hDAT was expressed in L. cardinalis
hairy root cells, which were subsequently “activation tagged” and selected on
medium containing MPP+. Methanolic extracts from the resulting population of
MPP+-resistant TR-2°HRs were subject to pharmacologic and chemical analysis
(see sections 7.4 and 7.5). MPP+-resistance in the TR-2°HR Subpopulations 1 –
3 was explained by the presence of beneficial gain-of-function mutations that
increased inhibitory modulation of the hDAT, increased biosynthesis of
cytoprotective

lipids,

or

increased

biosynthesis

of

other

cytoprotective

metabolites, respectively. However, resistance to MPP+ in Subpopulation-4 did
not arise via the aforementioned mechanisms.
12.2. Criterion leading to the designation of TR-2°HRs to Subpopulation-4
The designation of TR-2°HRs to Subpopulation-4 (mechanism of survival
undetermined) was made based on the following criteria: 1) DAT inhibitory
modulation produced by the TR-2°HRs’ extracts was less than three standard
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deviations above the mean of the ATMhDAT-2°HR population (see Table 9.1), 2)
chromatographic peaks representing cytoprotective lipids were not identified in
the TR-2°HRs’ GC traces, and 3) chromatographic peaks that were detectable in
trace amounts and/or were undetectable in controls were not present in greater
abundance in GC traces acquired from the TR-2°HRs’ extracts.
12.3. Subpopulation 4: mechanism of MPP+-resistance undetermined
In Subpopulation-4, the mechanism/s underlying TR-2°HRs’ resistance to
MPP+ was undetermined. This was the least common type of TR-2°HR
encountered

(n = 10, frequency = 9.17%). As seen in Figure 12.1, GC traces

acquired via analysis of the aforementioned TR-2°HRs’ extracts were devoid of
chromatographic peaks other than that which corresponded to lobinaline.
12.4. Discussion
A population of L. cardinalis TR-2°HRs that express the hDAT, yet are
resistant to MPP+, was generated. The vast majority of TR-2°HRs were resistant
to the toxin owing to increased inhibitory modulation of the hDAT (Subpopulation1) or increased biosynthesis of cytoprotective metabolites (Subpopulations 2 and
3). However, a small portion of the population survived selection on medium
containing MPP+ via a mechanism/s independent of DAT inhibition and increased
biosynthesis of metabolites capable of attenuating the deleterious effects of the
toxin. These TR-2°HRs were designated to Subpopulation-4. At present, the
mechanism/s underlying MPP+-resistance in this subpopulation is undetermined.
One could speculate that resistance to the toxin arose via enhanced expression
of cytoprotective genes that were capable of mitigating MPP+-induced
cytotoxicity. However, increased biosynthesis of cytoprotective metabolites that
were undetectable using the analytical instrumentation and methodology
employed in the present study cannot be ruled out. The former is predicted to
explain MPP+-resistance in these TR-2°HRs, as described below.
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The Arabidopsis genome was sequenced in 2000, and subsequent
analyses led to the realization that plant homologs exist for 71% of the genes
linked to human neurological disorders [243, 244]. Although the evolution of
plants and humans diverged roughly 1.6 billion years ago, plant orthologs exist
for the majority of genes linked to human disease [243, 244]. Furthermore, the
aforementioned genes serve related functions in plant and human cells, despite
differences the organisms’ morphological structure, cellular requirements for the
production of energy (i.e. autotrophs and heterotrophs, respectively), and
challenges encountered during their existence [243]. These observations have
spiked interest in the use of plants to model human disease, including
neurodegenerative diseases [243-245]. In fact, knowledge relating to the function
of plant genes, and their respective proteins products, facilitated the discovery of
genes associated with several neuropathological disorders, including PD,
Alzheimer’s disease, Rett syndrome, and Friedreich’s ataxia [243-245]. Plant
models may be particularly well-suited to delineate certain genetic defects that
contribute to the manifestation of PD, considering plant orthologs exist for all PDlinked genes, with the exception of PARK1 and PARK3 [244]. Furthermore,
aberrant gene variants, such as mutant SPK1-like1-1 (ask1-1), produce similar
cellular defects in human and plant cells [246]. Ask1-1 is homologous to SPK1
present in mammalian cells [246]. Downregulation of SPK1 in mouse embryonic
substantia nigra-derive DAergic cells produces a phenotype that resembles that
of sporadic PD [246]. A loss-of-function mutant form of ask1-1 produces cellular
defects in Arabidopsis analogous to those observed in mammalian cells,
including the formation of intracellular aggregates, aberrant cell division, and
ultimately cell death [246]. Given plants such as Arabidopsis have shot lifespans, are easily maintained in the laboratory at relatively low costs, can be
genetically modified rapidly using well-established methodology, and ethical
constraints are less of an issue, plants represent an excellent alternative to
model neurological disorders [244].
A variety of genes have been demonstrated exert cytoprotective effects in
models of DAergic neurodegeneration, including models of PD wherein lesions
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are created via the administration of cytotoxic DAT substrates [247-251]. For
example, DJ-1 reduces oxidative stress caused by MPP+ and paraquat in SHSY5Y cells via activation of superoxide dismutase (SOD) [247]. The plant
ortholog of DJ-1, AtDJ-1a, also increases SOD activity, thereby playing a role
cellular defense system that prevent the deleterious effects of reactive oxygen
species [244, 252, 253]. Overexpression of the vesicular monoamine transporter
type-2 (VMAT-2) decreases the neurotoxic effects of MPP+ in a mouse model of
PD [248]. Undifferentiated SH-SY5Y cells are less vulnerable to MPP+, compared
to SH-SY5Y cells differentiated toward a DAergic phenotype, which is believed to
arise due to differences in the DAT: VMAT-2 expression ratio [124]. The DAT:
VMAT-2 expression ratio is lower in the former, which is believed reduce uptake
and enhance vesicular sequestration of the toxin thereby reducing cytotoxicity
caused by MPP+ [124]. Plant express transporters for auxins, hormones that
influence the growth and differentiation of plant cells, and auxin transporters and
VMAT-2

share

homology

with

p-glycoprotein

[254-258].

Therefore,

overexpression of transporters for auxins, or structurally related molecules, may
lead to the sequestration of MPP+ in storage organelles present in plant cells,
thereby abrogating MPP+-induced cytotoxicity. Plant also express homologs of
Keap1, which regulates the activity of Nrf2 (see section 11.4), the latter of which
has been proposed as the master regulator of antioxidant defense systems [238,
239]. Given Keap1’s role in the regulation of Nrf2, induction of genes whose
protein products reduce Keap1 activity may lead increased expression of
antioxidant defense systems, which would also be predicted to attenuate the
cytotoxic effects of MPP+ [238, 240, 241]. Lastly, plants and mammals express
the anti-apoptotic protein Bcl-2, which has been reported to attenuate toxicity
caused by MPP+ [251, 259]. Clearly, a vast array of genes present in plants may
lead to MPP+ resistance if their genes were directly or indirectly “activated” by
gain-of-function mutations introduced in TR-2°HRs via ATM.
The induction of cytoprotective genes was predicted to explain resistance
to MPP+ in Subpopulation-4, although the presence of cytoprotective metabolites
that were undetectable using the analytical techniques employed in the current
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study cannot be ruled out. Plants express a variety of genes that are homologous
to human genes linked to neurological disorders, and which serve similar
functions in plant and animal cells [243-245]. Since the “activation tag” allows
one to identify and rescue genes up-regulated via ATM, the TR-2°HRs
designated to Subpopulation-4 are a potential source of putatively “novel”
cytoprotective genes capable of reducing the effects of the DAergic neurotoxin
MPP+. DAergic neurodegeneration caused by MPP+ recreates many of the
symptoms observed in PD, such as rigidity and bradykinesia [89-91]. Considering
many genes linked to human neuropathological disorders (e.g. PD) share
homology with those present in plants, human homologs of cytoprotective genes
capable of mitigating the deleterious effects of MPP+ in TR-2°HRs may exist
[243-245]. Future studies examining genes flanking the “activation tag” in TR2°HRs remain to be performed. If “novel” cytoprotective genes are identified in
these TR-2°HRs, their sequences could be utilized to identify homologous human
genes, thereby accelerating the identification of new molecular targets for the
development of therapeutics to treat and/or prevent PD.

Copyright © Dustin Paul Brown 2015
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Figure 12.1. Overlay of GC traces from a representative hDAT-1HRs and a TR2°HR in which a cytoprotective gene/s has putatively been activated. No
appreciable difference was apparent upon comparison, however the TR-2°HR
survived selection, suggesting survival due to the induction of a cytoprotective
gene/s.
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Chapter 13

Evaluation of TR-2°HR extracts for the presence of putatively “novel” DAT
inhibitors and/or potentially neuroprotective metabolites

13.1 Introduction
In the present dissertation, the fundamental principles underlying evolution
by natural selection were applied to develop a novel plant-based drug discovery
platform. The innovative biotechnology described herein, referred to as targetdirected

biosynthesis,

essentially

redirects

plant

evolution

favoring

the

biosynthesis of metabolites meant to interact with a specific human target
protein. Here, the hDAT was used as an example to demonstrate the application
of the technology.
Two fundamental requirements for evolution via natural selection are: 1)
genetic/phenotypic heterogeneity within a given population, and 2) environmental
selection pressures favoring the survival of individuals with the greatest
reproductive fitness [12]. In nature, genetic heterogeneity within a plant
population arises from sexual reproduction and germline mutations, whereas
environmental selection pressures arise from a vast array of abiotic and biotic
sources [12-14]. For example, ultraviolet (UV) radiation favored the survival of
plants whose genome encoded the biosynthetic machinery responsible for the
synthesis of carotenes and flavonoids, metabolites capable of absorbing UV
energy and scavenging free radicals thereby abrogating the deleterious effects of
UV radiation [13, 14]. As described above (see section 1.2), the presence of
herbivorous insects favored the survival of plants having genomes that encoded
biosynthetic pathways responsible for the synthesis of secondary metabolites,
such as nicotine or cocaine, which function as natural insect deterrents [13, 14].
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We sought to emulate the process of evolution via natural selection in the
laboratory setting to revolutionize and revitalize drug discovery from plant
sources. This was accomplished by creating an artificial environment wherein
survival was dependent upon the biosynthesis of plant metabolites with a
required bioactivity at a specific human protein. The hDAT, a molecular target for
therapeutics in drug abuse and Parkinson’s disease, was chosen as an example
to illustrate the application of target-directed biosynthesis [59, 60, 65, 66, 70, 79,
95-101]. A. rhizogenes-mediated genetic transformation was utilized to express
the hDAT in L. cardinalis, which contains the relatively weak DAT inhibitor
lobinaline. Transgenic L. cardinalis plant cells expressing the hDAT displayed
increased sensitivity to MPP+, a cytotoxic DAT substrate [89, 90]. MPP+-induced
toxicity in the aforementioned cells was prevented via pharmacological blockade
of the transporter with GBR12909, a highly potent and selective DAT inhibitor
[84-88]. As such, one requirement for evolution in the laboratory setting was
fulfilled: selection of transgenic L. cardinalis plant cells expressing the hDAT on
medium containing MPP+ favoring survival of individuals that synthesized 1) DAT
inhibitors of sufficient potency, or at a concentration to prevent MPP+ uptake and
ensuing toxicity and/or 2) metabolites that interfere with MPP+-induced toxicity
downstream of DAT-mediated uptake. Furthermore, the former favored
biosynthesis of metabolites that were optimized for activity at a human target
protein, i.e. the hDAT. Given DAT inhibitors present in plants evolved to target
the insect variant of the transporter, the artificial selection conditions created
should “redirect” plant evolution favoring biosynthesis of molecules meant to
target the hDAT [30].
Next, agrobacterium-mediated ATM was performed on transgenic L.
cardinalis plant cells expressing the hDAT to create a heterogeneous population
of gain-of-function mutants. ATM produces dominant, gain-of-function mutations
in plant cells via integration of T-DNA containing a tetramer of the CaMV 35S
promoter

enhancer

sequence

“activating”

genes

10-kb

upstream

and

downstream of its integration site [221]. Since the integration of agrobacterial TDNA occurs randomly throughout the plant genome, each mutant generated has
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a unique gain-of-function mutation [14, 16-19]. Thus, the utilization of ATM
fulfilled the second fundamental requirement needed for evolution via natural
selection. ATM was already shown to have the capacity to alter plant metabolism
in studies conducted in Nicotiana tabacum, wherein mutant cultures with
increased yields of nicotine, or novel nicAchR ligands, were successfully
obtained [14, 260]. If ATM increased yields of lobinaline, a novel DAT inhibitor of
greater potency, and/or induced biosynthesis of cytoprotective metabolites that
were capable of mitigating intracellular events preceding MPP+-induced cell
death, then the gain-of-function mutants should be resistant to the toxin.
Indeed, MPP+-resistant transgenic gain-of-function L. cardinalis plant cells
expressing the hDAT were obtained. Additionally, TR-2°HRs were resistant to
MPP+ via both of the predicted mechanisms: 1) increased inhibitory modulation
of the DAT and 2) biosynthesis of cytoprotective metabolites that prevent the
deleterious effects of MPP+ via a mechanism independent of DAT inhibition (i.e.
prevent MPP+-induced cytotoxicity intracellularly). To provide proof-of-concept,
two studies were performed: 1) a MeOH extract from a TR-2°HR that survived via
DAT inhibition was sub-fractionated via pHPLC in an effort to identify a novel
DAT inhibitor, and 2) a MeOH extract from a TR-2°HR was evaluated for its
ability to attenuate MPP+-induced cytotoxicity in SH-SY5Y cells. In the former
study, a MeOH extract from a TR-2°HR that displayed DAT inhibitory activity,
exceeding that which could be expressed as lobinaline equivalents, was chosen
to increase the probability of identifying a novel DAT inhibitor. In the latter study,
the cytoprotective effect of a TR-2°HR aqueous extract was compared to that of
an aqueous extract from a hDAT-1°HR. Treatment of SH-SY5Y cells with MPP+
is widely accepted as an in vitro model of DAergic neurodegeneration seen in PD
[92, 107-126]. In the latter study, it was predicted that cytoprotective metabolites
that attenuated MPP+-induced cytotoxicity in TR-2°HRs would also exert
cytoprotective effects in mammalian cells challenged with the toxin.
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13.2. Study 1: Methods
13.2.1. Chemicals and supplies
Methanol, acetonitrile, and o-phosphoric acid were purchased from Sigma
Aldrich (St. Louis, MO, USA). [3H]-DA (S.A. = 60 Ci/mmol) was purchased from
American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). All other
chemicals and materials were purchased from Fisher Scientific (Pittsburgh, PA,
USA), unless otherwise stated.
13.2.2. pHPLC sub-fractionation of L. cardinalis hairy root methanolic extracts
Hairy root tissue was collected and MeOH extracts were prepared as
described above (see sections 5.15 and 5.16, respectively). Hairy root MeOH
extracts were sub-fractionated via pHPLC using a Waters XBridge Prep C18 (5
µm OBD, 19 x 150 mm) column attached to a Waters 600E Multisolvent Delivery
System coupled to a Waters 2998 Photodiode Array Detector and Waters 2767
Sample Manager, Injector, and Collector. The pHPLC instrument was operated
using Waters MassLynx Software (Version 4.1) and FractionLnyx Collection
Control Software (Version 4.1). The mobile phase consisted of a mixture of
Solvent A (100% acetonitrile, pHPLC grade) Solvent B (0.1% o-phosphoric acid
in Milli-Q water, pH = 1.890), and Solvent C (100% Milli-Q water, pH 7.0). Dried
hairy root MeOH extract samples were dissolved in a mixture of Solvents A – C
(20% A, 1% B, 79% C) to achieve a final concentration of 20 mg/ml. Samples
were vortex briefly (~30 seconds), sonicated (~45 seconds), and then syringe
filtered (pore size, 0.22 µm) prior to injection (sample injection volume = 200 µl).
Separation was performed with the following gradient at a flow rate of 10
ml/minute: initial conditions, 10% A in C; 0 – 3 minutes, gradient curve = 5, 10 –
15% A in C; 3 – 6 minutes, gradient curve = 5, 15 – 20% A in C; 6 – 12 minutes,
gradient curve = 7, 20 – 30% A in C; 12 – 24 minutes, gradient curve = 6, 30 –
50% A in C; 24 – 25 minutes, gradient curve = 6, 50 – 84% A in C; 25 – 30
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minutes, gradient curve = 6, 84 – 10% A in C; B was held at 1% throughout the
entire run. Sub-fractions (SFs) were dried, and then re-suspended in uptake
buffer containing 0.1% DMSO (final concentration, 66.7 – 16.7 µg/ml) or
methanol (final volume, 150 µl) for [3H]-DA uptake studies and GC-MS analysis,
respectively (see sections 5.17 and 5.18, respectively). In [3H]-DA uptake
studies, lobinaline was evaluated at four concentrations (51.5 – 6.4 µg/ml) in
each 96-well plate to allow comparison to pHPLC SFs, and to ensure
consistency between experiments.
13.2.3 Data Analysis
Graphical presentation of data were performed using GraphPad Prism
software (Version 6.0; GraphPad Software, San Diego, CA, USA). Data were
expressed as the mean ± S.E.M.
13.3. Study 2: Methods
13.3.1. Chemicals and supplies
Penicillin (10,000 units/ml), streptomycin (10,000 µg/mL), 2.5% trypsin
(10x), heat inactivated fetal bovine serum (FBS), Dulbecco's Modified Eagle
Medium (DMEM), and Hanks Balanced Salt Solution (HBSS) were purchased
from Life Technologies Corporation (Grand Island, NY, USA). 1-methyl-4phenylpyridinium (MPP+) iodide, and 7-hydroxy-3H-phenoxazin-3-one-10-oxide
sodium salt (resazurin) were purchased from Sigma-Aldrich (St Louis, MO, USA).
All other chemicals and supplies were purchased from Fischer Scientific
(Pittsburgh, PA, USA), unless stated otherwise.
13.3.2. Preparation of hairy root aqueous extracts and MPP+ treatment solutions
L. cardinalis hairy root tissue was collected, flash frozen with liquid
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nitrogen, and lyophilized. Immediately after removing tissue from the lyophilizer,
freeze-dried plant tissue was ground to a fine powder and extracted with 3
volumes of water for 24-hours in the dark. The following day, L. cardinalis hairy
root aqueous extracts (LCE) were obtained via vacuum filtration, filter sterilized
(pore size, 0.45 µm), frozen, and dried with a lyophilizer. Solutions of LCEs (final
concentration, 50.0 µg/ml) were prepared by dissolving the extracts in an
appropriate volume of serum-free DMEM containing 0.5% DMSO, then 1:1 serial
dilutions were performed (concentration of final dilution, 9.4 – 150.0 µg/ml). A
solution of MPP+ (final concentration, 3.0 mM) was prepared by dissolving the
cytotoxin in serum-free DMEM containing 0.5% DMSO. Solutions of LCEs and
MPP+ in serum-free DMEM were prepared fresh on the day of the experiment,
and filter sterilized (pore size, 0.45 µm).
13.3.3. SH-SY5Y Cell Culture
SY-SY5Y human neuroblastoma cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cultured as described
previously with minor modifications [113, 124]. Cells were cultured in 60 mm
dishes containing DMEM supplemented with 10% FBS (v/v), penicillin (100
units/ml), and streptomycin (100 µg/ml) in humidified 5% CO2/95% air at 37°C.
Culture medium was changed at 3-day intervals, and cells were subcultured
roughly twice per week, or upon reaching 80% confluence.
13.3.4. MPP+ treatment and measurement of cell viability
Experiments assessing the ability of LCEs to inhibit MPP+ toxicity in SHSY5Y were performed as previously described with minor modifications [113,
124]. SH-SY5Y cells were seeded in 96-well plates at a density of 5 x 105
cells/ml (final volume, 100 µl) in DMEM supplemented with 10% FBS (v/v),
penicillin (100 units/ml), and streptomycin (100 µg/ml), and maintained at 37°C in
humidified 5% CO2/95% air for ≥ 24 hours prior to further manipulation. After cells
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adhered and reached ~80% confluence, cell culture medium was aspirated, cells
were gently washed with HBSS, and then 50 µl of serum-free FBS or serum-free
FBS containing LCE (final concentration, 3.1 – 50.0 µg/ml) was added to each
well. LCEs did not cause toxicity at the concentration used in the present study.
96-well plates were incubated with various treatment solutions for 1 hour at 37°C,
after which serum-free FBS containing 3.0 mM MPP+ was added (final
concentration, 1.0 mM), and then 96-well plates were maintained at 37°C in
humidified 5% CO2/95% air for 60 hours prior to assessing cell viability. In each
96-well plate, one column contained serum-free medium only, and a second
column contained cells that were subject to all manipulations, but were only
challenged with serum-free DMEM (i.e. no MPP+ and/or LCE treatment). The
former was used to subtract background signal, and the latter served as control.
After 60 hours, resazurin (final concentration, 100.0 µM) was added to each well,
and then 4 hours later fluorescence (excitation wavelength = 560 nm, emission
wavelength = 590 nm) was measured using a Wallac 1420 VICTOR plate reader
(PerkinElmer, MA, USA). Background fluorescence measured in wells containing
serum-free FBS and resazurin only was subtracted from all treatment groups,
and cell viability was normalized to that of controls.
13.3.5 Data analysis
Statistical analyses and graphical presentation of data were performed
using GraphPad Prism software (Version 6.0; GraphPad Software, San Diego,
CA, USA). Two-way ANOVA (treatment type x concentration) followed by
Bonferroni’s post-hoc analysis was performed to determine whether the extract
from the TR-2°HR exerted significantly greater cytoprotection against MPP+induced cytotoxicity, compared the hDAT-1°HR extract, and to determine the
concentrations at which the difference was significant. Here, treatment type
refers to extracts from the hDAT-1°HR or the TR-2°HR. Two-way analysis of
variance (treatment x concentration) followed by Tukey’s post-hoc analysis was
performed to determine the effect of the hDAT-1HR extract and the TR-2°HR
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extract significantly attenuated MPP+-induced cytotoxicity as compared to
vehicle treated controls, and to determine the concentrations at which each
extract significantly attenuated MPP+-induced cytotoxicity. Data are expressed
as the mean ± S.E.M. A p-value < 0.05 was defined as statistically significant.
13.4. Study 1: Results
13.4.1. Study 1: pHPLC SFs 1 – 9 from TR-2HR #479 inhibited [3H]-DA uptake
and contained negligible quantities of lobinaline
The MeOH extract from TR-2°HR #479 was sub-fractionated via pHPLC,
and the SFs thus obtained were evaluated for their ability to inhibit DAT-mediated
[3H]-DA uptake in rat striatal synaptosomes. The SFs were also analyzed via GCMS to identify the metabolites present and to quantify the amount of lobinaline
present in each of the SFs.
SF-1 and SFs 3 – 8 dose-dependently inhibited [3H]-DA uptake in rat
striatal synaptosomes (Figure 13.1). Lobinaline was not detected in any of the
SFs indicating that DAT inhibition produced by the SFs was contingent upon the
presence of another bioactive metabolite/s. SF-2 and SF-9 also dosedependently inhibited DAT-mediated [3H]-DA uptake in rat striatal synaptosomes,
which contained only trace amounts of lobinaline (AUC = 1.3% and 2.3%,
respectively). The lobinaline content of all SFs is depicted in Figure 13.2. SFs
beyond SF9 contained quantities of lobinaline that were readily detectably.
Therefore, these fractions were not included in the present dissertation, since the
presence of lobinaline presented a confound. The major metabolites detected in
SF-1 and SF-2 were 2,4-bis(1,1-dimethylethyl)phenol (2,4-DTBP) and dodecyl
acrylate. The identity of 2,4-DTBP and dodecyl acrylate was determined based
on the MS spectra extracted from their respective chromatographic peaks. SFs 3
– 9 contained a mixture of metabolites, the majority of which could not be
assigned a chemical structure.
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13.5 Study 2: Results
Attenuation of MPP+-induced cytotoxicity in SH-SY5Y cells pretreated with
an TR-2°HR aqueous extract was significantly greater than that observed in SHSY5Y cells pretreated with an hDAT-1°HR extract (Figure 13.3). Two-way
ANOVA (treatment type x concentration) revealed a significant effect of treatment
type (p < 0.001), a significant effect of concentration (p < 0.001), and a significant
treatment type x concentration interaction (p < 0.05). The aforementioned twoway ANOVA was performed to determine if the difference between treatment
types was significant (i.e. hDAT-1°HR extract vs. TR-2°HR extract). An additional
two-way ANOVA (treatment x concentration) revealed a significant effect of
treatment (p < 0.001), a significant effect of concentration (p < 0.001), and a
significant treatment by concentration interaction (p = 0.0255). This two-way
ANOVA was utilized to compare the effect of the hDAT-1°HR extract or the TR2°HR extract, as compared to vehicle treated controls. MPP+-induced cytotoxicity
in SH-SY5Y cells was significantly reduced by both the hDAT-1°HR and the TR2°HR extracts, as compared to vehicle pretreated SH-SY5Y cells. However, at
concentrations of 3.1, 6.3, and 12.5 µg/mL, the cytoprotective effect the
TR-2°HR extract was significantly greater than that produced by the hDAT-1°HR
extract (p = 0.0123, p = 0.0288, and p = 0.0203, respectively). At higher
concentrations (25.0 and 100 µg/ml), the attenuation of MPP+-induced
cytotoxicity by the hDAT-1°HR and the TR-2°HR extract was not significantly
different. The TR-2°HR extract displayed greater efficacy at attenuating MPP+induced cytotoxicity in SH-SY5Y cells, given the TR-2°HR extract’s cytoprotective
effect was significant at 3.1 µg/ml (p < 0.001), whereas a concentration ~8-fold
greater (25.0 µg/ml, p = 0.0100) was required for the hDAT-1°HR extract’s
cytoprotective effect to reach significance.
13.6. Discussion
Plant cells were made to resemble DAergic neurons on a fundamental

165	
  

	
  
level, i.e. the hDAT was expressed in transgenic plant cells of L. cardinalis [43,
52]. The transgenic plant cells were activation tagged creating a heterogeneous
population of transgenic plant cells expressing the hDAT. This population was
subject to selection on medium containing the neurotoxin MPP+, which is
accumulated via the DAT [89, 90]. Since L. cardinalis has the inherent
biosynthetic potential to synthesize DAT inhibitors, gain-of-function mutations
that enhanced transcription of genes that increased inhibitory modulation of the
DAT was predicted to confer resistance to MPP+. Indeed, the population of MPP+
resistant mutant was enriched with mutants highly active at the DAT, or which
survived selection via increased biosynthesis of cytoprotective compounds.
A gain-of-function mutant that displayed a dramatic increase in DAT
inhibitory modulation (TR-2°HR #479) was chosen in an effort to identify a novel
DAT inhibitor. A MeOH extracted prepared from the hairy root was subfractionated via pHPLC, and the SFs were evaluated for their ability to inhibit
DAT-mediated DA uptake in rat striatal synaptosomes. In addition, the SFs were
subject to chemical analysis to quantify lobinaline present in each SF. Indeed,
SFs that lacked lobinaline, or only contained the alkaloid in trace amounts,
inhibited the DAT-mediated [3H]-DA uptake in rat striatal synaptosomes.
The two primary metabolites, if not the only metabolites present in SFs 1 –
2 were 2,4-DTBP and dodecyl acrylate. The former resembles tertbutylhydroquinone (tBHQ), which has previously been reported to activate Nrf2
signaling, which has been shown to exert neuroprotective effects [238, 240-242,
261]. Dodecyl acrylate resembles PUFAs, which may explain DAT inhibition
produced by the SFs, considering a variety of PUFAs have been demonstrated to
inhibit the DAT [74, 75]. That said, 2,4-DTBPs effects on the DAT cannot be
ruled out. Thus, future studies remain to be performed to determine whether DAT
inhibition caused by SFs 1 – 2 was attributable to 2,4-DTBP or dodecyl acrylate,
or perhaps additive or synergistic actions of the two molecules.
In an additional set of studies, an hDAT-1°HR aqueous extract and a TR2°HR extract were evaluated for their ability to attenuate MPP+-toxicity in SHSY5Y cells. Cytotoxicity caused by MPP+ in SH-SY5Y cells is commonly utilized
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as an in vitro to model DAergic neurodegeneration that occurs in PD, and to
evaluate the potential cytoprotective and/or neuroprotective effects of molecules
[92, 107-126]. Given TR-2°HRs were made to resemble DAergic neurons via
expression of hDAT in the transgenic plant cells, and metabolites present in TR2°HRs were predicted to exert similar cytoprotective effects in mammalian cells,
the TR-2°HR extract was predicted to exert cytoprotection that was superior to
that of the hDAT-1°HR extract. Both the hDAT-1°HR extract and the TR-2°HR
extract attenuated MPP+-induced cytotoxicity in SH-SY5Y cells. Furthermore, the
cytoprotective effect of the TR-2°HRs’ extract attenuated MPP+-induced
cytotoxicity at doses lower than that of the hDAT-1°HR extract. The fact that an
~8-fold higher concentration of the hDAT-1°HR extract was required to reach
significance, as compared to the TR-2°HR extract, indicated that selection
favored the survival of mutants whose extracts were more effective at preventing
insults caused by DAergic neurotoxins. Although these data are preliminary in
nature, they warrant further evaluation of the population to identify mutants that
synthesize novel neuroprotective agents, given only a single TR-2°HRs’ extract
was tested.
The selection strategy used in the present study, target-directed
biosynthesis, was capable of generating mutant plant cultures optimized for their
pharmacological actions at a specific human target protein, here the hDAT.
Additionally, mutants were generated whose extracts contained increased yields
of cytoprotective metabolites previously reported to attenuate the effects of
selective DAergic neurotoxins. Given these limited number of proof-of-concept
studies successfully identified SFs that inhibited DAT and lacked lobinaline, and
extracts from TR-2°HRs were superior to hDAT-1°HRs extracts with regards to
their ability to attenuate MPP+-induced toxicity, the technology seems very
promising indeed. Future evaluation of the aforementioned TR-2°HRs population
described in the present dissertation is warranted, such that the potential of
target-directed biosynthesis can be truly be realized.

Copyright © Dustin Paul Brown 2015
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Figure 13.1. Sub-fractions 1 – 9 dose-dependently inhibited DAT-mediated
[3H]-DA uptake in rat striatal synaptosomes. Data expressed as the mean ±
S.E.M. SFs 1 – 9, which lacked lobinaline or only contained trace amounts of
the alkaloid, dose-dependently inhibited the DAT. SF-1 and SFs 3 – 8 lacked
lobinaline, indicating DAT inhibition was dependent upon the presence of
other bioactive metabolites. SF-1 and SF-9 contained only trace amounts of
lobinaline, yet were still capable of inhibiting the DAT. The dotted line indicates
the magnitude of specific [3H]-DA uptake observed in rat striatal
synaptosomes pretreated with vehicle. n = 3 – 4.
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Figure 13.2. Lobinaline content of various pHPLC sub-fractions. Sub-fractions 1
– 9 contained undetectable or trace amounts of lobinaline.
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Figure 13.3. The X-2°HR (gray fill) aqueous extract’s cytoprotective effect was
significantly greater than the hDAT-1°HR (white fill) aqueous extract in SHSY5Y cells treated with MPP+. Data are expressed as the mean ± S.E.M. Both
the hDAT-1°HR and the X-2°HR extract significantly attenuated MPP+-induced
cytotoxicity as compared to vehicle pretreated cells (black fill), albeit higher
concentrations of the hDAT-1°HR extract were required to reach significance.
^^^ p < 0.001 vs. vehicle treated cells, ## p < 0.01 vs. vehicle treated cells,
two-way ANOVA, Tukey’s post hoc test. * p < 0.05, hDAT-1°HR extract vs. X2°HR extract, two-way ANOVA, Bonferroni’s post-hoc test. n = 6 – 21.
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Chapter 14

Major findings and future directions

Herein, principles underlying the evolution of species via natural selection
were applied to plant-based drug discovery to develop a novel approach to
genomically optimize a plant’s pharmacological profile, coined target-directed
biosynthesis. The technology enables one to redirect plant evolution such that
the biosynthesis of metabolites meant to interact with a specific human target
protein is favored.
In the present dissertation, proof-of-concept was demonstrated in the
species Lobelia cardinalis. The major alkaloid present in L. cardinalis was
identified as possessing a unique combination of pharmacological effects
relevant to the treatment of drug abuse and dopaminergic neurodegeneration
[80, 81, 135, 174, 175]. The complex multifunctional decahydroquinoline alkaloid
acts as an agonist at nicAchRs, an inhibitor of the DAT, and a relatively potent
free radical scavenger [80, 81, 135, 174, 175]. To the best of our knowledge, this
combination of multi-target effects has not been reported for any other natural
product, representing a structural scaffold with potential for the development of
pharmaceuticals with the aforementioned multifunctional pharmacological
activities.
The activity of L. cardinalis was optimized for activity at the hDAT, a
potential target for therapeutics aimed for the treatment of drug abuse and/or
neurodegeneration [59, 60, 65, 66, 70, 79, 95-101]. The hDAT was expressed in
transgenic L. cardinalis plant cells increasing their susceptibility to the cytotoxic
DAT substrate MPP+ [89, 90]. DAT inhibitors prevented the cytotoxic actions of
MPP+ in transgenic L. cardinalis plant cells. As such, selection of a population of
genetically heterogeneous plant cells on medium containing MPP+ would be
predicted to favor the survival of individuals with a greater capacity to synthesize
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DAT inhibitors. Genetic heterogeneity was achieved by creating a population of
gain-of-function mutant L. cardinalis plant cells expressing the hDAT, each
possessing a unique mutation, which enhanced of gene transcription [14, 16-19,
221]. Indeed, selection of the gain-of-function mutant population favored
individuals with a marked increase in DAT inhibitory activity. This provides proofof-concept for the ability of the technology to evolve a plant species toward a
desired pharmacological phenotype. In addition, DAT inhibition arose due to
increased biosynthesis of lobinaline, in addition to “novel” DAT inhibitors (i.e.
active metabolites not readily detectable in the wild-type plant). This provides
proof-of-concept for the ability of the technology to act as a plant drug discovery
platform targeted on a specific protein. In parallel, subpopulations of gain-offunction mutants resistant to MPP+ via mechanisms independent of DAT
inhibition were generated. This included gain-of-function mutants with increased
yields of metabolites previously reported to attenuate the cytotoxic effects of the
DAergic neurotoxins, including squalene and polyunsaturated fatty acids, in
addition to individuals with increased yields of putatively “novel” cytoprotective
metabolites and as yet undetermined mechanisms of MPP+-resistance [93, 94,
226, 227].
This novel approach to plant-based drug discovery could be applied to
numerous molecular targets and plant species, representing a new approach to
develop drug leads whose “druggability” may be superior to than that of
synthetics.

Target-directed

biosynthesis

could

potentially

revitalize

and

revolutionize plant-based drug discovery fueling the parched pipelines of drug
discovery programs with leads of increased diversity and complexity.
Furthermore, the application of the technology is not limited to the production of
pharmaceuticals. Rather, target-directed biosynthesis represents a viable
strategy for other avenues such as the production of valuable agrochemicals and
the generation of plants suitable for phytoremediation (i.e. those capable of
removing accumulating toxins facilitating their removal from contaminated soil).
Target-directed biosynthesis has tremendous potential for application to
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numerous disciplines. It is a technology which could revolutionize the way in
which we view evolution of the plant genome.

Copyright © Dustin Paul Brown 2015
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